{"ts": "2025-09-04T07:43:22.750867Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/us%20fda%20cgmp%2021%20cfr%20part%20210.pdf", "anchor": "210.1  Status of current good \r\nmanufacturing practice regulations | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/acecb21f2b_us fda cgmp 21 cfr part 210.pdf", "size": 271152, "headers": {"Date": "Thu, 04 Sep 2025 07:43:22 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"42330-63c8b01e4969c\"", "Accept-Ranges": "bytes", "Content-Length": "271152", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:24.059119Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20A.pdf", "anchor": "General \r\nProvisions | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6dec5f7764_us fda cgmp 21 cfr part 211 subpart A.pdf", "size": 261981, "headers": {"Date": "Thu, 04 Sep 2025 07:43:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"3ff5d-63c8b01e69657\"", "Accept-Ranges": "bytes", "Content-Length": "261981", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:24.331257Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20B.pdf", "anchor": "Organization and Personnel | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ce96390d8f_us fda cgmp 21 cfr part 211 subpart B.pdf", "size": 283799, "headers": {"Date": "Thu, 04 Sep 2025 07:43:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"45497-63c8b01e6fbe8\"", "Accept-Ranges": "bytes", "Content-Length": "283799", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:24.594538Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20C.pdf", "anchor": "Buildings and Facilities | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a69a817a4b_us fda cgmp 21 cfr part 211 subpart C.pdf", "size": 315030, "headers": {"Date": "Thu, 04 Sep 2025 07:43:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"4ce96-63c8b01e76d30\"", "Accept-Ranges": "bytes", "Content-Length": "315030", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:24.906393Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20D.pdf", "anchor": "Equipment | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/38003f21ed_us fda cgmp 21 cfr part 211 subpart D.pdf", "size": 294488, "headers": {"Date": "Thu, 04 Sep 2025 07:43:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"47e58-63c8b01e7de79\"", "Accept-Ranges": "bytes", "Content-Length": "294488", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:25.177501Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20E.pdf", "anchor": "Control of Components and Drug Product Containers and \r\nClosures | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/247f928bed_us fda cgmp 21 cfr part 211 subpart E.pdf", "size": 342356, "headers": {"Date": "Thu, 04 Sep 2025 07:43:25 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"53954-63c8b01e84bd9\"", "Accept-Ranges": "bytes", "Content-Length": "342356", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:25.447105Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20F.pdf", "anchor": "Production and Process \r\nControls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ebf0b7a738_us fda cgmp 21 cfr part 211 subpart F.pdf", "size": 316018, "headers": {"Date": "Thu, 04 Sep 2025 07:43:25 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"4d272-63c8b01e8a99a\"", "Accept-Ranges": "bytes", "Content-Length": "316018", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:25.731775Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20G.pdf", "anchor": "Packaging and Labeling \r\nControl | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/1c07b306cc_us fda cgmp 21 cfr part 211 subpart G.pdf", "size": 381678, "headers": {"Date": "Thu, 04 Sep 2025 07:43:25 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"5d2ee-63c8b01e9075a\"", "Accept-Ranges": "bytes", "Content-Length": "381678", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:25.999217Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20H.pdf", "anchor": "Holding and \r\nDistribution | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/794480397b_us fda cgmp 21 cfr part 211 subpart H.pdf", "size": 259087, "headers": {"Date": "Thu, 04 Sep 2025 07:43:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"3f40f-63c8b01e993fb\"", "Accept-Ranges": "bytes", "Content-Length": "259087", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:26.259105Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20I.pdf", "anchor": "Laboratory Controls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c27cc8b113_us fda cgmp 21 cfr part 211 subpart I.pdf", "size": 357595, "headers": {"Date": "Thu, 04 Sep 2025 07:43:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"574db-63c8b01ea10fc\"", "Accept-Ranges": "bytes", "Content-Length": "357595", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:26.519889Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20J.pdf", "anchor": "Records and Reports | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/fb4d3d626f_us fda cgmp 21 cfr part 211 subpart J.pdf", "size": 389201, "headers": {"Date": "Thu, 04 Sep 2025 07:43:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"5f051-63c8b01ea8dfc\"", "Accept-Ranges": "bytes", "Content-Length": "389201", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:26.769939Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/usfdacgmp211/us%20fda%20cgmp%2021%20cfr%20part%20211%20subpart%20K.pdf", "anchor": "Returned and Salvaged Drug \r\nProdu | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Returned and Salvaged Drug \r\nProdu cts", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/3cc68742d5_us fda cgmp 21 cfr part 211 subpart K.pdf", "size": 271242, "headers": {"Date": "Thu, 04 Sep 2025 07:43:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"4238a-63c8b01eb0afd\"", "Accept-Ranges": "bytes", "Content-Length": "271242", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:27.258479Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/cgmppreamblesummary.pdf", "anchor": "Summary | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0eddccaba9_cgmppreamblesummary.pdf", "size": 155346, "headers": {"Date": "Thu, 04 Sep 2025 07:43:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"25ed2-63c8b01d471b7\"", "Accept-Ranges": "bytes", "Content-Length": "155346", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:27.520674Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch1GeneralComments.pdf", "anchor": "General Comments | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8a071e7b82_Ch1GeneralComments.pdf", "size": 262842, "headers": {"Date": "Thu, 04 Sep 2025 07:43:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"402ba-63c8b01d87ce4\"", "Accept-Ranges": "bytes", "Content-Length": "262842", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:27.788647Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch7Definitions.pdf", "anchor": "Definitions | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/66bf683581_Ch7Definitions.pdf", "size": 364564, "headers": {"Date": "Thu, 04 Sep 2025 07:43:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"59014-63c8b01d8f215\"", "Accept-Ranges": "bytes", "Content-Length": "364564", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:28.050395Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch8OrganizationAndPersonnel.pdf", "anchor": "Organization and Personnel | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/5679e48d80_Ch8OrganizationAndPersonnel.pdf", "size": 380530, "headers": {"Date": "Thu, 04 Sep 2025 07:43:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"5ce72-63c8b01d94bed\"", "Accept-Ranges": "bytes", "Content-Length": "380530", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:28.309885Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch9BuildingsAndFacilities.pdf", "anchor": "Buildings and Facilities | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/d1c6452ddf_Ch9BuildingsAndFacilities.pdf", "size": 326745, "headers": {"Date": "Thu, 04 Sep 2025 07:43:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"4fc59-63c8b01d9c11e\"", "Accept-Ranges": "bytes", "Content-Length": "326745", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:28.559594Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch10Equipment.pdf", "anchor": "Equipment | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/08aa45be7b_Ch10Equipment.pdf", "size": 288978, "headers": {"Date": "Thu, 04 Sep 2025 07:43:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"468d2-63c8b01d4eeb7\"", "Accept-Ranges": "bytes", "Content-Length": "288978", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:28.897639Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch11Components.pdf", "anchor": "Control of Components and Drug \r\nProduct Containers and Closures | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0981942daf_Ch11Components.pdf", "size": 546384, "headers": {"Date": "Thu, 04 Sep 2025 07:43:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"85650-63c8b01d57b58\"", "Accept-Ranges": "bytes", "Content-Length": "546384", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:29.167518Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch12ProductionProcessControl.pdf", "anchor": "Production and Process Controls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a7d9828bfb_Ch12ProductionProcessControl.pdf", "size": 362677, "headers": {"Date": "Thu, 04 Sep 2025 07:43:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"588b5-63c8b01d5f471\"", "Accept-Ranges": "bytes", "Content-Length": "362677", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:29.479243Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch13PackagingLabeling.pdf", "anchor": "Packaging and Labeling Control | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/f5cf3bac3c_Ch13PackagingLabeling.pdf", "size": 579293, "headers": {"Date": "Thu, 04 Sep 2025 07:43:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"8d6dd-63c8b01d665b9\"", "Accept-Ranges": "bytes", "Content-Length": "579293", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:29.707434Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch14HoldingDistribution.pdf", "anchor": "Holding and Distribution | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/2540d1a08b_Ch14HoldingDistribution.pdf", "size": 135993, "headers": {"Date": "Thu, 04 Sep 2025 07:43:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"21339-63c8b01d6b7c2\"", "Accept-Ranges": "bytes", "Content-Length": "135993", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:29.979434Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch15LaboratoryControl.pdf", "anchor": "Laboratory Controls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6b93bb9f47_Ch15LaboratoryControl.pdf", "size": 376242, "headers": {"Date": "Thu, 04 Sep 2025 07:43:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"5bdb2-63c8b01d71582\"", "Accept-Ranges": "bytes", "Content-Length": "376242", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:30.293431Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch16RecordsReports.pdf", "anchor": "Records and Reports | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0f33e531ad_Ch16RecordsReports.pdf", "size": 707072, "headers": {"Date": "Thu, 04 Sep 2025 07:43:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"aca00-63c8b01d7bd7b\"", "Accept-Ranges": "bytes", "Content-Length": "707072", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:30.528720Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Ch17Returnedproducts.pdf", "anchor": "Returned and Salvaged Drug Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4f952670e8_Ch17Returnedproducts.pdf", "size": 193419, "headers": {"Date": "Thu, 04 Sep 2025 07:43:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"2f38b-63c8b01d8230c\"", "Accept-Ranges": "bytes", "Content-Length": "193419", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:30.966210Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblecgmp/Amendments%20to%20CGMP%202008%20FR.pdf", "anchor": "Amendments to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals; Final Rule (Federal Register: September 8, 2008: Volume 73, Number 174) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/579f2fa72d_Amendments to CGMP 2008 FR.pdf", "size": 1126325, "headers": {"Date": "Thu, 04 Sep 2025 07:43:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"112fb5-63c8b01d4100e\"", "Accept-Ranges": "bytes", "Content-Length": "1126325", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:31.223273Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/21%20cfr%20part%204%20combination%20products.pdf", "anchor": "21 CFR Part 4 - Regulation of Combination Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/be95059cb7_21 cfr part 4 combination products.pdf", "size": 157852, "headers": {"Date": "Thu, 04 Sep 2025 07:43:31 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"2689c-63c8b01d33165\"", "Accept-Ranges": "bytes", "Content-Length": "157852", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:31.491405Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/21%20cfr%20part%2011%202024%205%2026.pdf", "anchor": "21 CFR Part 11 - Electronic Records; Electronic \r\nSignatures | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/efc51a6dac_21 cfr part 11 2024 5 26.pdf", "size": 337953, "headers": {"Date": "Thu, 04 Sep 2025 07:43:31 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"52821-63c8b01d2d78c\"", "Accept-Ranges": "bytes", "Content-Length": "337953", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:31.768519Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20summary%20background%20highlights.pdf", "anchor": "Summary | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/1419784762_21 cfr part 11 preamble  1997 summary background highlights.pdf", "size": 188634, "headers": {"Date": "Thu, 04 Sep 2025 07:43:31 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"2e0da-63c8b01db43d8\"", "Accept-Ranges": "bytes", "Content-Length": "188634", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:32.452709Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20iii%20comments%20on%20the%20proposed%20rule.pdf", "anchor": "Comments on the Proposed Rule | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/cdf40fad65_21 cfr part 11 preamble  1997 iii comments on the proposed rule.pdf", "size": 401721, "headers": {"Date": "Thu, 04 Sep 2025 07:43:32 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"62139-63c8b01da3a36\"", "Accept-Ranges": "bytes", "Content-Length": "401721", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:32.698653Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20iv%20scope.pdf", "anchor": "Scope | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/545ebe58ef_21 cfr part 11 preamble  1997 iv scope.pdf", "size": 322356, "headers": {"Date": "Thu, 04 Sep 2025 07:43:32 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"4eb34-63c8b01da9027\"", "Accept-Ranges": "bytes", "Content-Length": "322356", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:32.928442Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20v%20implementation.pdf", "anchor": "Implementation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/2e5b4679e5_21 cfr part 11 preamble  1997 v implementation.pdf", "size": 120286, "headers": {"Date": "Thu, 04 Sep 2025 07:43:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"1d5de-63c8b01dba968\"", "Accept-Ranges": "bytes", "Content-Length": "120286", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:33.194252Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20vi%20definitions.pdf", "anchor": "Definitions | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/fbc893da88_21 cfr part 11 preamble  1997 vi definitions.pdf", "size": 321509, "headers": {"Date": "Thu, 04 Sep 2025 07:43:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"4e7e5-63c8b01dc16c9\"", "Accept-Ranges": "bytes", "Content-Length": "321509", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:33.495801Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20vii%20electronic%20records%20controls%20for%20closed%20systems.pdf", "anchor": "Electronic Records - Controls for Closed Systems | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/32a94bf3bf_21 cfr part 11 preamble  1997 vii electronic records controls for closed systems.pdf", "size": 624416, "headers": {"Date": "Thu, 04 Sep 2025 07:43:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"98720-63c8b01dc8bf9\"", "Accept-Ranges": "bytes", "Content-Length": "624416", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:33.745844Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20viii%20electronic%20records%20controls%20for%20open%20systems.pdf", "anchor": "Electronic Records - Controls for Open Systems | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/49672c4124_21 cfr part 11 preamble  1997 viii electronic records controls for open systems.pdf", "size": 149232, "headers": {"Date": "Thu, 04 Sep 2025 07:43:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"246f0-63c8b01dcd632\"", "Accept-Ranges": "bytes", "Content-Length": "149232", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:33.984029Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20ix%20electronic%20records%20signature%20manifestations.pdf", "anchor": "Electronic Records - Signature Manifestations | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/aeacb4acf4_21 cfr part 11 preamble  1997 ix electronic records signature manifestations.pdf", "size": 189463, "headers": {"Date": "Thu, 04 Sep 2025 07:43:34 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"2e417-63c8b01dad677\"", "Accept-Ranges": "bytes", "Content-Length": "189463", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:34.221084Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20x%20electronic%20records%20signature%20record%20linking.pdf", "anchor": "Electronic Records - Signature/Record Linking | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/d61deee375_21 cfr part 11 preamble  1997 x electronic records signature record linking.pdf", "size": 160515, "headers": {"Date": "Thu, 04 Sep 2025 07:43:34 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"27303-63c8b01dd14b2\"", "Accept-Ranges": "bytes", "Content-Length": "160515", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:34.460081Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20xi%20electronic%20signatures%20general%20requirements.pdf", "anchor": "Electronic Signatures - General Requirements | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e1e45de892_21 cfr part 11 preamble  1997 xi electronic signatures general requirements.pdf", "size": 242069, "headers": {"Date": "Thu, 04 Sep 2025 07:43:34 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"3b195-63c8b01dda923\"", "Accept-Ranges": "bytes", "Content-Length": "242069", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:34.705680Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20xii%20electronic%20signature%20components%20and%20controls.pdf", "anchor": "Electronic Signature\r\n- Components and Controls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/95b1794eae_21 cfr part 11 preamble  1997 xii electronic signature components and controls.pdf", "size": 243748, "headers": {"Date": "Thu, 04 Sep 2025 07:43:34 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"3b824-63c8b01de2624\"", "Accept-Ranges": "bytes", "Content-Length": "243748", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:34.947148Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart11/21%20cfr%20part%2011%20preamble%20%201997%20xiii%20electronic%20signatures%20controls%20for%20id%20codes%20pw.pdf", "anchor": "Electronic\r\nSignatures - Controls for Identification Codes/Passwords | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/1bafded507_21 cfr part 11 preamble  1997 xiii electronic signatures controls for id codes pw.pdf", "size": 239603, "headers": {"Date": "Thu, 04 Sep 2025 07:43:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"3a7f3-63c8b01de705c\"", "Accept-Ranges": "bytes", "Content-Length": "239603", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:35.285099Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/us%20fda%20medical%20device%20qsr%2021%20cfr%20part%20820.pdf", "anchor": "21 CFR Part 820 - Quality System Regulation (for Medical \r\nDevices) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/89c166507b_us fda medical device qsr 21 cfr part 820.pdf", "size": 726903, "headers": {"Date": "Thu, 04 Sep 2025 07:43:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"b1777-63c8b01e52ef5\"", "Accept-Ranges": "bytes", "Content-Length": "726903", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:35.541663Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesummary.pdf", "anchor": "Summary & Supplementary Information | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/aa2b20f14b_part820preamblesummary.pdf", "size": 330512, "headers": {"Date": "Thu, 04 Sep 2025 07:43:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"50b10-63c8b01e41d84\"", "Accept-Ranges": "bytes", "Content-Length": "330512", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:35.917076Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpartAgeneralprovisions.pdf", "anchor": "General Provisions | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/43bc9a5b50_part820preamblesubpartAgeneralprovisions.pdf", "size": 706877, "headers": {"Date": "Thu, 04 Sep 2025 07:43:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"ac93d-63c8b01e2d17a\"", "Accept-Ranges": "bytes", "Content-Length": "706877", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:36.190575Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpartBqualitysystemrequirements.pdf", "anchor": "Quality System Requirements | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/20fa587b35_part820preamblesubpartBqualitysystemrequirements.pdf", "size": 345218, "headers": {"Date": "Thu, 04 Sep 2025 07:43:36 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"54482-63c8b01e32f3a\"", "Accept-Ranges": "bytes", "Content-Length": "345218", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:36.499670Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpartC%20design%20controls.pdf", "anchor": "Design Controls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a17035317e_part820preamblesubpartC design controls.pdf", "size": 631294, "headers": {"Date": "Thu, 04 Sep 2025 07:43:36 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"9a1fe-63c8b01e3a083\"", "Accept-Ranges": "bytes", "Content-Length": "631294", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:36.758137Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20D%20document%20controls.pdf", "anchor": "Document Controls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a7e636a325_part820preamblesubpart D document controls.pdf", "size": 174380, "headers": {"Date": "Thu, 04 Sep 2025 07:43:36 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"2a92c-63c8b01ded9d5\"", "Accept-Ranges": "bytes", "Content-Length": "174380", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:37.035588Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20E%20purchasing%20controls.pdf", "anchor": "Purchasing Controls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/b590a767f0_part820preamblesubpart E purchasing controls.pdf", "size": 315463, "headers": {"Date": "Thu, 04 Sep 2025 07:43:37 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"4d047-63c8b01df628d\"", "Accept-Ranges": "bytes", "Content-Length": "315463", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:37.291799Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20F%20identification%20and%20traceability.pdf", "anchor": "Identification & Traceability | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/9a192cc2ba_part820preamblesubpart F identification and traceability.pdf", "size": 144336, "headers": {"Date": "Thu, 04 Sep 2025 07:43:37 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"233d0-63c8b01dfa8de\"", "Accept-Ranges": "bytes", "Content-Length": "144336", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:37.583728Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20G%20Production%20and%20Process%20Controls.pdf", "anchor": "Production & Process Controls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/69988465f8_part820preamblesubpart G Production and Process Controls.pdf", "size": 400660, "headers": {"Date": "Thu, 04 Sep 2025 07:43:37 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"61d14-63c8b01e00a86\"", "Accept-Ranges": "bytes", "Content-Length": "400660", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:37.835955Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20H%20acceptance%20activities.pdf", "anchor": "Acceptance Activities | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e346f133b8_part820preamblesubpart H acceptance activities.pdf", "size": 187886, "headers": {"Date": "Thu, 04 Sep 2025 07:43:37 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"2ddee-63c8b01e058a7\"", "Accept-Ranges": "bytes", "Content-Length": "187886", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:38.359232Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20I%20nonconforming%20product.pdf", "anchor": "Nonconforming Product | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ec4e82e234_part820preamblesubpart I nonconforming product.pdf", "size": 143400, "headers": {"Date": "Thu, 04 Sep 2025 07:43:38 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"23028-63c8b01e0ba4f\"", "Accept-Ranges": "bytes", "Content-Length": "143400", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:38.626577Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20J%20corrective%20and%20preventive%20action.pdf", "anchor": "Corrective and Preventive Action | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/02e00d83ff_part820preamblesubpart J corrective and preventive action.pdf", "size": 190390, "headers": {"Date": "Thu, 04 Sep 2025 07:43:38 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"2e7b6-63c8b01e0fcb7\"", "Accept-Ranges": "bytes", "Content-Length": "190390", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:38.913924Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20k%20labeling%20and%20packaging.pdf", "anchor": "Labeling and Packaging Control | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/9784224f34_part820preamblesubpart k labeling and packaging.pdf", "size": 233163, "headers": {"Date": "Thu, 04 Sep 2025 07:43:38 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"38ecb-63c8b01e14ec0\"", "Accept-Ranges": "bytes", "Content-Length": "233163", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:39.149377Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20l%20handling%20storage%20distribution%20and%20installation.pdf", "anchor": "Handling, Storage, Distribution, and Installation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/231191fda7_part820preamblesubpart l handling storage distribution and installation.pdf", "size": 174948, "headers": {"Date": "Thu, 04 Sep 2025 07:43:39 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"2ab64-63c8b01e19128\"", "Accept-Ranges": "bytes", "Content-Length": "174948", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:39.433532Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20m%20records.pdf", "anchor": "Records | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/d715ea8842_part820preamblesubpart m records.pdf", "size": 345791, "headers": {"Date": "Thu, 04 Sep 2025 07:43:39 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"546bf-63c8b01e1eb01\"", "Accept-Ranges": "bytes", "Content-Length": "345791", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:39.664157Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/gmp/preamblepart820/part820preamblesubpart%20n%20servicing.pdf", "anchor": "Servicing | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/9ddf1f99a1_part820preamblesubpart n servicing.pdf", "size": 124845, "headers": {"Date": "Thu, 04 Sep 2025 07:43:39 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:49 GMT", "ETag": "\"1e7ad-63c8b01e22d69\"", "Accept-Ranges": "bytes", "Content-Length": "124845", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:40.290348Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20manufacturing%20considerations%20for%20cellular%20and%20gene%20therapy%20products.pdf", "anchor": "Guidance for Industry: Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/cbe23ebd51_gfi manufacturing considerations for cellular and gene therapy products.pdf", "size": 287162, "headers": {"Date": "Thu, 04 Sep 2025 07:43:40 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"461ba-63c8b0203945e\"", "Accept-Ranges": "bytes", "Content-Length": "287162", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:40.715128Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20systems%20approach.pdf", "anchor": "Guidance for Industry: Quality System Approach to Pharmaceutical Current Good Manufacturing Practice Regulations | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8a36733589_gfi quality systems approach.pdf", "size": 1242144, "headers": {"Date": "Thu, 04 Sep 2025 07:43:40 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"12f420-63c8b020bcde1\"", "Accept-Ranges": "bytes", "Content-Length": "1242144", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:41.051746Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20process%20validation%20final.pdf", "anchor": "Guidance for Industry: Process Validation: General Principles and Practices | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Guidance for Industry: Process Validation: General Principles and Practices (2011)", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/d1979a6f2a_gfi process validation final.pdf", "size": 738849, "headers": {"Date": "Thu, 04 Sep 2025 07:43:41 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"b4621-63c8b02089d75\"", "Accept-Ranges": "bytes", "Content-Length": "738849", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:41.299347Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/software%20validation.pdf", "anchor": "General \r\nPrinciples of Software Validation: Final Guidance for Industry and FDA \r\nStaf f | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4da1ab2409_software validation.pdf", "size": 277627, "headers": {"Date": "Thu, 04 Sep 2025 07:43:41 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"43c7b-63c8b021e7753\"", "Accept-Ranges": "bytes", "Content-Length": "277627", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:41.609781Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20investigating%20oos%20rev%201%202022%205.pdf", "anchor": "Guidance for Industry: Investigating Out of Specification (OOS) \r\nTest Results for Pharmaceutical Production (2022) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ebd63679db_gfi investigating oos rev 1 2022 5.pdf", "size": 592259, "headers": {"Date": "Thu, 04 Sep 2025 07:43:41 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"90983-63c8b0201c384\"", "Accept-Ranges": "bytes", "Content-Length": "592259", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:41.908670Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20sterile%20drug%20products%20by%20aseptic%20processing%20CGMP.pdf", "anchor": "Guidance for Industry: Sterile Drug \r\nProducts Produced by Aseptic Processing - Current Good Manufacturing \r\nPractice | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a609b3f035_gfi sterile drug products by aseptic processing CGMP.pdf", "size": 270403, "headers": {"Date": "Thu, 04 Sep 2025 07:43:41 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"42043-63c8b020f831e\"", "Accept-Ranges": "bytes", "Content-Length": "270403", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:42.183162Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20part%2011%20electronic%20records%20electronic%20signature.pdf", "anchor": "Guidance for Industry: Part 11, Electronic Records; Electronic \r\nSignatures - Scope & Application | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/62f56c4354_gfi part 11 electronic records electronic signature.pdf", "size": 407417, "headers": {"Date": "Thu, 04 Sep 2025 07:43:42 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"63779-63c8b0206094a\"", "Accept-Ranges": "bytes", "Content-Length": "407417", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:42.466168Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/guideline%20on%20preparation%20of%20IND%20products.pdf", "anchor": "Guideline on the Preparation of Investigational New Drug Products (Human and Animal) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/08b1757e34_guideline on preparation of IND products.pdf", "size": 337608, "headers": {"Date": "Thu, 04 Sep 2025 07:43:42 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"526c8-63c8b021c6410\"", "Accept-Ranges": "bytes", "Content-Length": "337608", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:42.791873Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20CGMP%20for%20Phase%201%20investigational%20drugs.pdf", "anchor": "Guidance for Industry: CGMP for Phase I Investigational Drugs | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/dd49fe02a2_gfi CGMP for Phase 1 investigational drugs.pdf", "size": 651273, "headers": {"Date": "Thu, 04 Sep 2025 07:43:42 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"9f009-63c8b01f269bf\"", "Accept-Ranges": "bytes", "Content-Length": "651273", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:43.064633Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/guideline%20for%20drug%20master%20file.pdf", "anchor": "Guideline for Drug \r\nMaster File | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7387f74a5e_guideline for drug master file.pdf", "size": 378368, "headers": {"Date": "Thu, 04 Sep 2025 07:43:43 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"5c600-63c8b021be327\"", "Accept-Ranges": "bytes", "Content-Length": "378368", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:43.318676Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20dmf%20bulk%20antibiotic%20drug%20substances.pdf", "anchor": "Guidance for Industry: Drug Master Files for Bulk Antibiotic Drug \r\nSubstances | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4ec07985a1_gfi dmf bulk antibiotic drug substances.pdf", "size": 269283, "headers": {"Date": "Thu, 04 Sep 2025 07:43:43 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"41be3-63c8b01fd858e\"", "Accept-Ranges": "bytes", "Content-Length": "269283", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:43.641435Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20PAT%20framework.pdf", "anchor": "Guidance for Industry: PAT – A Framework for\r\nInnovative Pharmaceutical Development, Manufacturing, and Quality Assurance | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/02161c1b92_gfi PAT framework.pdf", "size": 638733, "headers": {"Date": "Thu, 04 Sep 2025 07:43:43 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"9bf0d-63c8b0206a973\"", "Accept-Ranges": "bytes", "Content-Length": "638733", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:43.921327Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20and%20fda%20staff%20current%20good%20manufacturing%20practice%20requirements%20for%20combination%20products%20final%202017%201.pdf", "anchor": "Guidance for Industry\r\n& FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/3bd030d25f_gfi and fda staff current good manufacturing practice requirements for combination products final 2017 1.pdf", "size": 250849, "headers": {"Date": "Thu, 04 Sep 2025 07:43:44 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"3d3e1-63c8b01eedf7a\"", "Accept-Ranges": "bytes", "Content-Length": "250849", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:44.202276Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20container%20closure%20integrity.pdf", "anchor": "Guidance for Industry: Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6f059cf837_gfi container closure integrity.pdf", "size": 369484, "headers": {"Date": "Thu, 04 Sep 2025 07:43:44 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"5a34c-63c8b01fa225a\"", "Accept-Ranges": "bytes", "Content-Length": "369484", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:44.485640Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20computerized%20systems%20in%20clinical%20investigations.pdf", "anchor": "Guidance for Industry: Computerized Systems Used in Clinical Investigations | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/b8b83d1e91_gfi computerized systems in clinical investigations.pdf", "size": 452571, "headers": {"Date": "Thu, 04 Sep 2025 07:43:44 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"6e7db-63c8b01f86507\"", "Accept-Ranges": "bytes", "Content-Length": "452571", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:44.766766Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/non%20penicillin%20beta%20lactam%20CGMP%20framework.pdf", "anchor": "Guidance for Industry: Non-Penicillin Beta-Lactam Risk\r\nAssessment: A CGMP Framework | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6dd5ed2097_non penicillin beta lactam CGMP framework.pdf", "size": 363021, "headers": {"Date": "Thu, 04 Sep 2025 07:43:44 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"58a0d-63c8b021d7d51\"", "Accept-Ranges": "bytes", "Content-Length": "363021", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:45.063829Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20pyrogen%20and%20endotoxins%20testing%20questions%20and%20answers.pdf", "anchor": "Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/70b221360e_gfi pyrogen and endotoxins testing questions and answers.pdf", "size": 495848, "headers": {"Date": "Thu, 04 Sep 2025 07:43:45 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"790e8-63c8b02092dfe\"", "Accept-Ranges": "bytes", "Content-Length": "495848", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:45.332752Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20blood%20establishment%20computer%20system%20validation%20in%20the%20user%20facility.pdf", "anchor": "Guidance for Industry: Blood Establishment Computer System Validation in the User's Facility | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a133916bcf_gfi blood establishment computer system validation in the user facility.pdf", "size": 422076, "headers": {"Date": "Thu, 04 Sep 2025 07:43:45 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"670bc-63c8b01f1d166\"", "Accept-Ranges": "bytes", "Content-Length": "422076", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:45.625224Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20contract%20manufactruing%20arrangements%20for%20drugs%20quality%20agreements%20final%202016%2011.pdf", "anchor": "Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a8c3261ddc_gfi contract manufactruing arrangements for drugs quality agreements final 2016 11.pdf", "size": 566697, "headers": {"Date": "Thu, 04 Sep 2025 07:43:45 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"8a5a9-63c8b01fc165c\"", "Accept-Ranges": "bytes", "Content-Length": "566697", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:45.922241Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20heparin%20for%20drug%20and%20medical%20device%20use%20monitoring%20crude%20heparin%20for%20quality.pdf", "anchor": "Guidance for Industry: Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e1fe12b9c0_gfi heparin for drug and medical device use monitoring crude heparin for quality.pdf", "size": 338852, "headers": {"Date": "Thu, 04 Sep 2025 07:43:45 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"52ba4-63c8b0200295a\"", "Accept-Ranges": "bytes", "Content-Length": "338852", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:46.190569Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20allowable%20excess%20volume%20and%20labeled%20vial%20fill%20size%202015%20final.pdf", "anchor": "Guidance for Industry: Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/af2c3597f3_gfi allowable excess volume and labeled vial fill size 2015 final.pdf", "size": 311649, "headers": {"Date": "Thu, 04 Sep 2025 07:43:46 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"4c161-63c8b01ed1670\"", "Accept-Ranges": "bytes", "Content-Length": "311649", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:46.547834Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20submission%20of%20quality%20metrics%20data%202016%2011%20draft.pdf", "anchor": "Guidance for Industry: Submission of Quality Metrics Data (draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/27b3df11a6_gfi submission of quality metrics data 2016 11 draft.pdf", "size": 813780, "headers": {"Date": "Thu, 04 Sep 2025 07:43:46 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"c6ad4-63c8b021134b9\"", "Accept-Ranges": "bytes", "Content-Length": "813780", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:46.884169Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20metrics%20technical%20conformance%20guide%20draft.pdf", "anchor": "Quality Metrics Technical Conformance Guide (draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/890b6f4623_gfi quality metrics technical conformance guide draft.pdf", "size": 348324, "headers": {"Date": "Thu, 04 Sep 2025 07:43:46 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"550a4-63c8b020adf98\"", "Accept-Ranges": "bytes", "Content-Length": "348324", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:47.148412Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20scientific%20considerations%20in%20demonstrating%20biosimilarity%20to%20a%20reference%20product.pdf", "anchor": "Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/2eb7786e7f_gfi scientific considerations in demonstrating biosimilarity to a reference product.pdf", "size": 227071, "headers": {"Date": "Thu, 04 Sep 2025 07:43:47 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"376ff-63c8b020db244\"", "Accept-Ranges": "bytes", "Content-Length": "227071", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:47.394541Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20considerations%20in%20demonstrating%20biosimilarity%20of%20a%20therapeutic%20protein%20product.pdf", "anchor": "Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Protein to a Reference Product | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/78f87feca8_gfi quality considerations in demonstrating biosimilarity of a therapeutic protein product.pdf", "size": 227049, "headers": {"Date": "Thu, 04 Sep 2025 07:43:47 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"376e9-63c8b020a4f0f\"", "Accept-Ranges": "bytes", "Content-Length": "227049", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:47.705217Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20circumstances%20that%20constitute%20delaying%20denying%20limiting%20or%20refusing%20a%20drug%20or%20device%20inspection%20rev%201%202024%206.pdf", "anchor": "Guidance for Industry: Circumstances that Constitute Delaying, Denying, Limiting or Refusing a Drug or Device Inspection (2024. 6) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/9f1d2c3e90_gfi circumstances that constitute delaying denying limiting or refusing a drug or device inspection rev 1 2024 6.pdf", "size": 556558, "headers": {"Date": "Thu, 04 Sep 2025 07:43:47 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"87e0e-63c8b01f37b31\"", "Accept-Ranges": "bytes", "Content-Length": "556558", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:47.971535Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20expiration%20dating%20of%20unit%20dose%20repackaged%20solid%20oral%20dosage%20form%20drug%20products.pdf", "anchor": "Guidance for Industry: Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c7a731b0b1_gfi expiration dating of unit dose repackaged solid oral dosage form drug products.pdf", "size": 220064, "headers": {"Date": "Thu, 04 Sep 2025 07:43:48 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"35ba0-63c8b01fe6437\"", "Accept-Ranges": "bytes", "Content-Length": "220064", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:48.285059Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20data%20integrity%20and%20compliance%20with%20drug%20cgmp%20final%202018%2012.pdf", "anchor": "Guidance for Industry: Data Integrity and Compliance with CGMP | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/39c017fef1_gfi data integrity and compliance with drug cgmp final 2018 12.pdf", "size": 616967, "headers": {"Date": "Thu, 04 Sep 2025 07:43:48 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"96a07-63c8b01fcb29d\"", "Accept-Ranges": "bytes", "Content-Length": "616967", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:48.634980Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20micro%20quality%20considerations%20in%20non%20sterile%20drug%20manufacturing.pdf", "anchor": "Guidance for Industry: Microbiological Quality Considerations in Non-Sterile Drug Manufacturing (draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0d81915530_gfi micro quality considerations in non sterile drug manufacturing.pdf", "size": 821213, "headers": {"Date": "Thu, 04 Sep 2025 07:43:48 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"c87dd-63c8b02050f48\"", "Accept-Ranges": "bytes", "Content-Length": "821213", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:48.964557Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20inspection%20of%20injectable%20products%20for%20visible%20particulates%20draft%202021%2012.pdf", "anchor": "Guidance for Industry: Inspection of Injectable Products for Visible Particulates (draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/2858d0585c_gfi inspection of injectable products for visible particulates draft 2021 12.pdf", "size": 539650, "headers": {"Date": "Thu, 04 Sep 2025 07:43:49 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"83c02-63c8b02012f13\"", "Accept-Ranges": "bytes", "Content-Length": "539650", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:49.262272Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20field%20alert%20report%20submission%20questions%20and%20answers.pdf", "anchor": "Guidance for Industry: Field Alert Report Submission: Questions and Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a881c19cc7_gfi field alert report submission questions and answers.pdf", "size": 446998, "headers": {"Date": "Thu, 04 Sep 2025 07:43:49 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"6d216-63c8b01ff2b70\"", "Accept-Ranges": "bytes", "Content-Length": "446998", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:49.549644Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20questions%20and%20answers%20on%20quality%20related%20controlled%20correspondence.pdf", "anchor": "Guidance for Industry: Questions and Answers on Quality Related Controlled Correspondence | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/fdb82c3002_gfi questions and answers on quality related controlled correspondence.pdf", "size": 450300, "headers": {"Date": "Thu, 04 Sep 2025 07:43:49 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"6defc-63c8b020c4ae2\"", "Accept-Ranges": "bytes", "Content-Length": "450300", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:49.898552Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20testing%20for%20diethylene%20glycol%20and%20ethylene%20glycol.pdf", "anchor": "Guidance for Industry: Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for DEG and EG | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8ce4bd8d3a_gfi testing for diethylene glycol and ethylene glycol.pdf", "size": 471945, "headers": {"Date": "Thu, 04 Sep 2025 07:43:49 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"73389-63c8b0211b989\"", "Accept-Ranges": "bytes", "Content-Length": "471945", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:50.255847Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20manufacturing%20changes%20and%20comparability%20for%20human%20cellular%20and%20gene%20therapy%20products%20draft.pdf", "anchor": "Guidance for Industry: Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products (Draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/b9619eec7f_gfi manufacturing changes and comparability for human cellular and gene therapy products draft.pdf", "size": 869914, "headers": {"Date": "Thu, 04 Sep 2025 07:43:50 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"d461a-63c8b02030ba6\"", "Accept-Ranges": "bytes", "Content-Length": "869914", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:50.564127Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20remote%20interactive%20evaluations%20of%20drug%20manufacturing%20and%20bioresearch%20monitoring%20facilities.pdf", "anchor": "Guidance for Industry: Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities (Draft | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Guidance for Industry: Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities (Draft", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8a635730c5_gfi remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities.pdf", "size": 504744, "headers": {"Date": "Thu, 04 Sep 2025 07:43:50 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"7b3a8-63c8b020ce33b\"", "Accept-Ranges": "bytes", "Content-Length": "504744", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:51.105352Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20conducting%20remote%20regulatory%20assessments%20questions%20and%20answers%20draft%202024%201.pdf", "anchor": "Guidance for Industry: Conducting Remote Regulatory Assessments - Questions and Answers (Draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/93c5974ada_gfi conducting remote regulatory assessments questions and answers draft 2024 1.pdf", "size": 687274, "headers": {"Date": "Thu, 04 Sep 2025 07:43:51 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"a7caa-63c8b01f90148\"", "Accept-Ranges": "bytes", "Content-Length": "687274", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:51.424326Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20alternative%20tools%20assessing%20drug%20manufacturing%20facilities.pdf", "anchor": "Guidance for Industry: Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications (Draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/bfe15a6e1c_gfi alternative tools assessing drug manufacturing facilities.pdf", "size": 550852, "headers": {"Date": "Thu, 04 Sep 2025 07:43:51 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"867c4-63c8b01edaae1\"", "Accept-Ranges": "bytes", "Content-Length": "550852", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:51.758935Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20application%20of%20human%20factors%20engineering%20principles%20for%20combination%20products.pdf", "anchor": "Guidance for Industry and FDA Staff: Application of Human Factors Engineering Principles for Combination Products: Questions and Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/be50bdc4bf_gfi application of human factors engineering principles for combination products.pdf", "size": 715813, "headers": {"Date": "Thu, 04 Sep 2025 07:43:51 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"aec25-63c8b01f1601e\"", "Accept-Ranges": "bytes", "Content-Length": "715813", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:52.039140Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20considerations%20for%20complying%20with%2021%20cfr%20211%20110%20draft.pdf", "anchor": "Guidance for Industry: Considerations for Complying With 21 CFR 211.110 | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e85308b9e7_gfi considerations for complying with 21 cfr 211 110 draft.pdf", "size": 461913, "headers": {"Date": "Thu, 04 Sep 2025 07:43:52 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"70c59-63c8b01f99d89\"", "Accept-Ranges": "bytes", "Content-Length": "461913", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:52.336133Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20sterilization%20process%20validation%20documentation.pdf", "anchor": "Guidance for Indsutry: for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/f68f5a7c34_gfi sterilization process validation documentation.pdf", "size": 556952, "headers": {"Date": "Thu, 04 Sep 2025 07:43:52 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"87f98-63c8b021007ef\"", "Accept-Ranges": "bytes", "Content-Length": "556952", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:52.798395Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20container%20closure%20systems.pdf", "anchor": "Guidance for Industry: Container Closure Systems for Packaging \r\nHuman Drugs and Biologics | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/32c7d7e5d3_gfi container closure systems.pdf", "size": 1369742, "headers": {"Date": "Thu, 04 Sep 2025 07:43:52 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"14e68e-63c8b01fb9574\"", "Accept-Ranges": "bytes", "Content-Length": "1369742", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:53.045344Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20container%20closure%20systems%20for%20packaging%20human%20drugs%20and%20biologics%20questions%20and%20answers.pdf", "anchor": "Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics: Questions and Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/cfa39b9e82_gfi container closure systems for packaging human drugs and biologics questions and answers.pdf", "size": 201498, "headers": {"Date": "Thu, 04 Sep 2025 07:43:53 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"3131a-63c8b01fa93a2\"", "Accept-Ranges": "bytes", "Content-Length": "201498", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:53.352704Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20rdna%20mab.pdf", "anchor": "Guidance for Industry: CMC Information for a Therapeutic \r\nRecombinant DNA-derived Product or a Monoclonal Antibody Product for In Vivo \r\nUse | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/65f3786cb8_gfi cmc rdna mab.pdf", "size": 545327, "headers": {"Date": "Thu, 04 Sep 2025 07:43:53 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"8522f-63c8b01f5f404\"", "Accept-Ranges": "bytes", "Content-Length": "545327", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:53.647762Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20impurities%20in%20drug%20substances.pdf", "anchor": "Guidance for Industry: ANDAs: Impurities in Drug Substancese | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/74ddb7d040_gfi andas impurities in drug substances.pdf", "size": 404235, "headers": {"Date": "Thu, 04 Sep 2025 07:43:53 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"62b0b-63c8b01efcdc4\"", "Accept-Ranges": "bytes", "Content-Length": "404235", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:53.954543Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20impurities%20in%20drug%20products.pdf", "anchor": "Guidance for Industry: ANDAs: Impurities in Drug Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/829928d006_gfi andas impurities in drug products.pdf", "size": 391618, "headers": {"Date": "Thu, 04 Sep 2025 07:43:54 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"5f9c2-63c8b01ef73eb\"", "Accept-Ranges": "bytes", "Content-Length": "391618", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:54.323764Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20CMC%20vaccines%20and%20related%20products.pdf", "anchor": "Guidance for Industry: Content\r\nand Format of Chemistry, Manufacturing and Control Information and\r\nEstablishment Description Information for a Vaccine or Related Product | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4d8fe0e15f_gfi CMC vaccines and related products.pdf", "size": 952405, "headers": {"Date": "Thu, 04 Sep 2025 07:43:54 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"e8855-63c8b01f7095d\"", "Accept-Ranges": "bytes", "Content-Length": "952405", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:54.716697Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfivaccinesCMC.pdf", "anchor": "gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Guidance for Industry: Content\r\nand Format of Chemistry, Manufacturing and Control Information and\r\nEstablishment Descri", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ccf09714b0_gfivaccinesCMC.pdf", "size": 969577, "headers": {"Date": "Thu, 04 Sep 2025 07:43:54 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"ecb69-63c8b02130593\"", "Accept-Ranges": "bytes", "Content-Length": "969577", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:54.980337Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20submission%20of%20documentation%20in%20applications%20for%20parametric%20release.pdf", "anchor": "Guidance for Industry: Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/2457683d06_gfi submission of documentation in applications for parametric release.pdf", "size": 382832, "headers": {"Date": "Thu, 04 Sep 2025 07:43:55 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"5d770-63c8b02107938\"", "Accept-Ranges": "bytes", "Content-Length": "382832", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:55.249696Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20residual%20solvents%20in%20drug%20products.pdf", "anchor": "Guidance for Industry: Residual Solvents in Drug Products Marketed in the United States | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/edd269d5b0_gfi residual solvents in drug products.pdf", "size": 254919, "headers": {"Date": "Thu, 04 Sep 2025 07:43:55 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"3e3c7-63c8b020d603c\"", "Accept-Ranges": "bytes", "Content-Length": "254919", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:55.533341Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20monoclonal%20antibody%20reagents.pdf", "anchor": "Guidance for Industry: Monoclonal\r\nAntibodies Used As Reagents in Drug Manufacturing | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/03d8bd1b1c_gfi monoclonal antibody reagents.pdf", "size": 347493, "headers": {"Date": "Thu, 04 Sep 2025 07:43:55 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"54d65-63c8b02058861\"", "Accept-Ranges": "bytes", "Content-Length": "347493", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:55.787337Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20stability%20testing%20of%20drug%20substances%20and%20products.pdf", "anchor": "Guidance for Industry: ANDAs: Stability Testing of Drug Substances and Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/f987192020_gfi andas stability testing of drug substances and products.pdf", "size": 213277, "headers": {"Date": "Thu, 04 Sep 2025 07:43:55 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"3411d-63c8b01f0c7c5\"", "Accept-Ranges": "bytes", "Content-Length": "213277", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:56.086112Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20analytical%20procedures%20and%20methods%20validation%20for%20drugs%20and%20biologics%202015%20final.pdf", "anchor": "Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/50a47b9629_gfi analytical procedures and methods validation for drugs and biologics 2015 final.pdf", "size": 572548, "headers": {"Date": "Thu, 04 Sep 2025 07:43:56 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"8bc84-63c8b01ee56c2\"", "Accept-Ranges": "bytes", "Content-Length": "572548", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:56.530997Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20nasal%20spray.pdf", "anchor": "Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products - Chemistry, Manufacturing, and Controls Documentations | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e57fbfe702_gfi cmc nasal spray.pdf", "size": 1313896, "headers": {"Date": "Thu, 04 Sep 2025 07:43:56 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"140c68-63c8b01f4cb22\"", "Accept-Ranges": "bytes", "Content-Length": "1313896", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:56.823023Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20format%20and%20content%20for%20cmc%20section%20of%20annual%20report.pdf", "anchor": "Guidance for Industry: Format and Content for the CMC Section of an Annual Report | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/f9d3b26f9c_gfi format and content for cmc section of annual report.pdf", "size": 299235, "headers": {"Date": "Thu, 04 Sep 2025 07:43:56 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"490e3-63c8b01ffa0a1\"", "Accept-Ranges": "bytes", "Content-Length": "299235", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:57.087692Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20development%20and%20submission%20of%20NIR%20analytical%20procedures%202021%20august.pdf", "anchor": "Guidance for Industry: Development and Submission of Near Infrared Analytical Procedures | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7de0cc6af5_gfi development and submission of NIR analytical procedures 2021 august.pdf", "size": 190501, "headers": {"Date": "Thu, 04 Sep 2025 07:43:57 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"2e825-63c8b01fd00bd\"", "Accept-Ranges": "bytes", "Content-Length": "190501", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:57.388341Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20andas%20stability%20testing%20of%20drug%20substances%20and%20products%20q%20and%20a.pdf", "anchor": "Guidance for Industry: ANDAs: Stability Testing of Drug Substances and Products - Questions and Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/9d71a8ab89_gfi andas stability testing of drug substances and products q and a.pdf", "size": 600208, "headers": {"Date": "Thu, 04 Sep 2025 07:43:57 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"92890-63c8b01f06234\"", "Accept-Ranges": "bytes", "Content-Length": "600208", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:57.777109Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20comparability%20protocols%20for%20postapproval%20changes%20to%20the%20CMC%20information%202022%2010.pdf", "anchor": "Guidance for Industry: Comparability Protocols for Postapproval Changes to the CMC Information in an NDA, ANDA or BLA | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/24b061cb32_gfi comparability protocols for postapproval changes to the CMC information 2022 10.pdf", "size": 1127348, "headers": {"Date": "Thu, 04 Sep 2025 07:43:57 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"1133b4-63c8b01f7e036\"", "Accept-Ranges": "bytes", "Content-Length": "1127348", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:58.031872Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20changes%20to%20an%20approved%20application%20certain%20biological%20products.pdf", "anchor": "Guidance for Industry: Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ca1874c06d_gfi cmc changes to an approved application certain biological products.pdf", "size": 211092, "headers": {"Date": "Thu, 04 Sep 2025 07:43:58 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"33894-63c8b01f3e891\"", "Accept-Ranges": "bytes", "Content-Length": "211092", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:58.286879Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20evaluation%20of%20internal%20standard%20responses%20questions%20and%20answers.pdf", "anchor": "Guidance for Industry: Evaluation of Internal Standard Responses During Chromatographic Bioanalysis: Questions and Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ab759fd0e5_gfi evaluation of internal standard responses questions and answers.pdf", "size": 356028, "headers": {"Date": "Thu, 04 Sep 2025 07:43:58 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"56ebc-63c8b01fdfea7\"", "Accept-Ranges": "bytes", "Content-Length": "356028", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:58.599439Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20ich%20q12%20implementation%20considerations%20for%20fda%20regulated%20products.pdf", "anchor": "Guidance for Industry: ICH Q12: Implementation Considerations for FDA-Regulated Products (Draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/bdc0c04acf_gfi ich q12 implementation considerations for fda regulated products.pdf", "size": 672163, "headers": {"Date": "Thu, 04 Sep 2025 07:43:58 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"a41a3-63c8b0200b9e2\"", "Accept-Ranges": "bytes", "Content-Length": "672163", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:58.938670Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20size%20shape%20other%20physical%20attributes%20of%20generic%20tablets%20and%20capsules%202022%2010%20revision%201.pdf", "anchor": "Guidance for Industry: Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0c4e721e58_gfi size shape other physical attributes of generic tablets and capsules 2022 10 revision 1.pdf", "size": 403400, "headers": {"Date": "Thu, 04 Sep 2025 07:43:58 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"627c8-63c8b020eb02d\"", "Accept-Ranges": "bytes", "Content-Length": "403400", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:59.217425Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20changes%20to%20disposable%20manufacturing%20materials%20questions%20and%20answers.pdf", "anchor": "Guidance for Industry: Changes to Disposable Manufacturing Materials: Questions and Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/399e5ed817_gfi changes to disposable manufacturing materials questions and answers.pdf", "size": 454449, "headers": {"Date": "Thu, 04 Sep 2025 07:43:59 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"6ef31-63c8b01f2e6c0\"", "Accept-Ranges": "bytes", "Content-Length": "454449", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:59.507979Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20setting%20endotoxin%20limits%20investigational%20oncology%20drugs%20and%20biological%20products%20draft.pdf", "anchor": "Guidance for Industry: Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/5663d97b9f_gfi setting endotoxin limits investigational oncology drugs and biological products draft.pdf", "size": 353265, "headers": {"Date": "Thu, 04 Sep 2025 07:43:59 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"563f1-63c8b020e3ee5\"", "Accept-Ranges": "bytes", "Content-Length": "353265", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:43:59.834461Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20potency%20assay%20considerations%20for%20monoclonal%20antibodies%20and%20other%20therapeutic%20proteins.pdf", "anchor": "Guidance for Industry: Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens (Draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8384066ee3_gfi potency assay considerations for monoclonal antibodies and other therapeutic proteins.pdf", "size": 572380, "headers": {"Date": "Thu, 04 Sep 2025 07:43:59 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"8bbdc-63c8b0207da24\"", "Accept-Ranges": "bytes", "Content-Length": "572380", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:00.121276Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20cmc%20postapproval%20manufacturing%20changes%20in%20annual%20reports.pdf", "anchor": "Guidance for Industry: CMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/844c5034e3_gfi cmc postapproval manufacturing changes in annual reports.pdf", "size": 455614, "headers": {"Date": "Thu, 04 Sep 2025 07:44:00 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:51 GMT", "ETag": "\"6f3be-63c8b01f54c0b\"", "Accept-Ranges": "bytes", "Content-Length": "455614", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:00.433459Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20advanced%20manufacturing%20technologies%20designation%20program.pdf", "anchor": "Guidance for Industry: Advanced Manufacturing Technologies Designation Program (draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/922dc237f6_gfi advanced manufacturing technologies designation program.pdf", "size": 626394, "headers": {"Date": "Thu, 04 Sep 2025 07:44:00 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"98eda-63c8b01ec996f\"", "Accept-Ranges": "bytes", "Content-Length": "626394", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:00.741458Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20quality%20considerations%20for%20topical%20ophthalmic%20drug%20products%20draft%202023%2012.pdf", "anchor": "Guidance for Industry: Quality Considerations for Topical Ophthalmic Drug Products (draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/3821703758_gfi quality considerations for topical ophthalmic drug products draft 2023 12.pdf", "size": 642023, "headers": {"Date": "Thu, 04 Sep 2025 07:44:00 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"9cbe7-63c8b0209ddc7\"", "Accept-Ranges": "bytes", "Content-Length": "642023", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:01.047634Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gfi%20postapproval%20manufacturing%20changes%20to%20biosimilar%20and%20interchangeable%20biosimilar%20products%20draft.pdf", "anchor": "Guidance for Industry: Postapproval Manufacturing Changes to Biosimilar and Interchangeable Bisimilar Products (draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/96c6802afe_gfi postapproval manufacturing changes to biosimilar and interchangeable biosimilar products draft.pdf", "size": 578439, "headers": {"Date": "Thu, 04 Sep 2025 07:44:01 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:52 GMT", "ETag": "\"8d387-63c8b0207516b\"", "Accept-Ranges": "bytes", "Content-Length": "578439", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:01.346216Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20foreign%20pharm%20manufacturers.pdf", "anchor": "Guide \r\nto Inspections of Foreign Pharmaceutical Manufacturers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/d830a9c71b_gti foreign pharm manufacturers.pdf", "size": 459542, "headers": {"Date": "Thu, 04 Sep 2025 07:44:01 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"70316-63c8b02157697\"", "Accept-Ranges": "bytes", "Content-Length": "459542", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:01.631130Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20foreign%20medical%20device%20manufacturers.pdf", "anchor": "Guide \r\nto Inspections of Foreign Medical Device Manufacturers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7641b77a75_gti foreign medical device manufacturers.pdf", "size": 311684, "headers": {"Date": "Thu, 04 Sep 2025 07:44:01 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"4c184-63c8b0214e226\"", "Accept-Ranges": "bytes", "Content-Length": "311684", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:02.019591Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20computerized%20systems%20in%20drug%20establishments.pdf", "anchor": "Guide to Inspections of Computerized Systems in Drug Establishments | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/3590640966_gti computerized systems in drug establishments.pdf", "size": 856943, "headers": {"Date": "Thu, 04 Sep 2025 07:44:02 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"d136f-63c8b0213c4fc\"", "Accept-Ranges": "bytes", "Content-Length": "856943", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:02.323177Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20high%20purity%20water%20systems.pdf", "anchor": "Guide \r\nto Inspections of High Purity Water Systems | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/545660b09c_gti high purity water systems.pdf", "size": 606947, "headers": {"Date": "Thu, 04 Sep 2025 07:44:02 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"942e3-63c8b02161e8f\"", "Accept-Ranges": "bytes", "Content-Length": "606947", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:02.591534Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20sterile%20drug%20substance.pdf", "anchor": "Guide \r\nto Inspections of Sterile Drug Substance Manufacturers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0f3b7071d2_gti sterile drug substance.pdf", "size": 426442, "headers": {"Date": "Thu, 04 Sep 2025 07:44:02 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"681ca-63c8b02199934\"", "Accept-Ranges": "bytes", "Content-Length": "426442", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:02.886049Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20microbiological%20pharm%20qc.pdf", "anchor": "Guide \r\nto Inspections of Microbiologicla Pharmaceutical Quality Control \r\nLaboratories | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/2732a2e5c6_gti microbiological pharm qc.pdf", "size": 358915, "headers": {"Date": "Thu, 04 Sep 2025 07:44:02 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"57a03-63c8b021737d1\"", "Accept-Ranges": "bytes", "Content-Length": "358915", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:03.181360Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20lyophilization%20of%20parenterals.pdf", "anchor": "Guide to \r\nInspections of Lyophilization of Parenterals | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6006a45874_gti lyophilization of parenterals.pdf", "size": 603474, "headers": {"Date": "Thu, 04 Sep 2025 07:44:03 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"93552-63c8b0216af18\"", "Accept-Ranges": "bytes", "Content-Length": "603474", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:03.502629Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20pharmaceutical%20qc%20lab.pdf", "anchor": "Guide to \r\nInspections of Pharmaceutical Quality Control \r\nLaboratories | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/f8c532102c_gti pharmaceutical qc lab.pdf", "size": 567537, "headers": {"Date": "Thu, 04 Sep 2025 07:44:03 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"8a8f1-63c8b0219201c\"", "Accept-Ranges": "bytes", "Content-Length": "567537", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:03.775787Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20validation%20of%20cleaning%20processes.pdf", "anchor": "Guide to \r\nInspections of Validation of Cleaning Processes | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/3116a28de3_gti validation of cleaning processes.pdf", "size": 381925, "headers": {"Date": "Thu, 04 Sep 2025 07:44:03 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"5d3e5-63c8b021ad1b6\"", "Accept-Ranges": "bytes", "Content-Length": "381925", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:04.079159Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20dosage%20form%20drug%20manufacturers.pdf", "anchor": "Guide to \r\nInspections of Dosage Form Drug Manufacturers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/1ae6ba7a3b_gti dosage form drug manufacturers.pdf", "size": 655828, "headers": {"Date": "Thu, 04 Sep 2025 07:44:04 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"a01d4-63c8b0214596d\"", "Accept-Ranges": "bytes", "Content-Length": "655828", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:04.417297Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20oral%20solids.pdf", "anchor": "Guide to \r\nInspections of Oral Solid Dosage Forms Pre/Post Approval Issues for Development \r\n& Validation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/b8b60a563a_gti oral solids.pdf", "size": 687648, "headers": {"Date": "Thu, 04 Sep 2025 07:44:04 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"a7e20-63c8b0217d412\"", "Accept-Ranges": "bytes", "Content-Length": "687648", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:04.686076Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20topical%20drug%20products.pdf", "anchor": "Guide to \r\nInspections of Topical Drug Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/df2ec5c289_gti topical drug products.pdf", "size": 381083, "headers": {"Date": "Thu, 04 Sep 2025 07:44:04 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"5d09b-63c8b0219f6f5\"", "Accept-Ranges": "bytes", "Content-Length": "381083", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:04.965612Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/gti%20oral%20solutions%20and%20suspensions.pdf", "anchor": "Guide to \r\nInspections of Oral Solutions and Suspensions | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7113a35b14_gti oral solutions and suspensions.pdf", "size": 336348, "headers": {"Date": "Thu, 04 Sep 2025 07:44:05 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:53 GMT", "ETag": "\"521dc-63c8b02188f93\"", "Accept-Ranges": "bytes", "Content-Length": "336348", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:05.346930Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/guidelines/biotechnology%20inspection%20guide.pdf", "anchor": "Biotechnology \r\nInspection Guide: Reference Materials & Training \r\nAids | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/12376ec88d_biotechnology inspection guide.pdf", "size": 1127327, "headers": {"Date": "Thu, 04 Sep 2025 07:44:05 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:50 GMT", "ETag": "\"11339f-63c8b01ec0cce\"", "Accept-Ranges": "bytes", "Content-Length": "1127327", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:05.648578Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207345%20848%20inspection%20of%20biological%20drug%20products%202010%2010%201.pdf", "anchor": "Program No. 7345.848 Inspection of Biological Drug Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/fde0789f08_cpgm 7345 848 inspection of biological drug products 2010 10 1.pdf", "size": 458518, "headers": {"Date": "Thu, 04 Sep 2025 07:44:05 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"6ff16-63c8b01cb3a4a\"", "Accept-Ranges": "bytes", "Content-Length": "458518", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:05.911650Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207345%20848%20inspection%20of%20biological%20drug%20products%202010%2010%201%20kr.pdf", "anchor": "¹ø¿ª¹®(¿ø¹®+¹ø¿ª¹®) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/bd73f3e932_cpgm 7345 848 inspection of biological drug products 2010 10 1 kr.pdf", "size": 154462, "headers": {"Date": "Thu, 04 Sep 2025 07:44:06 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"25b5e-63c8b01ca0998\"", "Accept-Ranges": "bytes", "Content-Length": "154462", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:06.239536Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207346%20832%20preapproval%20inspections%202022%2010%2017.pdf", "anchor": "Program No. 7346.832 Preapproval Inspections (2022) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/eb85d44690_cpgm 7346 832 preapproval inspections 2022 10 17.pdf", "size": 709966, "headers": {"Date": "Thu, 04 Sep 2025 07:44:06 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"ad54e-63c8b01cd361d\"", "Accept-Ranges": "bytes", "Content-Length": "709966", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:06.491538Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207346%20832%20preapproval%20inspections%202022%2010%2017%20kr.pdf", "anchor": "¹ø¿ª¹®(¿ø¹®+¹ø¿ª¹®) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e7f188cb81_cpgm 7346 832 preapproval inspections 2022 10 17 kr.pdf", "size": 307721, "headers": {"Date": "Thu, 04 Sep 2025 07:44:06 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"4b209-63c8b01cb9fdb\"", "Accept-Ranges": "bytes", "Content-Length": "307721", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:06.909207Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002%20drug%20manufacturing%20inspections%202022%2010%2017.pdf", "anchor": "Program No. 7356.002 Drug Manufacturing Inspections (2022) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/02e7a8e76c_cpgm 7356 002 drug manufacturing inspections 2022 10 17.pdf", "size": 1119196, "headers": {"Date": "Thu, 04 Sep 2025 07:44:06 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"1113dc-63c8b01cf418f\"", "Accept-Ranges": "bytes", "Content-Length": "1119196", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:07.155898Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002%20drug%20manufacturing%20inspections%202022%2010%2017%20kr.pdf", "anchor": "¹ø¿ª¹®(¿ø¹®+¹ø¿ª¹®) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4210bce643_cpgm 7356 002 drug manufacturing inspections 2022 10 17 kr.pdf", "size": 249586, "headers": {"Date": "Thu, 04 Sep 2025 07:44:07 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"3cef2-63c8b01cdc2bd\"", "Accept-Ranges": "bytes", "Content-Length": "249586", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:07.523237Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002a%20sterile%20drug%20processing%20inspections%202016%209%2011.pdf", "anchor": "Program No. 7356.002A Sterile Drug Process Inspections | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/de429b8822_cpgm 7356 002a sterile drug processing inspections 2016 9 11.pdf", "size": 958355, "headers": {"Date": "Thu, 04 Sep 2025 07:44:07 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"e9f93-63c8b01d0c832\"", "Accept-Ranges": "bytes", "Content-Length": "958355", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:07.779873Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002a%20sterile%20drug%20process%20inspections%202015%209%2011%20kr.pdf", "anchor": "¹ø¿ª¹®(¿ø¹®+¹ø¿ª¹®) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/9d8821661a_cpgm 7356 002a sterile drug process inspections 2015 9 11 kr.pdf", "size": 157084, "headers": {"Date": "Thu, 04 Sep 2025 07:44:07 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"2659c-63c8b01cfa338\"", "Accept-Ranges": "bytes", "Content-Length": "157084", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:08.099186Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002f%20api%20process%20inspection%202015%209%2011.pdf", "anchor": "Program No. 7356.002F Active Pharmaceutical Ingredients | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/bde09cda80_cpgm 7356 002f api process inspection 2015 9 11.pdf", "size": 738725, "headers": {"Date": "Thu, 04 Sep 2025 07:44:08 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"b45a5-63c8b01d22f93\"", "Accept-Ranges": "bytes", "Content-Length": "738725", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:08.350812Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cpgm%207356%20002f%20api%20process%20inspection%202015%209%2011%20kr.pdf", "anchor": "¹ø¿ª¹®(¿ø¹®+¹ø¿ª¹®) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/baf6844989_cpgm 7356 002f api process inspection 2015 9 11 kr.pdf", "size": 146254, "headers": {"Date": "Thu, 04 Sep 2025 07:44:08 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"23b4e-63c8b01d1220a\"", "Accept-Ranges": "bytes", "Content-Length": "146254", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:08.725508Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20002m%20surveillance%20inspections%20of%20protein%20DS%20manufacturers%202021%2010%201.pdf", "anchor": "Program No. 7356.002M Surveillance Inspections of Protein Drug Substance Manufacturers (2021) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8a9d95ec0b_cp 7356 002m surveillance inspections of protein DS manufacturers 2021 10 1.pdf", "size": 962588, "headers": {"Date": "Thu, 04 Sep 2025 07:44:08 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"eb01c-63c8b01c7c775\"", "Accept-Ranges": "bytes", "Content-Length": "962588", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:08.992830Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20002m%20surveillance%20inspections%20of%20protein%20drug%20substance%20manufacturers%202021%2010%201%20kr.pdf", "anchor": "¹ø¿ª¹®(¿ø¹®+¹ø¿ª¹®) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/96182a941f_cp 7356 002m surveillance inspections of protein drug substance manufacturers 2021 10 1 kr.pdf", "size": 343496, "headers": {"Date": "Thu, 04 Sep 2025 07:44:09 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"53dc8-63c8b01c5fe6b\"", "Accept-Ranges": "bytes", "Content-Length": "343496", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:09.308827Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20843%20postapproval%20inspections%202023%203%2013.pdf", "anchor": "Program No. 7356.843 Postapproval Inspections (2023) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8d7d76a6d1_cp 7356 843 postapproval inspections 2023 3 13.pdf", "size": 606271, "headers": {"Date": "Thu, 04 Sep 2025 07:44:09 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"9403f-63c8b01c9a020\"", "Accept-Ranges": "bytes", "Content-Length": "606271", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:09.578074Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpgm/cp%207356%20843%20postapproval%20inspections%202023%203%2013%20kr.pdf", "anchor": "¹ø¿ª¹®(¿ø¹®+¹ø¿ª¹®) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/40f1d4fcdb_cp 7356 843 postapproval inspections 2023 3 13 kr.pdf", "size": 261808, "headers": {"Date": "Thu, 04 Sep 2025 07:44:09 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"3feb0-63c8b01c8408e\"", "Accept-Ranges": "bytes", "Content-Length": "261808", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:09.830128Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20130%20300%20fda%20access%20to%20audit%20results.pdf", "anchor": "Sec. 130.300 FDA Access to Results of Quality\r\nAssurance Program Audits and Inspections (CPG 7151.02) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/731d3718ed_cpg sec 130 300 fda access to audit results.pdf", "size": 156716, "headers": {"Date": "Thu, 04 Sep 2025 07:44:09 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2642c-63c8b01c31c1f\"", "Accept-Ranges": "bytes", "Content-Length": "156716", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:10.068170Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20100%20cgmp%20applicatibility%20to%20hardware%20and%20software.pdf", "anchor": "Sec.425.100 Computerized Drug Processing; CGMP Applicability To \r\nHardware and Software (CPG 7132a.11) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/de590c4e64_cpg sec 425 100 cgmp applicatibility to hardware and software.pdf", "size": 138486, "headers": {"Date": "Thu, 04 Sep 2025 07:44:10 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"21cf6-63c8b01c38d68\"", "Accept-Ranges": "bytes", "Content-Length": "138486", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:10.318914Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20200%20vendor%20responsibility.pdf", "anchor": "Sec.425.200 Computerized Drug Processing; Vendor Responsibility \r\n(CPG 7132a.12) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/335c51af9b_cpg sec 425 200 vendor responsibility.pdf", "size": 138137, "headers": {"Date": "Thu, 04 Sep 2025 07:44:10 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"21b99-63c8b01c3f2f8\"", "Accept-Ranges": "bytes", "Content-Length": "138137", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:10.578754Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20300%20source%20code%20for%20process%20control%20application%20program.pdf", "anchor": "Sec.425.300 Computerized Drug Processing; Source Code for Process \r\nControl Application Programs (CPG 7132a.15) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/80506bf4e2_cpg sec 425 300 source code for process control application program.pdf", "size": 162333, "headers": {"Date": "Thu, 04 Sep 2025 07:44:10 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"27a1d-63c8b01c450b9\"", "Accept-Ranges": "bytes", "Content-Length": "162333", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:10.817004Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20400%20input%20output%20checking.pdf", "anchor": "Sec.425.400 Computerized Drug Processing; Input/Output Checking \r\n(CPG 7132a.07) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c89c064949_cpg sec 425 400 input output checking.pdf", "size": 148312, "headers": {"Date": "Thu, 04 Sep 2025 07:44:10 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"24358-63c8b01c4ba31\"", "Accept-Ranges": "bytes", "Content-Length": "148312", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:11.066633Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpg%20sec%20425%20500%20identification%20of%20persons%20on%20batch%20records.pdf", "anchor": "Sec.425.500 Computerized Drug Processing; Identification of \r\n\"Persons\" on Batch Production and Control Records (CPG 7132a.08) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/9b1dbbbd79_cpg sec 425 500 identification of persons on batch records.pdf", "size": 143180, "headers": {"Date": "Thu, 04 Sep 2025 07:44:11 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"22f4c-63c8b01c50082\"", "Accept-Ranges": "bytes", "Content-Length": "143180", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:11.328084Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cpg/cpgsec490100.pdf", "anchor": "Sec.490.100 Process Validation Requirements for Drug Products & \r\nActive Pharmaceutical Ingredients Subject to Pre-Market Approval (CPG \r\n7132c.08) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6e8f03fc21_cpgsec490100.pdf", "size": 288836, "headers": {"Date": "Thu, 04 Sep 2025 07:44:11 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:48 GMT", "ETag": "\"46844-63c8b01c5799a\"", "Accept-Ranges": "bytes", "Content-Length": "288836", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:11.901666Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20introduction%202011.pdf", "anchor": "Introduction | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/c1cfb71e45_eu gmp guide introduction 2011.pdf", "size": 192313, "headers": {"Date": "Thu, 04 Sep 2025 07:44:11 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"2ef39-63c8b015e8d67\"", "Accept-Ranges": "bytes", "Content-Length": "192313", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:12.173323Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%201%20pharmaceutical%20quality%20system.pdf", "anchor": "Pharmaceutical Quality System | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Pharmaceutical Quality System (2013³â 1¿ù 31ÀÏ ½ÃÇà)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/5cef89e3a7_eu gmp guide chapter 1 pharmaceutical quality system.pdf", "size": 362385, "headers": {"Date": "Thu, 04 Sep 2025 07:44:12 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"58791-63c8b0159de29\"", "Accept-Ranges": "bytes", "Content-Length": "362385", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:12.445842Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%202%20personnel%20effective%20from%202014%202%2016.pdf", "anchor": "Personnel | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Personnel (2014³â 2¿ù 16ÀÏ ½ÃÇà)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/d303aa3efb_eu gmp guide chapter 2 personnel effective from 2014 2 16.pdf", "size": 303665, "headers": {"Date": "Thu, 04 Sep 2025 07:44:12 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"4a231-63c8b015a5359\"", "Accept-Ranges": "bytes", "Content-Length": "303665", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:12.720307Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%203%20premises%20and%20equipment%202015%203%201.pdf", "anchor": "Premises and Equipment | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/de861ba0af_eu gmp guide chapter 3 premises and equipment 2015 3 1.pdf", "size": 296025, "headers": {"Date": "Thu, 04 Sep 2025 07:44:12 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"48459-63c8b015ac0ba\"", "Accept-Ranges": "bytes", "Content-Length": "296025", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:13.000215Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%204%20documentation%202011.pdf", "anchor": "Documentation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Documentation (revision January 2011)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/dc690be2a4_eu gmp guide chapter 4 documentation 2011.pdf", "size": 402376, "headers": {"Date": "Thu, 04 Sep 2025 07:44:13 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"623c8-63c8b015b2e1a\"", "Accept-Ranges": "bytes", "Content-Length": "402376", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:13.276146Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%205%20production%202015%203%201.pdf", "anchor": "Production | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/0b26bc7349_eu gmp guide chapter 5 production 2015 3 1.pdf", "size": 482149, "headers": {"Date": "Thu, 04 Sep 2025 07:44:13 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"75b65-63c8b015bbea3\"", "Accept-Ranges": "bytes", "Content-Length": "482149", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:13.533150Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%206%20quality%20control%202014.pdf", "anchor": "Quality Contro | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Quality Contro l (2014³â 10¿ù 1ÀÏ ½ÃÇà)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/1722a51ea8_eu gmp guide chapter 6 quality control 2014.pdf", "size": 352481, "headers": {"Date": "Thu, 04 Sep 2025 07:44:13 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"560e1-63c8b015cc45c\"", "Accept-Ranges": "bytes", "Content-Length": "352481", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:13.781486Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%207%20outsourced%20activities.pdf", "anchor": "Outsourced Activities (2013³â 1¿ù 31ÀÏ ½ÃÇà) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/9d0f3160d2_eu gmp guide chapter 7 outsourced activities.pdf", "size": 248887, "headers": {"Date": "Thu, 04 Sep 2025 07:44:13 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"3cc37-63c8b015d492d\"", "Accept-Ranges": "bytes", "Content-Length": "248887", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:14.060655Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%208%20complaints%20quality%20defects%20and%20product%20recalls%202015%203%201.pdf", "anchor": "Complaints, Quality Defects and Product \r\nRecalls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/367aaf4ede_eu gmp guide chapter 8 complaints quality defects and product recalls 2015 3 1.pdf", "size": 314742, "headers": {"Date": "Thu, 04 Sep 2025 07:44:14 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"4cd76-63c8b015dba76\"", "Accept-Ranges": "bytes", "Content-Length": "314742", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:14.305518Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20chapter%209.pdf", "anchor": "Self Inspection | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/60e4e24e46_eu gmp guide chapter 9.pdf", "size": 124415, "headers": {"Date": "Thu, 04 Sep 2025 07:44:14 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"1e5ff-63c8b015e2fa6\"", "Accept-Ranges": "bytes", "Content-Length": "124415", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:14.567535Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/eu%20gmp%20guide%20part%202%202014%208%2013.pdf", "anchor": "Basic Requirements for Active Substances used as Starting Materials | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Basic Requirements for Active Substances used as Starting Materials (2014³â 9¿ù 1ÀÏ ½ÃÇà)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/171a90ac05_eu gmp guide part 2 2014 8 13.pdf", "size": 273613, "headers": {"Date": "Thu, 04 Sep 2025 07:44:14 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"42ccd-63c8b015f1238\"", "Accept-Ranges": "bytes", "Content-Length": "273613", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:14.885846Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20gmp%20part%203%20site%20master%20file.pdf", "anchor": "Site Master File | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/faeb121dea_eu gmp part 3 site master file.pdf", "size": 265312, "headers": {"Date": "Thu, 04 Sep 2025 07:44:14 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"40c60-63c8b0157981d\"", "Accept-Ranges": "bytes", "Content-Length": "265312", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:15.153435Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/template%20for%20the%20written%20confirmation%20for%20active%20substances%20exported%20to%20the%20EU%202013.pdf", "anchor": "Template for the 'written confirmation' for active substances exported to the European Union for medicinal products for human use | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/faec7707a0_template for the written confirmation for active substances exported to the EU 2013.pdf", "size": 146362, "headers": {"Date": "Thu, 04 Sep 2025 07:44:15 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"23bba-63c8b0160db42\"", "Accept-Ranges": "bytes", "Content-Length": "146362", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:15.432185Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/health%20based%20exposure%20limits%20for%20use%20in%20risk%20identification%20in%20the%20manufacture%20of%20different%20medicinal%20products%20in%20shared%20facilities.pdf", "anchor": "Guideline on setting health based exposure limits\r\nfor use in risk identification in the manufacture of different medicinal\r\nproducts in shared facilities | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/c8f5f0bc4d_health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities.pdf", "size": 399006, "headers": {"Date": "Thu, 04 Sep 2025 07:44:15 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"6169e-63c8b01631595\"", "Accept-Ranges": "bytes", "Content-Length": "399006", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:15.675918Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20formalized%20ra%20for%20ascertaining%20appropriate%20gmp%20for%20excipients%20of%20medicinal%20products%20for%20human%20use%202015%203%2019.pdf", "anchor": "Guideline of 19 March 2015 on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/3b6e5a0363_eu formalized ra for ascertaining appropriate gmp for excipients of medicinal products for human use 2015 3 19.pdf", "size": 265470, "headers": {"Date": "Thu, 04 Sep 2025 07:44:15 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"40cfe-63c8b01571f05\"", "Accept-Ranges": "bytes", "Content-Length": "265470", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:15.954771Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/guideline%20on%20the%20responsibilities%20of%20the%20sponsor.pdf", "anchor": "Guideline on the responsibilities of the sponsor with regard to handling and shipping of investigational medicinal products for human use in accordance with Good Clinical Practice and Good Manufacturing Practice | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/404acf936a_guideline on the responsibilities of the sponsor.pdf", "size": 322403, "headers": {"Date": "Thu, 04 Sep 2025 07:44:16 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"4eb63-63c8b01622364\"", "Accept-Ranges": "bytes", "Content-Length": "322403", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:16.371550Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/reflection%20paper%20on%20GMP%20and%20MAH%202022%20ver%202.pdf", "anchor": "Reflection paper on Good Manufacturing Practice and Marketing Authorisation Holders | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/cb0389d07f_reflection paper on GMP and MAH 2022 ver 2.pdf", "size": 1307339, "headers": {"Date": "Thu, 04 Sep 2025 07:44:16 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"13f2cb-63c8b016403de\"", "Accept-Ranges": "bytes", "Content-Length": "1307339", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:16.649369Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%201%20manufacture%20of%20sterile%20medicinal%20products%202022%2008%2022%20final%20revision.pdf", "anchor": "Manufacture of Sterile Medicinal \r\nProducts | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Manufacture of Sterile Medicinal \r\nProducts (2022.8.22)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/5d8c2f954f_annex 1 manufacture of sterile medicinal products 2022 08 22 final revision.pdf", "size": 241382, "headers": {"Date": "Thu, 04 Sep 2025 07:44:16 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"3aee6-63c8b014e39a1\"", "Accept-Ranges": "bytes", "Content-Length": "241382", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:16.903568Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%202%20manufacture%20of%20biological%20active%20substances%20and%20medicinal%20products%20for%20human%20use%202018%206%2026.pdf", "anchor": "Manufacture of Biological Medicinal Products for Human \r\nUse | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Manufacture of Biological Medicinal Products for Human \r\nUse (26 June 2018)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/2ae4cf0eb7_annex 2 manufacture of biological active substances and medicinal products for human use 2018 6 26.pdf", "size": 121969, "headers": {"Date": "Thu, 04 Sep 2025 07:44:17 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"1dc71-63c8b0152ecc7\"", "Accept-Ranges": "bytes", "Content-Length": "121969", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:17.153576Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%203%20manufacture%20of%20radiopharmaceuticals.pdf", "anchor": "Manufacture of \r\nRadiopharmaceuticals | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/17ab9f4b09_annex 3 manufacture of radiopharmaceuticals.pdf", "size": 287757, "headers": {"Date": "Thu, 04 Sep 2025 07:44:17 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"4640d-63c8b01541d79\"", "Accept-Ranges": "bytes", "Content-Length": "287757", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:17.382841Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%204%20manufacture%20of%20veterinary%20medicinal%20products%20other%20than%20immunological%20ones.pdf", "anchor": "Manufacture of \r\nVeterinary Medicinal Products other than Immunological Veterinary Medicinal \r\nProducts | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/7a92f17f61_annex 4 manufacture of veterinary medicinal products other than immunological ones.pdf", "size": 135379, "headers": {"Date": "Thu, 04 Sep 2025 07:44:17 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"210d3-63c8b01546f81\"", "Accept-Ranges": "bytes", "Content-Length": "135379", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:17.641276Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%205%20manufacture%20of%20immunological%20veterinary%20medicinal%20products.pdf", "anchor": "Manufacture of \r\nImmunological Venterinary Medicinal Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/9fc971c305_annex 5 manufacture of immunological veterinary medicinal products.pdf", "size": 377208, "headers": {"Date": "Thu, 04 Sep 2025 07:44:17 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"5c178-63c8b0154e89a\"", "Accept-Ranges": "bytes", "Content-Length": "377208", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:17.932802Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%206%20manufacture%20of%20medicinal%20gases.pdf", "anchor": "Manufacture of \r\nMedicinal Gases | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/fad5acd98d_annex 6 manufacture of medicinal gases.pdf", "size": 386529, "headers": {"Date": "Thu, 04 Sep 2025 07:44:18 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"5e5e1-63c8b01557d0b\"", "Accept-Ranges": "bytes", "Content-Length": "386529", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:18.175511Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%207%20manufacture%20of%20herbal%20medicinal%20products%202009%209%2001.pdf", "anchor": "Manufacture of \r\nHerbal Medicinal Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/bd8975879a_annex 7 manufacture of herbal medicinal products 2009 9 01.pdf", "size": 220277, "headers": {"Date": "Thu, 04 Sep 2025 07:44:18 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"35c75-63c8b0155e29b\"", "Accept-Ranges": "bytes", "Content-Length": "220277", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:18.415430Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%208%20sampling%20of%20starting%20and%20packaging%20materials.pdf", "anchor": "Sampling of Starting and Packaging \r\nMaterials | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/9bbda906bb_annex 8 sampling of starting and packaging materials.pdf", "size": 178919, "headers": {"Date": "Thu, 04 Sep 2025 07:44:18 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"2bae7-63c8b01564ffc\"", "Accept-Ranges": "bytes", "Content-Length": "178919", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:18.648710Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%209%20manufacture%20of%20liquids%20creams%20and%20ointments.pdf", "anchor": "Manufacture of Liquids, Creams and \r\nOintments | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/949ef81fde_annex 9 manufacture of liquids creams and ointments.pdf", "size": 160961, "headers": {"Date": "Thu, 04 Sep 2025 07:44:18 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"274c1-63c8b0156a9d4\"", "Accept-Ranges": "bytes", "Content-Length": "160961", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:18.921859Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2010%20manufacture%20of%20pressurised%20metered%20dose%20aerosol.pdf", "anchor": "Manufacture of Pressurized Metered Dose Aerosol \r\nPreparations for Inhalation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/2af8567e88_annex 10 manufacture of pressurised metered dose aerosol.pdf", "size": 174451, "headers": {"Date": "Thu, 04 Sep 2025 07:44:19 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"2a973-63c8b014e9761\"", "Accept-Ranges": "bytes", "Content-Length": "174451", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:19.167756Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2011%20computerised%20systems%202011.pdf", "anchor": "Computerized Systems (revision January 2011) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/601e0ac78e_annex 11 computerised systems 2011.pdf", "size": 302006, "headers": {"Date": "Thu, 04 Sep 2025 07:44:19 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"49bb6-63c8b014f107a\"", "Accept-Ranges": "bytes", "Content-Length": "302006", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:19.419528Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2012%20use%20of%20inonising%20radiation%20in%20the%20manufacture%20of%20medicinal%20products.pdf", "anchor": "Use of Ionising \r\nRadiation in the Manufacture of Medicinal \r\nProducts | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/35de33421d_annex 12 use of inonising radiation in the manufacture of medicinal products.pdf", "size": 267519, "headers": {"Date": "Thu, 04 Sep 2025 07:44:19 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"414ff-63c8b014f954b\"", "Accept-Ranges": "bytes", "Content-Length": "267519", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:19.716537Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2013%20manufacture%20of%20investigational%20medicinal%20products%202010%202%203.pdf", "anchor": "Manufacture of \r\nInvestigational Medicinal Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7e8633d0bf_annex 13 manufacture of investigational medicinal products 2010 2 3.pdf", "size": 601586, "headers": {"Date": "Thu, 04 Sep 2025 07:44:19 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"92df2-63c8b0150395b\"", "Accept-Ranges": "bytes", "Content-Length": "601586", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:20.019228Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/guidelines%20on%20gmp%20for%20investigational%20medicinal%20products%20for%20human%20use.pdf", "anchor": "Detailed Commission guideline on the good manufacturing practice for investigational medicinal products pursuant to the second paragraph of the Article 63(1) of Regulation (EU) No 536/2014 | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c932d706aa_guidelines on gmp for investigational medicinal products for human use.pdf", "size": 519198, "headers": {"Date": "Thu, 04 Sep 2025 07:44:20 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"7ec1e-63c8b0162a064\"", "Accept-Ranges": "bytes", "Content-Length": "519198", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:20.287850Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2014%20manufacture%20of%20products%20derived%20from%20human%20blood%20or%20human%20plasma2011%2011.pdf", "anchor": "Manufacture of Products derived from Human Blood or \r\nHuman Plasma | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Manufacture of Products derived from Human Blood or \r\nHuman Plasma (2011³â 11¿ù 30ÀÏ ½ÃÇà)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/ab36d3fa11_annex 14 manufacture of products derived from human blood or human plasma2011 11.pdf", "size": 423232, "headers": {"Date": "Thu, 04 Sep 2025 07:44:20 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"67540-63c8b0150ae8c\"", "Accept-Ranges": "bytes", "Content-Length": "423232", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:20.609890Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2015%20qualification%20and%20validation%202015%20final.pdf", "anchor": "Qualification and Validation (2015³â 10¿ù 1ÀÏ ½ÃÇà) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/0646aa1d61_annex 15 qualification and validation 2015 final.pdf", "size": 590024, "headers": {"Date": "Thu, 04 Sep 2025 07:44:20 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"900c8-63c8b01512b8d\"", "Accept-Ranges": "bytes", "Content-Length": "590024", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:20.922485Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2016%20certification%20by%20a%20qualified%20person%20and%20batch%20release%202015%2010%2012.pdf", "anchor": "Certification by \r\na Qualified person and Batch Release (2016³â 4¿ù 15ÀÏ ½ÃÇà) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/76999d0184_annex 16 certification by a qualified person and batch release 2015 10 12.pdf", "size": 389755, "headers": {"Date": "Thu, 04 Sep 2025 07:44:20 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"5f27b-63c8b0151a4a5\"", "Accept-Ranges": "bytes", "Content-Length": "389755", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:21.189780Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2017%20real%20time%20release%20testing%20and%20parametric%20release%202018%2012%2026.pdf", "anchor": "Real Time Release Testing and Parametric \r\nRelease (2018³â 12¿ù 26ÀÏ ½ÃÇà) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/b550422c40_annex 17 real time release testing and parametric release 2018 12 26.pdf", "size": 347275, "headers": {"Date": "Thu, 04 Sep 2025 07:44:21 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"54c8b-63c8b01521dbe\"", "Accept-Ranges": "bytes", "Content-Length": "347275", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:21.460985Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2019%20reference%20and%20retention%20samples.pdf", "anchor": "Reference \r\nSamples and Retention Samples | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Reference \r\nSamples and Retention Samples (December 2005)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/98112b941f_annex 19 reference and retention samples.pdf", "size": 282212, "headers": {"Date": "Thu, 04 Sep 2025 07:44:21 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"44e64-63c8b01529ea7\"", "Accept-Ranges": "bytes", "Content-Length": "282212", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:21.705537Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2021%20importation%20of%20medicinal%20products%202022%2002%2016.pdf", "anchor": "Importation of Medicinal Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Importation of Medicinal Products (2022³â 8¿ù 21ÀÏ ½ÃÇà)", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/922340716d_annex 21 importation of medicinal products 2022 02 16.pdf", "size": 212529, "headers": {"Date": "Thu, 04 Sep 2025 07:44:21 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"33e31-63c8b015365e0\"", "Accept-Ranges": "bytes", "Content-Length": "212529", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:21.967186Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/annex%2022%20artificial%20intelligence%202025%207.pdf", "anchor": "Artificial Intelligence (draft) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/eb5a039b84_annex 22 artificial intelligence 2025 7.pdf", "size": 357521, "headers": {"Date": "Thu, 04 Sep 2025 07:44:22 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"57491-63c8b0153ac30\"", "Accept-Ranges": "bytes", "Content-Length": "357521", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:22.218974Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eugmp/Glossary.pdf", "anchor": "Glossary | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/dd8491c5c0_Glossary.pdf", "size": 305043, "headers": {"Date": "Thu, 04 Sep 2025 07:44:22 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"4a793-63c8b01607999\"", "Accept-Ranges": "bytes", "Content-Length": "305043", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:22.485394Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20gmp%20part%204%20gmp%20for%20advanced%20therapy%20medicinal%20products.pdf", "anchor": "Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/e923f1f330_eu gmp part 4 gmp for advanced therapy medicinal products.pdf", "size": 304685, "headers": {"Date": "Thu, 04 Sep 2025 07:44:22 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"4a62d-63c8b01581136\"", "Accept-Ranges": "bytes", "Content-Length": "304685", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:22.737036Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20good%20distribution%20practice%20of%20medicinal%20products%20for%20human%20use%202013%2011%205.pdf", "anchor": "Guidelines on Good Distribution Practice of Medicinal Products for Human Use | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/62faec92ff_eu good distribution practice of medicinal products for human use 2013 11 5.pdf", "size": 114063, "headers": {"Date": "Thu, 04 Sep 2025 07:44:22 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"1bd8f-63c8b01592e60\"", "Accept-Ranges": "bytes", "Content-Length": "114063", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:22.975777Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/eu%20good%20distribution%20practice%20of%20active%20substances%20for%20medicinal%20products%20for%20human%20use%202015%203%2019.pdf", "anchor": "Gudelines of 19 March 2015 on principles of Good Distribution Practice of active substances for medicinal products for human use | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/c118b4172a_eu good distribution practice of active substances for medicinal products for human use 2015 3 19.pdf", "size": 93831, "headers": {"Date": "Thu, 04 Sep 2025 07:44:23 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"16e87-63c8b01586727\"", "Accept-Ranges": "bytes", "Content-Length": "93831", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:23.255656Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/guidance%20related%20to%20GMP%20GDP%20and%20PMF%20distant%20assessments.pdf", "anchor": "Guidance related to GMP/GDP and PMF distant assessments | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/e34fda6f3e_guidance related to GMP GDP and PMF distant assessments.pdf", "size": 409974, "headers": {"Date": "Thu, 04 Sep 2025 07:44:23 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"64176-63c8b0161c1bb\"", "Accept-Ranges": "bytes", "Content-Length": "409974", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:23.510921Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/gmp/gmp%20requirements%20applicable%20to%20the%20early%20manufacturing%20stpes%20for%20comminuted%20plants%20and%20herbal%20extracts.pdf", "anchor": "GMP requirements applicable to the early manufacturing steps for comminuted plants and herbal extracts used as active substances | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/37e0bb2207_gmp requirements applicable to the early manufacturing stpes for comminuted plants and herbal extracts.pdf", "size": 117362, "headers": {"Date": "Thu, 04 Sep 2025 07:44:23 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"1ca72-63c8b0161351a\"", "Accept-Ranges": "bytes", "Content-Length": "117362", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:24.304551Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/EC%20guidelines%20on%20the%20details%20of%20the%20various%20categories%20of%20variations.pdf", "anchor": "EU variations guidelines - Guidelines on the details of the various categories of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/9f5c19c5bd_EC guidelines on the details of the various categories of variations.pdf", "size": 1930106, "headers": {"Date": "Thu, 04 Sep 2025 07:44:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"1d737a-63c8b0166f5ca\"", "Accept-Ranges": "bytes", "Content-Length": "1930106", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:24.546556Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/EC%20guidelines%20on%20the%20details%20of%20the%20various%20categories%20of%20variations%20kr%20annex.pdf", "anchor": "¹ø¿ª¹® | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/dbe2f3212c_EC guidelines on the details of the various categories of variations kr annex.pdf", "size": 274349, "headers": {"Date": "Thu, 04 Sep 2025 07:44:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"42fad-63c8b01650d80\"", "Accept-Ranges": "bytes", "Content-Length": "274349", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:24.882843Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20the%20chemistry%20of%20active%20substances.pdf", "anchor": "Guideline on the Chemistry of New Active Substances | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/f6f8a31cc3_guideline on the chemistry of active substances.pdf", "size": 478883, "headers": {"Date": "Thu, 04 Sep 2025 07:44:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"74ea3-63c8b016b4360\"", "Accept-Ranges": "bytes", "Content-Length": "478883", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:25.160338Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Summary%20of%20Requirements%20for%20Active%20Substances.pdf", "anchor": "Guideline on Summary of Requirements for Active Substances in the Quality Part of the Dossier | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/3576165bd3_Summary of Requirements for Active Substances.pdf", "size": 344502, "headers": {"Date": "Thu, 04 Sep 2025 07:44:25 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"541b6-63c8b01731b3b\"", "Accept-Ranges": "bytes", "Content-Length": "344502", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:25.444317Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/reflection%20paper%20on%20selection%20of%20starting%20materials%20for%20manufacture%20of%20chemical%20active%20substances.pdf", "anchor": "Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/59e3f1ab4b_reflection paper on selection of starting materials for manufacture of chemical active substances.pdf", "size": 410803, "headers": {"Date": "Thu, 04 Sep 2025 07:44:25 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"644b3-63c8b01715a00\"", "Accept-Ranges": "bytes", "Content-Length": "410803", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:25.683486Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20on%20api%20mix.pdf", "anchor": "Quality Working Party questions and answers on API mix | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/8c13896491_q and a on api mix.pdf", "size": 183749, "headers": {"Date": "Thu, 04 Sep 2025 07:44:25 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"2cdc5-63c8b016f2b65\"", "Accept-Ranges": "bytes", "Content-Length": "183749", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:25.973006Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20process%20%20validation%20for%20finished%20products%20final.pdf", "anchor": "Guideline on Process Validation for Finished Products - information and data to be provided in regulatory submissions | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/fad66d0029_guideline on process  validation for finished products final.pdf", "size": 565555, "headers": {"Date": "Thu, 04 Sep 2025 07:44:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"8a133-63c8b01699996\"", "Accept-Ranges": "bytes", "Content-Length": "565555", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:26.269934Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20manufacture%20of%20the%20finished%20dosage%20form.pdf", "anchor": "Guideline on Manufacture of the Finished Dosage Form | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/2b41e56115_guideline on manufacture of the finished dosage form.pdf", "size": 426273, "headers": {"Date": "Thu, 04 Sep 2025 07:44:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"68121-63c8b0168fd55\"", "Accept-Ranges": "bytes", "Content-Length": "426273", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:26.495948Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Start%20Of%20Shelf%20Life%20Of%20the%20Finished%20Dosage%20Form.pdf", "anchor": "Annex: Start of Shelf-Life of the Finished Dosage Form | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/1f1c23bfd9_Start Of Shelf Life Of the Finished Dosage Form.pdf", "size": 92842, "headers": {"Date": "Thu, 04 Sep 2025 07:44:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"16aaa-63c8b017238aa\"", "Accept-Ranges": "bytes", "Content-Length": "92842", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:26.891776Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20the%20sterilization%20of%20the%20medicinal%20product%20active%20substance%20excipient%20and%20primary%20container.pdf", "anchor": "Guideline on the Sterilisation of the Medicinal Product, Active Substance, Excipient and Primary Container | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/cc4a757499_guideline on the sterilization of the medicinal product active substance excipient and primary container.pdf", "size": 932638, "headers": {"Date": "Thu, 04 Sep 2025 07:44:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"e3b1e-63c8b016c7fca\"", "Accept-Ranges": "bytes", "Content-Length": "932638", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:27.162383Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/real%20time%20release%20testing%20final.pdf", "anchor": "Guideline on Real Time Release Testing (formerly Guideline on Parametric Release) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/1e7dec8332_real time release testing final.pdf", "size": 455758, "headers": {"Date": "Thu, 04 Sep 2025 07:44:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"6f44e-63c8b0170e8b8\"", "Accept-Ranges": "bytes", "Content-Length": "455758", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:27.410500Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/nir%20spectroscopy%20data%20requirements%20for%20new%20submissions%20and%20variations%202014%201%2027.pdf", "anchor": "Use of Near Infrared Spectroscopy (NIRS) by the Pharmaceutical Industry and the Data Requirements for New Submissions and Variations | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/282638f1e3_nir spectroscopy data requirements for new submissions and variations 2014 1 27.pdf", "size": 132062, "headers": {"Date": "Thu, 04 Sep 2025 07:44:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"203de-63c8b016db84b\"", "Accept-Ranges": "bytes", "Content-Length": "132062", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:27.680095Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/addendum%20to%20nirs%20guideline%20defining%20the%20scope%20of%20an%20nirs%20procedure.pdf", "anchor": "Addendum to Guideline on the Use of Near Infrared Spectroscopy (NIRS) by the Pharmaceutical Industry and the Data Requirements for New Submissions and Variations: Defining the Scope of an NIRS Procedure | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/4049f7a20c_addendum to nirs guideline defining the scope of an nirs procedure.pdf", "size": 348983, "headers": {"Date": "Thu, 04 Sep 2025 07:44:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"55337-63c8b0164a7ef\"", "Accept-Ranges": "bytes", "Content-Length": "348983", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:27.957771Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20the%20quality%20of%20water%20for%20pharmaceutical%20use.pdf", "anchor": "Guideline on the Quality of Water for Pharmaceutical Use | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/532d1dfb60_guideline on the quality of water for pharmaceutical use.pdf", "size": 420470, "headers": {"Date": "Thu, 04 Sep 2025 07:44:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"66a76-63c8b016bb891\"", "Accept-Ranges": "bytes", "Content-Length": "420470", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:28.273734Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20production%20of%20wfi%20by%20non%20distillation%20methods.pdf", "anchor": "Questions and Answers on Production of Water for Injections by Non-distillation Methods - Reverse Osmosis and Biofilms and Control Strategies | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/3faa2a5941_q and a production of wfi by non distillation methods.pdf", "size": 586204, "headers": {"Date": "Thu, 04 Sep 2025 07:44:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"8f1dc-63c8b01705447\"", "Accept-Ranges": "bytes", "Content-Length": "586204", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:28.547793Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Excipients%20in%20the%20Dossier%20for%20Application.pdf", "anchor": "Guideline on Excipients in the Dossier for Application for Marketing Authorization of a Medicinal Product | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/3c99c3f5c8_Excipients in the Dossier for Application.pdf", "size": 406643, "headers": {"Date": "Thu, 04 Sep 2025 07:44:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"63473-63c8b0167ebe4\"", "Accept-Ranges": "bytes", "Content-Length": "406643", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:28.826879Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/plastic%20immediate%20packaging%20materials.pdf", "anchor": "Plastic Primary Packaging Materials | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/fbab31b7e5_plastic immediate packaging materials.pdf", "size": 419870, "headers": {"Date": "Thu, 04 Sep 2025 07:44:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"6681e-63c8b016e354c\"", "Accept-Ranges": "bytes", "Content-Length": "419870", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:29.059356Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/In%20Use%20Stability%20Testing.pdf", "anchor": "In-Use Stability Testing of Human Medicinal Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/ca8994c1da_In Use Stability Testing.pdf", "size": 156316, "headers": {"Date": "Thu, 04 Sep 2025 07:44:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"2629c-63c8b016cd9a2\"", "Accept-Ranges": "bytes", "Content-Length": "156316", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:29.320185Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/Maximum%20ShelfLife%20After%20Opening.pdf", "anchor": "Maximum Shelf-Life for Sterile Products for Human Use After First Opening or Following Reconstitution | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/2806ed7385_Maximum ShelfLife After Opening.pdf", "size": 185395, "headers": {"Date": "Thu, 04 Sep 2025 07:44:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"2d433-63c8b016d4ed3\"", "Accept-Ranges": "bytes", "Content-Length": "185395", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:29.611509Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/stability%20testing%20for%20applications%20for%20variations%20to%20a%20marketing%20authorization%202014.pdf", "anchor": "Guideline on Stability Testing for Applications for Variations to a Marketing Authorisation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/fd54643bc3_stability testing for applications for variations to a marketing authorization 2014.pdf", "size": 450030, "headers": {"Date": "Thu, 04 Sep 2025 07:44:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"6ddee-63c8b0171cf31\"", "Accept-Ranges": "bytes", "Content-Length": "450030", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:29.935173Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20development%20production%20characterisation%20and%20specification%20for%20monoclonal%20antibodies%20and%20related%20products.pdf", "anchor": "Development, Production, Characterisation and Specifications for Monoclonal Antibodies and Related Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/b7f1bb22bb_guideline on development production characterisation and specification for monoclonal antibodies and related products.pdf", "size": 437655, "headers": {"Date": "Thu, 04 Sep 2025 07:44:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"6ad97-63c8b016870b4\"", "Accept-Ranges": "bytes", "Content-Length": "437655", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:30.221961Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20process%20%20validation%20for%20the%20manufacture%20of%20biotechnology%20derived%20active%20substances.pdf", "anchor": "Process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/70809b9de2_guideline on process  validation for the manufacture of biotechnology derived active substances.pdf", "size": 480764, "headers": {"Date": "Thu, 04 Sep 2025 07:44:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"755fc-63c8b016a2637\"", "Accept-Ranges": "bytes", "Content-Length": "480764", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:30.492467Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20on%20comparability%20considerations%20for%20ATMP.pdf", "anchor": "Questions and answers on comparability considerations for advanced therapy medicinal products (ATMP) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/f712b56741_q and a on comparability considerations for ATMP.pdf", "size": 417767, "headers": {"Date": "Thu, 04 Sep 2025 07:44:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"65fe7-63c8b016fb41e\"", "Accept-Ranges": "bytes", "Content-Length": "417767", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:30.895856Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/guideline%20on%20quality%20documentation%20for%20medicinal%20products%20when%20used%20with%20a%20medical%20device.pdf", "anchor": "Guideline on quality documentation for medicinal products when used with a medical device | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/088fc86e42_guideline on quality documentation for medicinal products when used with a medical device.pdf", "size": 862686, "headers": {"Date": "Thu, 04 Sep 2025 07:44:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"d29de-63c8b016addd0\"", "Accept-Ranges": "bytes", "Content-Length": "862686", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:31.429765Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%201.pdf", "anchor": "Introduction | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/cf79aa6d66_ICH Q7 API GMP Guide Chapter 1.pdf", "size": 368259, "headers": {"Date": "Thu, 04 Sep 2025 07:44:31 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"59e83-63c8b0175652e\"", "Accept-Ranges": "bytes", "Content-Length": "368259", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:31.703981Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%202.pdf", "anchor": "Quality \r\nManagement | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/7f62b60eaa_ICH Q7 API GMP Guide Chapter 2.pdf", "size": 312301, "headers": {"Date": "Thu, 04 Sep 2025 07:44:31 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"4c3ed-63c8b017a85b5\"", "Accept-Ranges": "bytes", "Content-Length": "312301", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:31.972622Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%203.pdf", "anchor": "Personnel | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/d1ef345755_ICH Q7 API GMP Guide Chapter 3.pdf", "size": 270825, "headers": {"Date": "Thu, 04 Sep 2025 07:44:32 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"421e9-63c8b017b8b6e\"", "Accept-Ranges": "bytes", "Content-Length": "270825", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:32.244605Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%204.pdf", "anchor": "Buildings \r\nand Facilities | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/d506077f9b_ICH Q7 API GMP Guide Chapter 4.pdf", "size": 315508, "headers": {"Date": "Thu, 04 Sep 2025 07:44:32 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"4d074-63c8b017bf4e7\"", "Accept-Ranges": "bytes", "Content-Length": "315508", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:32.532654Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%205.pdf", "anchor": "Process \r\nEquipment | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/0ba339ea1e_ICH Q7 API GMP Guide Chapter 5.pdf", "size": 326639, "headers": {"Date": "Thu, 04 Sep 2025 07:44:32 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"4fbef-63c8b017c6247\"", "Accept-Ranges": "bytes", "Content-Length": "326639", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:32.808559Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%206.pdf", "anchor": "Documentation and Records | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/d488f5baf9_ICH Q7 API GMP Guide Chapter 6.pdf", "size": 358478, "headers": {"Date": "Thu, 04 Sep 2025 07:44:32 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"5784e-63c8b017cdb60\"", "Accept-Ranges": "bytes", "Content-Length": "358478", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:33.066359Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%207.pdf", "anchor": "Materials \r\nManagement | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/1806d7b0cf_ICH Q7 API GMP Guide Chapter 7.pdf", "size": 304862, "headers": {"Date": "Thu, 04 Sep 2025 07:44:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"4a6de-63c8b017d5479\"", "Accept-Ranges": "bytes", "Content-Length": "304862", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:33.317360Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%208.pdf", "anchor": "Production \r\nand In-Process Controls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/f71be619bf_ICH Q7 API GMP Guide Chapter 8.pdf", "size": 316454, "headers": {"Date": "Thu, 04 Sep 2025 07:44:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"4d426-63c8b017dbdf1\"", "Accept-Ranges": "bytes", "Content-Length": "316454", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:33.590733Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%209.pdf", "anchor": "Packaging and \r\nIdentification Labelling of APIs and Intermediates | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/b2ca0459a4_ICH Q7 API GMP Guide Chapter 9.pdf", "size": 282549, "headers": {"Date": "Thu, 04 Sep 2025 07:44:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"44fb5-63c8b017e2f3a\"", "Accept-Ranges": "bytes", "Content-Length": "282549", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:33.897619Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2010.pdf", "anchor": "Storage and \r\nDistribution | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/728ead0085_ICH Q7 API GMP Guide Chapter 10.pdf", "size": 271229, "headers": {"Date": "Thu, 04 Sep 2025 07:44:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"4237d-63c8b0175e22e\"", "Accept-Ranges": "bytes", "Content-Length": "271229", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:34.173850Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2011.pdf", "anchor": "Laboratory \r\nControls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/625fa5afb0_ICH Q7 API GMP Guide Chapter 11.pdf", "size": 341952, "headers": {"Date": "Thu, 04 Sep 2025 07:44:34 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"537c0-63c8b01765b47\"", "Accept-Ranges": "bytes", "Content-Length": "341952", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:34.452900Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2012.pdf", "anchor": "Validation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/2dc3395a02_ICH Q7 API GMP Guide Chapter 12.pdf", "size": 351591, "headers": {"Date": "Thu, 04 Sep 2025 07:44:34 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"55d67-63c8b0176cc90\"", "Accept-Ranges": "bytes", "Content-Length": "351591", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:34.729836Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2013.pdf", "anchor": "Change \r\nControl | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/6b933b411c_ICH Q7 API GMP Guide Chapter 13.pdf", "size": 271062, "headers": {"Date": "Thu, 04 Sep 2025 07:44:34 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"422d6-63c8b017739f0\"", "Accept-Ranges": "bytes", "Content-Length": "271062", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:34.980325Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2014.pdf", "anchor": "Rejection and \r\nRe-use of Materials | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/989b579c32_ICH Q7 API GMP Guide Chapter 14.pdf", "size": 292119, "headers": {"Date": "Thu, 04 Sep 2025 07:44:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"47517-63c8b0177af21\"", "Accept-Ranges": "bytes", "Content-Length": "292119", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:35.250871Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2015.pdf", "anchor": "Complaints and \r\nRecalls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/2a92371d9a_ICH Q7 API GMP Guide Chapter 15.pdf", "size": 257912, "headers": {"Date": "Thu, 04 Sep 2025 07:44:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"3ef78-63c8b017810c9\"", "Accept-Ranges": "bytes", "Content-Length": "257912", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:35.516412Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2016.pdf", "anchor": "Contract \r\nManufactures (including Laboratories) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/40b694b590_ICH Q7 API GMP Guide Chapter 16.pdf", "size": 269982, "headers": {"Date": "Thu, 04 Sep 2025 07:44:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"41e9e-63c8b01788212\"", "Accept-Ranges": "bytes", "Content-Length": "269982", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:35.800010Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2017.pdf", "anchor": "Agents, \r\nBrokers, Traders, Distributors, Repackers, and \r\nRelabellers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/9f2d358965_ICH Q7 API GMP Guide Chapter 17.pdf", "size": 291221, "headers": {"Date": "Thu, 04 Sep 2025 07:44:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"47195-63c8b017906e3\"", "Accept-Ranges": "bytes", "Content-Length": "291221", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:36.086416Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2018.pdf", "anchor": "Specific \r\nGuidance for APIs Manufactured by Cell \r\nCulture/Fermentation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/dd6a82e616_ICH Q7 API GMP Guide Chapter 18.pdf", "size": 339863, "headers": {"Date": "Thu, 04 Sep 2025 07:44:36 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"52f97-63c8b017987cb\"", "Accept-Ranges": "bytes", "Content-Length": "339863", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:36.363624Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2019.pdf", "anchor": "APIs for Use \r\nin Clinical Trials | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/d06123753a_ICH Q7 API GMP Guide Chapter 19.pdf", "size": 304733, "headers": {"Date": "Thu, 04 Sep 2025 07:44:36 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"4a65d-63c8b017a00e4\"", "Accept-Ranges": "bytes", "Content-Length": "304733", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:36.655246Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/ICH%20Q7%20API%20GMP%20Guide%20Chapter%2020.pdf", "anchor": "Glossary | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/ad22c57982_ICH Q7 API GMP Guide Chapter 20.pdf", "size": 364568, "headers": {"Date": "Thu, 04 Sep 2025 07:44:36 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"59018-63c8b017b0e6d\"", "Accept-Ranges": "bytes", "Content-Length": "364568", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:37.023295Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/gmp/Q7%20iwg%20q%20and%20a%2010%20june%202015.pdf", "anchor": "ICH Q7 Implementation Working Group - ICH Q7 Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients: Questions & Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/b4150c681b_Q7 iwg q and a 10 june 2015.pdf", "size": 873757, "headers": {"Date": "Thu, 04 Sep 2025 07:44:37 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"d551d-63c8b017ee2eb\"", "Accept-Ranges": "bytes", "Content-Length": "873757", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:37.574571Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4%20Organization%20of%20The%20Common%20Technical%20Document.pdf", "anchor": "Organization of The Common Technical Document for the Registration of Pharmaceuticals for Human Use | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/4110efe7e4_M4 Organization of The Common Technical Document.pdf", "size": 449263, "headers": {"Date": "Thu, 04 Sep 2025 07:44:37 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"6daef-63c8b017ff844\"", "Accept-Ranges": "bytes", "Content-Length": "449263", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:37.825085Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4%20Implementation%20Working%20Group%20Questions%20and%20Answers%20R3.pdf", "anchor": "M4 Implementation Working Group - M4 Questions & Answers (R3) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/3bafc41a6c_M4 Implementation Working Group Questions and Answers R3.pdf", "size": 304688, "headers": {"Date": "Thu, 04 Sep 2025 07:44:37 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"4a630-63c8b017f7373\"", "Accept-Ranges": "bytes", "Content-Length": "304688", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:38.134403Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4QR1%20The%20Common%20Technical%20Document%20Quality%20Part%20Module%202%20Module%203.pdf", "anchor": "The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality - Module 2: QOS & Module 3 | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/17e68d3980_M4QR1 The Common Technical Document Quality Part Module 2 Module 3.pdf", "size": 665290, "headers": {"Date": "Thu, 04 Sep 2025 07:44:38 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"a26ca-63c8b01814066\"", "Accept-Ranges": "bytes", "Content-Length": "665290", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:38.449897Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4Q%20Implementation%20Working%20Group%20Questions%20and%20Answers%20R1.pdf", "anchor": "M4Q Implementation Working Group - M4Q Questions & Answers (R1) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/0f0ee12087_M4Q Implementation Working Group Questions and Answers R1.pdf", "size": 689119, "headers": {"Date": "Thu, 04 Sep 2025 07:44:38 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"a83df-63c8b018088cd\"", "Accept-Ranges": "bytes", "Content-Length": "689119", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:38.703898Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/M4QR2%20The%20Common%20Technical%20Document%20Quality%20Part%20Draft%202025%205%2014.pdf", "anchor": "The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/fde35a1c85_M4QR2 The Common Technical Document Quality Part Draft 2025 5 14.pdf", "size": 290022, "headers": {"Date": "Thu, 04 Sep 2025 07:44:38 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"46ce6-63c8b0181adc6\"", "Accept-Ranges": "bytes", "Content-Length": "290022", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:38.972941Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1%20stability%20testing%20of%20new%20drug%20substances%20and%20drug%20products.pdf", "anchor": "Stability Testing of  \r\nDrug Substances and Drug Products (draft) (2025. 4. 11) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/4f714fee7e_Q1 stability testing of new drug substances and drug products.pdf", "size": 290262, "headers": {"Date": "Thu, 04 Sep 2025 07:44:39 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"46dd6-63c8b01822ac7\"", "Accept-Ranges": "bytes", "Content-Length": "290262", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:39.368465Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1AR2%20stability%20testing%20of%20new%20drug%20substances%20and%20dproducts.pdf", "anchor": "Stability Testing of New \r\nDrug Substances and Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/b9ef08be80_Q1AR2 stability testing of new drug substances and dproducts.pdf", "size": 636693, "headers": {"Date": "Thu, 04 Sep 2025 07:44:39 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"9b715-63c8b0186d61d\"", "Accept-Ranges": "bytes", "Content-Length": "636693", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:39.682574Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1B%20photostability%20testing%20of%20new%20drug%20substances%20and%20products.pdf", "anchor": "Stability \r\nTesting: Photostability Testing of New Drug \r\nSubstances and Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/5528867004_Q1B photostability testing of new drug substances and products.pdf", "size": 368427, "headers": {"Date": "Thu, 04 Sep 2025 07:44:39 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"59f2b-63c8b01875706\"", "Accept-Ranges": "bytes", "Content-Length": "368427", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:39.911896Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1C%20stability%20testing%20for%20new%20dosage%20forms.pdf", "anchor": "Sability Testing for New Dosage \r\nForms | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/ec3d80d853_Q1C stability testing for new dosage forms.pdf", "size": 119278, "headers": {"Date": "Thu, 04 Sep 2025 07:44:40 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"1d1ee-63c8b0187acf7\"", "Accept-Ranges": "bytes", "Content-Length": "119278", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:40.166042Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1D%20bracketing%20and%20matrixing%20designs%20for%20stability%20testing.pdf", "anchor": "Bracketing and Matrixing Designs for Stability Testing of New \r\nDrug Substances and Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/18654e001a_Q1D bracketing and matrixing designs for stability testing.pdf", "size": 300383, "headers": {"Date": "Thu, 04 Sep 2025 07:44:40 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"4955f-63c8b01881e3f\"", "Accept-Ranges": "bytes", "Content-Length": "300383", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:40.458843Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q1E%20evaluation%20for%20stability%20data.pdf", "anchor": "Evaluation for Stability Data | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/6a773d16d5_Q1E evaluation for stability data.pdf", "size": 577430, "headers": {"Date": "Thu, 04 Sep 2025 07:44:40 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"8cf96-63c8b0188d1f0\"", "Accept-Ranges": "bytes", "Content-Length": "577430", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:40.719447Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q2R2%20validation%20of%20analytical%20procedures%202023%2011%201.pdf", "anchor": "Validation of Analytical Procedures (2023. 11. 1.) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/93655f92ca_Q2R2 validation of analytical procedures 2023 11 1.pdf", "size": 245605, "headers": {"Date": "Thu, 04 Sep 2025 07:44:40 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"3bf65-63c8b01894721\"", "Accept-Ranges": "bytes", "Content-Length": "245605", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:40.978896Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5AR2%20viral%20safety%20evaluation%20of%20biotechnology%20products%20derived%20from%20cell%20lines%20of%20human%20or%20animal%20origin%202023%2011%201.pdf", "anchor": "Viral Safety Evaluation of Biotechnology Products Derived \r\nfrom Cell Lines of Human or Animal Origin | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Viral Safety Evaluation of Biotechnology Products Derived \r\nfrom Cell Lines of Human or Animal Origin (2023. 11. 1.)", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/0d31e5a210_Q5AR2 viral safety evaluation of biotechnology products derived from cell lines of human or animal origin 2023 11 1.pdf", "size": 334688, "headers": {"Date": "Thu, 04 Sep 2025 07:44:41 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"51b60-63c8b0189b869\"", "Accept-Ranges": "bytes", "Content-Length": "334688", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:41.252306Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5B%20analysis%20of%20expression%20construct%20in%20cells%20used%20for%20production.pdf", "anchor": "Quality of Biotechnological Products : Analysis of the \r\nExpression Construct in Cells Used for Production of r-DNA Derived Protein \r\nProducts | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/a74868bdad_Q5B analysis of expression construct in cells used for production.pdf", "size": 293378, "headers": {"Date": "Thu, 04 Sep 2025 07:44:41 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"47a02-63c8b018a25ca\"", "Accept-Ranges": "bytes", "Content-Length": "293378", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:41.526630Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5C%20stability%20testing%20of%20biotechnological%20biological%20products.pdf", "anchor": "Quality of Biotechnological Products: Stability Testing of \r\nBiotechnological/Biological Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/9cb1b07550_Q5C stability testing of biotechnological biological products.pdf", "size": 435628, "headers": {"Date": "Thu, 04 Sep 2025 07:44:41 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"6a5ac-63c8b018aa2cb\"", "Accept-Ranges": "bytes", "Content-Length": "435628", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:41.825106Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5D%20derivation%20and%20characterisation%20of%20cell%20substrates.pdf", "anchor": "Derivation and Characterization of Cell Substrates Used For \r\nProduction of Biotechnological/Biological Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/99c936260f_Q5D derivation and characterisation of cell substrates.pdf", "size": 492134, "headers": {"Date": "Thu, 04 Sep 2025 07:44:41 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"78266-63c8b018b23b3\"", "Accept-Ranges": "bytes", "Content-Length": "492134", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:42.127686Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q5E%20comparability%20biotech%20bio%20products%20subject%20to%20changes%20in%20manufacturing%20process.pdf", "anchor": "Comparability of Biotechnological/Biological Products Subject \r\nto Changes in Their Manufacturing Process | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/41fb3ef7d4_Q5E comparability biotech bio products subject to changes in manufacturing process.pdf", "size": 555943, "headers": {"Date": "Thu, 04 Sep 2025 07:44:42 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"87ba7-63c8b018ba0b4\"", "Accept-Ranges": "bytes", "Content-Length": "555943", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:42.520259Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q6A%20specifications%20for%20chemical%20drug%20substances%20and%20drug%20products.pdf", "anchor": "Specifications: Test Procedures & Acceptance Criteria \r\nfor New Drug Substances & New Drug Products: Chemical \r\nSubstances | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/73365eaf16_Q6A specifications for chemical drug substances and drug products.pdf", "size": 1164385, "headers": {"Date": "Thu, 04 Sep 2025 07:44:42 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"11c461-63c8b018c584d\"", "Accept-Ranges": "bytes", "Content-Length": "1164385", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:42.892732Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q6B%20specifications%20for%20biotechnological%20biological%20products.pdf", "anchor": "Specifications: Test Procedures and Acceptance\r\nCriteria for Biotechnological / Biological Products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/44bbc8065d_Q6B specifications for biotechnological biological products.pdf", "size": 739341, "headers": {"Date": "Thu, 04 Sep 2025 07:44:42 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"b480d-63c8b018d0816\"", "Accept-Ranges": "bytes", "Content-Length": "739341", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:43.250241Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q8%20R2%20Pharmaceutical%20Development%20Annex.pdf", "anchor": "Pharmaceutical Development | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/44cc9c3ed0_Q8 R2 Pharmaceutical Development Annex.pdf", "size": 935979, "headers": {"Date": "Thu, 04 Sep 2025 07:44:43 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"e482b-63c8b018e63c0\"", "Accept-Ranges": "bytes", "Content-Length": "935979", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:43.614953Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q9(R1)%20Quality%20Risk%20Management%202023%201%2018%20final.pdf", "anchor": "Quality Risk Management | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Quality Risk Management (2023. 1. 18.)", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/5cf78d03a6_Q9(R1) Quality Risk Management 2023 1 18 final.pdf", "size": 1018522, "headers": {"Date": "Thu, 04 Sep 2025 07:44:43 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"f8a9a-63c8b018f1b59\"", "Accept-Ranges": "bytes", "Content-Length": "1018522", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:44.001817Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q10%20pharmaceutical%20quality%20system.pdf", "anchor": "Pharmaceutical Quality System | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/2a183e3852_Q10 pharmaceutical quality system.pdf", "size": 819536, "headers": {"Date": "Thu, 04 Sep 2025 07:44:44 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"c8150-63c8b0182caf0\"", "Accept-Ranges": "bytes", "Content-Length": "819536", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:44.276645Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q8%20Q9%20Q10%20QNA%20R4%20Step%204%202010%20November.pdf", "anchor": "ICH Q8, Q9, Q10 Questions & Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/252521342a_Q8 Q9 Q10 QNA R4 Step 4 2010 November.pdf", "size": 472490, "headers": {"Date": "Thu, 04 Sep 2025 07:44:44 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"735aa-63c8b018db00f\"", "Accept-Ranges": "bytes", "Content-Length": "472490", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:44.593462Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/quality%20iwg%20ptc%20r2%20dec%206%202011.pdf", "anchor": "ICH Quality Implementation Working Group Points to Consider (R2): ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/e4c6a9e59c_quality iwg ptc r2 dec 6 2011.pdf", "size": 602023, "headers": {"Date": "Thu, 04 Sep 2025 07:44:44 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"92fa7-63c8b018fbb81\"", "Accept-Ranges": "bytes", "Content-Length": "602023", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:45.037206Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q11%20development%20and%20manufacture%20of%20drug%20substances%20step%204.pdf", "anchor": "Development and Manufacture of Drug Substances | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/6e22228962_Q11 development and manufacture of drug substances step 4.pdf", "size": 1080825, "headers": {"Date": "Thu, 04 Sep 2025 07:44:44 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"107df9-63c8b01839611\"", "Accept-Ranges": "bytes", "Content-Length": "1080825", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:45.430163Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q11%20iwg%20q%20and%20a%2023%20august%202017.pdf", "anchor": "ICH Q11 Questions & Answers | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/2e92c7a42e_Q11 iwg q and a 23 august 2017.pdf", "size": 1094089, "headers": {"Date": "Thu, 04 Sep 2025 07:44:45 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"10b1c9-63c8b0184557a\"", "Accept-Ranges": "bytes", "Content-Length": "1094089", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:45.685976Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q12%20pharmaceutical%20product%20lifecycle%20management%202019%2011%2020%20final.pdf", "anchor": "Technical & Regulatory Considerations for Pharmaceutical Product Lifecycle Management | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/e83549567b_Q12 pharmaceutical product lifecycle management 2019 11 20 final.pdf", "size": 187603, "headers": {"Date": "Thu, 04 Sep 2025 07:44:45 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"2dcd3-63c8b0184d27b\"", "Accept-Ranges": "bytes", "Content-Length": "187603", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:45.946484Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q12%20pharmaceutical%20product%20lifecycle%20management%20annex%202019%2011%2020.pdf", "anchor": "Annexes | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/d048b04d9e_Q12 pharmaceutical product lifecycle management annex 2019 11 20.pdf", "size": 217914, "headers": {"Date": "Thu, 04 Sep 2025 07:44:46 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"3533a-63c8b01854b93\"", "Accept-Ranges": "bytes", "Content-Length": "217914", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:46.206974Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q13%20continuous%20manufacturing%20of%20drug%20substances%20and%20drug%20products%20final%20version%202022%2011%2016.pdf", "anchor": "Continuous Manufacturing of Drug Substances and Drug Products (Final version, 2022. 11. 16.) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/8cb59912c0_Q13 continuous manufacturing of drug substances and drug products final version 2022 11 16.pdf", "size": 263092, "headers": {"Date": "Thu, 04 Sep 2025 07:44:46 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"403b4-63c8b0185c4ac\"", "Accept-Ranges": "bytes", "Content-Length": "263092", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:46.453550Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/ich/guidelines/Q14%20analytical%20procedure%20development%20final%202023%2011%201.pdf", "anchor": "Analytical Procedure Development (2023. 11. 1) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "ICH", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/ICH/29d3ca830d_Q14 analytical procedure development final 2023 11 1.pdf", "size": 241949, "headers": {"Date": "Thu, 04 Sep 2025 07:44:46 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:43 GMT", "ETag": "\"3b11d-63c8b01862e25\"", "Accept-Ranges": "bytes", "Content-Length": "241949", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:46.995105Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20introduction.pdf", "anchor": "Introduction | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/d90309691c_who gmp 2014 trs 986 introduction.pdf", "size": 189239, "headers": {"Date": "Thu, 04 Sep 2025 07:44:47 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2e337-63c8b02263f8d\"", "Accept-Ranges": "bytes", "Content-Length": "189239", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:47.275359Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20glossary.pdf", "anchor": "Glossary | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/381d1676c8_who gmp 2014 trs 986 glossary.pdf", "size": 175448, "headers": {"Date": "Thu, 04 Sep 2025 07:44:47 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2ad58-63c8b0225f93d\"", "Accept-Ranges": "bytes", "Content-Length": "175448", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:47.527451Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%201%20pharmaceutical%20quality%20system.pdf", "anchor": "Pharmaceutical quality system | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/a73cb5027e_who gmp 2014 trs 986 ch 1 pharmaceutical quality system.pdf", "size": 177314, "headers": {"Date": "Thu, 04 Sep 2025 07:44:47 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2b4a2-63c8b02210b7e\"", "Accept-Ranges": "bytes", "Content-Length": "177314", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:47.785453Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%202%20good%20manufacturing%20practices.pdf", "anchor": "Good manufacturing practices for pharmaceutical products | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/8187e67bb3_who gmp 2014 trs 986 ch 2 good manufacturing practices.pdf", "size": 93494, "headers": {"Date": "Thu, 04 Sep 2025 07:44:47 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"16d36-63c8b0223e9e2\"", "Accept-Ranges": "bytes", "Content-Length": "93494", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:48.037835Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%203%20sanitation%20and%20hygiene.pdf", "anchor": "Sanitation and hygiene | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/3d3e4ab2bc_who gmp 2014 trs 986 ch 3 sanitation and hygiene.pdf", "size": 57837, "headers": {"Date": "Thu, 04 Sep 2025 07:44:48 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"e1ed-63c8b0224341b\"", "Accept-Ranges": "bytes", "Content-Length": "57837", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:48.279317Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%204%20qualification%20and%20validation.pdf", "anchor": "Qualification and validation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/bbbcc09084_who gmp 2014 trs 986 ch 4 qualification and validation.pdf", "size": 94279, "headers": {"Date": "Thu, 04 Sep 2025 07:44:48 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"17047-63c8b02247683\"", "Accept-Ranges": "bytes", "Content-Length": "94279", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:48.513794Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%205%20complaints.pdf", "anchor": "Complaints | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/1171671d8f_who gmp 2014 trs 986 ch 5 complaints.pdf", "size": 76960, "headers": {"Date": "Thu, 04 Sep 2025 07:44:48 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"12ca0-63c8b0224b503\"", "Accept-Ranges": "bytes", "Content-Length": "76960", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:48.737575Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%206%20product%20recalls.pdf", "anchor": "Product recalls | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/c5f0c8063e_who gmp 2014 trs 986 ch 6 product recalls.pdf", "size": 77587, "headers": {"Date": "Thu, 04 Sep 2025 07:44:48 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"12f13-63c8b0224f384\"", "Accept-Ranges": "bytes", "Content-Length": "77587", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:48.968757Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%207%20contract%20production%20analysis%20and%20other%20activities.pdf", "anchor": "Contract production, analysis and other activities | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/89b7c86ebe_who gmp 2014 trs 986 ch 7 contract production analysis and other activities.pdf", "size": 121055, "headers": {"Date": "Thu, 04 Sep 2025 07:44:49 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"1d8df-63c8b02253204\"", "Accept-Ranges": "bytes", "Content-Length": "121055", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:49.208165Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%208%20self%20inspection%20quality%20audits%20and%20supplier%20audits%20and%20approval.pdf", "anchor": "Self-inspection, quality audits and supplier's audits and approval | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/9976bbc2ed_who gmp 2014 trs 986 ch 8 self inspection quality audits and supplier audits and approval.pdf", "size": 105288, "headers": {"Date": "Thu, 04 Sep 2025 07:44:49 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"19b48-63c8b02256c9c\"", "Accept-Ranges": "bytes", "Content-Length": "105288", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:49.463474Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%209%20personnel.pdf", "anchor": "Personnel | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/dbddd2164b_who gmp 2014 trs 986 ch 9 personnel.pdf", "size": 156945, "headers": {"Date": "Thu, 04 Sep 2025 07:44:49 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"26511-63c8b0225b2ed\"", "Accept-Ranges": "bytes", "Content-Length": "156945", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:49.730201Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2010%20training.pdf", "anchor": "Training | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/333c2764fc_who gmp 2014 trs 986 ch 10 training.pdf", "size": 80159, "headers": {"Date": "Thu, 04 Sep 2025 07:44:49 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"1391f-63c8b0221616f\"", "Accept-Ranges": "bytes", "Content-Length": "80159", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:49.958817Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2011%20personal%20hygiene.pdf", "anchor": "Personal hygiene | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/619b520668_who gmp 2014 trs 986 ch 11 personal hygiene.pdf", "size": 84596, "headers": {"Date": "Thu, 04 Sep 2025 07:44:50 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"14a74-63c8b02219fef\"", "Accept-Ranges": "bytes", "Content-Length": "84596", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:50.193998Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2012%20premises.pdf", "anchor": "Premises | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/92a0e632b9_who gmp 2014 trs 986 ch 12 premises.pdf", "size": 161258, "headers": {"Date": "Thu, 04 Sep 2025 07:44:50 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"275ea-63c8b0221e257\"", "Accept-Ranges": "bytes", "Content-Length": "161258", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:50.426566Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2013%20equipment.pdf", "anchor": "Equipment | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/bef9ea00f8_who gmp 2014 trs 986 ch 13 equipment.pdf", "size": 91622, "headers": {"Date": "Thu, 04 Sep 2025 07:44:50 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"165e6-63c8b022220d8\"", "Accept-Ranges": "bytes", "Content-Length": "91622", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:50.670315Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2014%20materials.pdf", "anchor": "Materials | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/0d194353fd_who gmp 2014 trs 986 ch 14 materials.pdf", "size": 192453, "headers": {"Date": "Thu, 04 Sep 2025 07:44:50 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2efc5-63c8b02226b10\"", "Accept-Ranges": "bytes", "Content-Length": "192453", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:50.937575Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2015%20documentation.pdf", "anchor": "Documentation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/f4aa3942f2_who gmp 2014 trs 986 ch 15 documentation.pdf", "size": 286337, "headers": {"Date": "Thu, 04 Sep 2025 07:44:51 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"45e81-63c8b0222d871\"", "Accept-Ranges": "bytes", "Content-Length": "286337", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:51.188481Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2016%20good%20practices%20in%20production.pdf", "anchor": "Good practices in production | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/9505bfdf84_who gmp 2014 trs 986 ch 16 good practices in production.pdf", "size": 184863, "headers": {"Date": "Thu, 04 Sep 2025 07:44:51 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2d21f-63c8b022322a9\"", "Accept-Ranges": "bytes", "Content-Length": "184863", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:51.446744Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20ch%2017%20good%20practices%20in%20quality%20control.pdf", "anchor": "Good practices in quality control | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/c3c313c295_who gmp 2014 trs 986 ch 17 good practices in quality control.pdf", "size": 183627, "headers": {"Date": "Thu, 04 Sep 2025 07:44:51 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2cd4b-63c8b02238c22\"", "Accept-Ranges": "bytes", "Content-Length": "183627", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:51.672538Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/who/gmp/who%20gmp%202014%20trs%20986%20references.pdf", "anchor": "References | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/0934b432ad_who gmp 2014 trs 986 references.pdf", "size": 56537, "headers": {"Date": "Thu, 04 Sep 2025 07:44:51 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"dcd9-63c8b02267a26\"", "Accept-Ranges": "bytes", "Content-Length": "56537", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:52.296360Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/general%201%20USP%20999.pdf", "anchor": "USP ÀÏ¹Ý ±âÁØ (<999> ÀÌÈÄ ) Àº FDA °¡ÀÌµå ¹®¼­¿Í µ¿µîÇÑ °ÍÀ¸·Î °£ÁÖµÇ ´Â°¡ ? ÀÏ¹Ý ±âÁØ Ç×¸ñ ÀÇ ¸ñÀûÀº ¹«¾ùÀÌ°í , Á¦Á¶¾÷Ã¼´Â ÀÌ Ç×¸ñÀ» ¾î¶»°Ô È°¿ë ÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a8fa2e52d6_general 1 USP 999.pdf", "size": 133607, "headers": {"Date": "Thu, 04 Sep 2025 07:44:52 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"209e7-63c8b01b0e7de\"", "Accept-Ranges": "bytes", "Content-Length": "133607", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:52.542353Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/general%202%20comment.pdf", "anchor": "FDA ÀÇ °¡ÀÌµå¶óÀÎ ÃÊ¾È¿¡ ´ëÇÑ ÀÇ°ßÀ» ¾î¶»°Ô Á¦ÃâÇÏ´Â°¡ ? USP °³Á¤¾È¿¡ ´ëÇØ¼­´Â ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0f924f7b32_general 2 comment.pdf", "size": 136244, "headers": {"Date": "Thu, 04 Sep 2025 07:44:52 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"21434-63c8b01b141b7\"", "Accept-Ranges": "bytes", "Content-Length": "136244", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:52.786729Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%201%20what%20is%20penicillin.pdf", "anchor": "Æä´Ï½Ç¸°ÀÌ¶õ ¹«¾ùÀÎ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/bb9e0caa68_buildings and facilities 1 what is penicillin.pdf", "size": 117443, "headers": {"Date": "Thu, 04 Sep 2025 07:44:52 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"1cac3-63c8b01a3a92c\"", "Accept-Ranges": "bytes", "Content-Length": "117443", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:53.030351Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%202%20what%20are%20the%20penicillin%20drugs.pdf", "anchor": "Æä´Ï½Ç¸° ÀÇ¾àÇ°ÀÌ¶õ ¹«¾ùÀÎ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e111a4bcdc_buildings and facilities 2 what are the penicillin drugs.pdf", "size": 139071, "headers": {"Date": "Thu, 04 Sep 2025 07:44:53 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"21f3f-63c8b01a48006\"", "Accept-Ranges": "bytes", "Content-Length": "139071", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:53.286792Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%203%20is%20cross%20contamination%20a%20concern%20with%20penicillin%20drugs.pdf", "anchor": "Æä´Ï½Ç¸° ÀÇ¾à Ç° ±³Â÷¿À¿°ÀÌ ¹®Á¦°¡ µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/f1a47add98_buildings and facilities 3 is cross contamination a concern with penicillin drugs.pdf", "size": 121523, "headers": {"Date": "Thu, 04 Sep 2025 07:44:53 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"1dab3-63c8b01a4e1ae\"", "Accept-Ranges": "bytes", "Content-Length": "121523", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:53.540835Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%204%20are%20there%20special%20manufacturing%20requirements%20for%20penicillin%20drugs.pdf", "anchor": "Æä´Ï½Ç¸° ÀÇ¾àÇ°°ú °ü·ÃÇÏ¿© Æ¯º° Á¦Á¶ ±âÁØÀÌ ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8a606a8365_buildings and facilities 4 are there special manufacturing requirements for penicillin drugs.pdf", "size": 143416, "headers": {"Date": "Thu, 04 Sep 2025 07:44:53 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"23038-63c8b01a53f6f\"", "Accept-Ranges": "bytes", "Content-Length": "143416", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:53.779661Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%205%20why%20is%20fda%20concerned%20about%20drug%20contamination%20with%20alogenated%20anisole%20compounds.pdf", "anchor": "ÇÒ·Î°ÕÈ­ ¾Æ´Ï¼Ö È­ÇÕ¹° ( ¿¹ , TBA) ÀÇ ÀÇ¾àÇ° ¿À¿°À» FDA °¡ ¿ì·ÁÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀÎ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0262fbf57f_buildings and facilities 5 why is fda concerned about drug contamination with alogenated anisole compounds.pdf", "size": 133919, "headers": {"Date": "Thu, 04 Sep 2025 07:44:53 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"20b1f-63c8b01a59d2f\"", "Accept-Ranges": "bytes", "Content-Length": "133919", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:54.020917Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%206%20are%20there%20any%20health%20effects.pdf", "anchor": "ÇÒ·Î°ÕÈ­ ¾Æ´Ï¼Ö È­ÇÕ¹°ÀÇ ¼·Ãë°¡ °Ç°­¿¡ ¿µÇâÀ» ÁÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/3850f9a1fa_buildings and facilities 6 are there any health effects.pdf", "size": 126211, "headers": {"Date": "Thu, 04 Sep 2025 07:44:54 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1ed03-63c8b01a5dbaf\"", "Accept-Ranges": "bytes", "Content-Length": "126211", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:54.283326Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%207%20has%20fda%20identified%20the%20source.pdf", "anchor": "ÀÇ¾àÇ°¿¡ ¿À¿°µÈ ÇÒ·Î°ÕÈ­ ¾Æ´Ï¼Ö È­ÇÕ¹°ÀÇ ÃâÃ³¸¦ FDA °¡ ÆÄ¾ÇÇß´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/64328c294e_buildings and facilities 7 has fda identified the source.pdf", "size": 128992, "headers": {"Date": "Thu, 04 Sep 2025 07:44:54 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1f7e0-63c8b01a61a30\"", "Accept-Ranges": "bytes", "Content-Length": "128992", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:54.550936Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%208%20what%20is%20fda%20expectation.pdf", "anchor": "ÇÒ·Î°ÕÈ­ ¾Æ´Ï¼Ö È­ÇÕ¹° ¿À¿° ¹æÁö¿Í °ü·ÃÇÏ¿© FDA ´Â ¾î¶² °ÍÀ» ¿ä±¸ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/43bdbaa440_buildings and facilities 8 what is fda expectation.pdf", "size": 129025, "headers": {"Date": "Thu, 04 Sep 2025 07:44:54 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1f801-63c8b01a67020\"", "Accept-Ranges": "bytes", "Content-Length": "129025", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:54.807600Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%209%20are%20there%20any%20standards%20applicable%20to%20preventing%20contamination.pdf", "anchor": "ÇÒ·Î°ÕÈ­ ¾Æ´Ï¼Ö È­ÇÕ¹°¿¡ ÀÇÇÑ ÀÇ¾àÇ°ÀÇ ¿À¿° ¹æÁö¿¡ Àû¿ëÇÒ ¼ö ÀÖ´Â Ç¥ÁØ ¹®¼­°¡ ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/5f0b37dfd4_buildings and facilities 9 are there any standards applicable to preventing contamination.pdf", "size": 126728, "headers": {"Date": "Thu, 04 Sep 2025 07:44:54 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1ef08-63c8b01a6e169\"", "Accept-Ranges": "bytes", "Content-Length": "126728", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:55.043995Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/buildings%20and%20facilities%2010%20can%20contamination%20of%20drug%20products%20be%20detected.pdf", "anchor": "ÇÒ·Î°ÕÈ­ ¾Æ´Ï¼Ö È­ÇÕ¹°¿¡ ÀÇÇÑ ÀÇ¾àÇ° ¿À¿°À» °ËÃâÇÒ ¼ö ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7ac50eb157_buildings and facilities 10 can contamination of drug products be detected.pdf", "size": 133723, "headers": {"Date": "Thu, 04 Sep 2025 07:44:55 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"20a5b-63c8b01a40ad5\"", "Accept-Ranges": "bytes", "Content-Length": "133723", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:55.282566Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2001%20lab%20control%201%20auto%20calibration%20balance.pdf", "anchor": "¸¹Àº ºÐ¼® Àú¿ï Á¦Á¶¾÷Ã¼°¡ \"ÀÚµ¿ ±³Á¤\" ±â´ÉÀ» Å¾ÀçÇÑ Àú¿ïÀ» ÆÇ¸ÅÇÏ°í ÀÖ´Ù. ÀÌ¿Í °°Àº ÀÚµ¿ ±³Á¤ ±â´ÉÀÌ ¿ÜÀû ¼º´É Á¡°ËÀ» ´ëÃ¼ÇÒ ¼ö ÀÖ´Â°¡? ±×·² ¼ö ¾ø´Ù¸é ±³Á¤ ÀÏÁ¤À» ¾î¶»°Ô Á¤ÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/336689b9d0_equipment 01 lab control 1 auto calibration balance.pdf", "size": 150176, "headers": {"Date": "Thu, 04 Sep 2025 07:44:55 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"24aa0-63c8b01ac1d48\"", "Accept-Ranges": "bytes", "Content-Length": "150176", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:55.541904Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2002%20approved%20equipment%20list.pdf", "anchor": "CDER ÀÌ ½ÂÀÎÇÑ ÀÇ¾àÇ° Á¦Á¶ ¼³ºñ ¸®½ºÆ®°¡ ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7f07f91b95_equipment 02 approved equipment list.pdf", "size": 145460, "headers": {"Date": "Thu, 04 Sep 2025 07:44:55 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"23834-63c8b01ac9279\"", "Accept-Ranges": "bytes", "Content-Length": "145460", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:55.783812Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2003%20lab%20control%204%20toc.pdf", "anchor": "¼¼Ã´ È¿°ú Æò°¡ ½Ã¿¡ ¿À¿° ¹°Áú ÀÜ·ù¹° °ËÃâ ¹æ¹ýÀ¸·Î TOC¸¦ »ç¿ëÇØµµ µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/030f2b529e_equipment 03 lab control 4 toc.pdf", "size": 154566, "headers": {"Date": "Thu, 04 Sep 2025 07:44:55 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"25bc6-63c8b01acd4e1\"", "Accept-Ranges": "bytes", "Content-Length": "154566", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:56.039109Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2004%20control%20of%20components%203%20production%20control%203%20media%20fill%20failure.pdf", "anchor": "¹èÁö ÃæÀü ½ÃÇèÀÌ ¿©·¯ Â÷·Ê ½ÇÆÐ·Î ³¡³­ È¸»ç°¡ ÀÖ´Ù. TSB¸¦ 0.2 ¹ÌÅ©·Ð Á¦±Õ ÇÊÅÍ·Î ¿©°úÇÑ °ÍÀ» ¹èÁö ÃæÀü ½ÃÇè¿¡ »ç¿ëÇß´Ù. Á¶»ç¸¦ ÇØµµ ¶Ñ·ÇÇÑ ¿øÀÎÀ» Ã£Áö ¸øÇß´Ù. ¿À¿°ÀÇ ÃâÃ³°¡ ¾îµð¶ó°í »ý°¢ÇÒ ¼ö ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/5f20e48199_equipment 04 control of components 3 production control 3 media fill failure.pdf", "size": 184586, "headers": {"Date": "Thu, 04 Sep 2025 07:44:56 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"2d10a-63c8b01ad4a11\"", "Accept-Ranges": "bytes", "Content-Length": "184586", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:56.276120Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2005%20cleaning%20validation%20requirements%20for%20potent%20compounds.pdf", "anchor": "°í¿ª°¡ È­ÇÕ¹°(¿¹, ¼¼Æ÷ µ¶¼º È­ÇÕ¹°, µ¹¿¬º¯ÀÌ¼º È­ÇÕ¹°, ¾à¸®ÇÐÀû È°¼ºÀÌ Å« È­ÇÕ¹°)ÀÇ ¼¼Ã´ ¹ë¸®µ¥ÀÌ¼Ç ±âÁØÀº ¹«¾ùÀÎ°¡? Àü¿ë ¼³ºñ¸¦ »ç¿ëÇØ¾ß ÇÏ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/9c855e67be_equipment 05 cleaning validation requirements for potent compounds.pdf", "size": 145536, "headers": {"Date": "Thu, 04 Sep 2025 07:44:56 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"23880-63c8b01adb38a\"", "Accept-Ranges": "bytes", "Content-Length": "145536", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:56.528255Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2006%20how%20do%20i%20perform%20cleaning%20validation.pdf", "anchor": "µ¿Á¾¿ä¹ý ÀÇ¾àÇ°À» Æ÷ÇÔÇØ ¼¼Ã´ ¹ë¸®µ¥ÀÌ¼ÇÀ» ¾î¶»°Ô ÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/95f765757c_equipment 06 how do i perform cleaning validation.pdf", "size": 147478, "headers": {"Date": "Thu, 04 Sep 2025 07:44:56 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"24016-63c8b01ae1533\"", "Accept-Ranges": "bytes", "Content-Length": "147478", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:56.787567Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2007%20does%20equpment%20need%20to%20be%20clean%20enough.pdf", "anchor": "¹Î°¨¼ºÀÌ °¡Àå ¿ì¼öÇÑ ÀÜ·ù¹° °ËÃâ ¶Ç´Â Á¤·® ¹æ¹ýÀ» Åä´ë·Î ÇÑ ÀÜ·ù¹° ±âÁØÀ» ÃæÁ·ÇÒ ¼ö ÀÖÀ» Á¤µµ·Î ¼³ºñ°¡ ±ú²ýÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6a134dc952_equipment 07 does equpment need to be clean enough.pdf", "size": 148127, "headers": {"Date": "Thu, 04 Sep 2025 07:44:56 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"2429f-63c8b01ae867b\"", "Accept-Ranges": "bytes", "Content-Length": "148127", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:57.046430Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2008%20do%20firms%20need%20to%20quantify%20total%20amount%20of%20residues.pdf", "anchor": "¼¼Ã´ ¹ë¸®µ¥ÀÌ¼Ç ½ÃÇèÀ» µÞ¹ÞÄ§ÇÏ±â À§ÇØ, Á¦Ç° Á¦Á¶ ÀÌÈÄ(¼¼Ã´ ÀÌÀü) ¼³ºñ Ç¥¸é¿¡ ³²Àº ÀÜ·ù¹°ÀÇ ÃÑ·®À» Á¤·®ÇÒ ÇÊ¿ä°¡ ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/57ad3d2e45_equipment 08 do firms need to quantify total amount of residues.pdf", "size": 157639, "headers": {"Date": "Thu, 04 Sep 2025 07:44:57 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"267c7-63c8b01aeec0c\"", "Accept-Ranges": "bytes", "Content-Length": "157639", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:57.303238Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2009%20should%20laboratory%20glassware%20be%20included%20in%20cleaning%20validation%20program.pdf", "anchor": "½ÃÇè½ÇÀÇ ÃÊÀÚ·ùµµ ¼³ºñ ¼¼Ã´ ¹ë¸®µ¥ÀÌ¼Ç ÇÁ·Î±×·¥¿¡ Æ÷ÇÔ½ÃÄÑ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e01a3a06ff_equipment 09 should laboratory glassware be included in cleaning validation program.pdf", "size": 157007, "headers": {"Date": "Thu, 04 Sep 2025 07:44:57 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"2654f-63c8b01af5584\"", "Accept-Ranges": "bytes", "Content-Length": "157007", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:57.555089Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2010%20acceptable%20level%20of%20detergent%20residue.pdf", "anchor": "¼¼Á¦ ÀÜ·ù¹° Çã¿ë ¼öÁØÀº ¾î¶»°Ô µÇ°í, ÀÌ ¼öÁØÀÇ ±Ù°Å´Â ¹«¾ùÀÎ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6db8cd74b2_equipment 10 acceptable level of detergent residue.pdf", "size": 123064, "headers": {"Date": "Thu, 04 Sep 2025 07:44:57 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1e0b8-63c8b01af97ed\"", "Accept-Ranges": "bytes", "Content-Length": "123064", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:57.813950Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2011%20material%20specific%20cleaning%20procedure.pdf", "anchor": "Æ¯Á¤ ÀçÁú(¿¹, ½ºÅ×ÀÎ¸®½º½ºÆ¿ 316)·Î ¸¸µç ¼³ºñÀÇ ¼¼Ã´ ´É·ÂÀÌ ÀûÇÕÇÏ°í ¹ë¸®µ¥ÀÌ¼ÇµÇ¾ú´Ù¸é, ±¤¹üÀ§ÇÑ ¹ë¸®µ¥ÀÌ¼ÇÀ» ÇÏÁö ¾Ê°íµµ \"ÀçÁú Æ¯ÀÌÀû\" ¼¼Ã´ ÀýÂ÷¸¦ ´Ù¸¥ ¼³ºñ¿Í È­ÇÕ¹°¿¡ Àû¿ëÇÒ ¼ö ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/5b72aa0bdc_equipment 11 material specific cleaning procedure.pdf", "size": 133320, "headers": {"Date": "Thu, 04 Sep 2025 07:44:57 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"208c8-63c8b01afda55\"", "Accept-Ranges": "bytes", "Content-Length": "133320", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:58.049026Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2012%20testing%20rinse%20solution.pdf", "anchor": "¸°½º¾× ½ÃÇèÀÌ¸é ¼¼Ã´ ¹ë¸®µ¥ÀÌ¼ÇÀ» À§ÇÑ ÀÜ·ù¹° ½ÃÇè ¹æ¹ýÀ¸·Î ÃæºÐÇÑ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/b3d68dd748_equipment 12 testing rinse solution.pdf", "size": 147158, "headers": {"Date": "Thu, 04 Sep 2025 07:44:58 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"23ed6-63c8b01b02c5d\"", "Accept-Ranges": "bytes", "Content-Length": "147158", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:58.286556Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/equipment%2013%20does%20fda%20prefer%20one%20type%20of%20material%20over%20another.pdf", "anchor": "ÁÖ»ç¿ë¼ö ½Ã½ºÅÛÀÇ Àç¼øÈ¯ ·çÇÁ ÀçÁú°ú °ü·ÃÇÏ¿© FDA°¡ ´õ ¼±È£ÇÏ´Â °ÍÀÌ ÀÖ´Â°¡(¿¹, ½ºÅ×ÀÎ¸®½º½ºÆ¿º¸´Ù PVDF)? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/f2d7701715_equipment 13 does fda prefer one type of material over another.pdf", "size": 144530, "headers": {"Date": "Thu, 04 Sep 2025 07:44:58 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"23492-63c8b01b095d6\"", "Accept-Ranges": "bytes", "Content-Length": "144530", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:58.537220Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%201%20record%20control%202%20audit%20report.pdf", "anchor": "½ÃÁ¤ Á¶Ä¡¸¦ ¿Ï·áÇÏ°í ³ª¸é ³»ºÎ Ç°Áú º¸Áõ °¨»ç º¸°í¼­¸¦ Æó±âÇØµµ µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0ed69ccde1_control of components 1 record control 2 audit report.pdf", "size": 150407, "headers": {"Date": "Thu, 04 Sep 2025 07:44:58 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"24b87-63c8b01a72f89\"", "Accept-Ranges": "bytes", "Content-Length": "150407", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:58.792795Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%202%20production%20control%202%20container%20closures%20ampling.pdf", "anchor": "º¸°ü ½Ã¼³¿¡¼­ ÀÔ°í °Ë»ç¸¦ À§ÇØ ¿ë±â, ¸¶°³, Æ÷Àå ÀÚÀç °ËÃ¼¸¦ Ã¤ÃëÇÒ ¼ö ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/40d39f99ca_control of components 2 production control 2 container closures ampling.pdf", "size": 154392, "headers": {"Date": "Thu, 04 Sep 2025 07:44:58 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"25b18-63c8b01a9d355\"", "Accept-Ranges": "bytes", "Content-Length": "154392", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:59.256546Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%204%20how%20many%20containers%20of%20each%20component%20sampled.pdf", "anchor": "ÀÔ°íºÐº°·Î ¸î °³ ÄÁÅ×ÀÌ³Ê¿¡¼­ °ËÃ¼¸¦ Ã¤ÃëÇØ ½ÃÇèÀ» ÇØ¾ß È®ÀÎ ½ÃÇè¿¡ ´ëÇÑ CGMP ±âÁØ¿¡ ºÎÇÕÇÏ´Â°¡ ? ¿©·¯ ÄÁÅ×ÀÌ³Ê¿¡¼­ °ËÃ¼¸¦ Ã¤ÃëÇÏ°í ¼¯°Å³ª ÇÕÃÄ¼­ È®ÀÎ ½ÃÇèÀ» ÇØµµ µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7cb2744a05_control of components 4 how many containers of each component sampled.pdf", "size": 212368, "headers": {"Date": "Thu, 04 Sep 2025 07:44:59 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"33d90-63c8b01aa40b5\"", "Accept-Ranges": "bytes", "Content-Length": "212368", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:59.485978Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%205%20melamine.pdf", "anchor": "ÀÇ¾àÇ° ¿ø·áÀÇ ¸á¶ó¹Î ¿À¿°À» ½ÃÇèÇÏ´Âµ¥ ÀûÇÕÇÑ ºÐ¼® ¹æ¹ýÀº? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/f3630ee0d8_control of components 5 melamine.pdf", "size": 135192, "headers": {"Date": "Thu, 04 Sep 2025 07:44:59 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"21018-63c8b01aa96a6\"", "Accept-Ranges": "bytes", "Content-Length": "135192", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:59.754409Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%206%20animal%20derived%20ingredients.pdf", "anchor": "¿À¿° ¹æÁö¸¦ À§ÇØ µ¿¹° À¯·¡ ¼ººÐÀÇ Á¦Á¶¿¡ ´ëÇÏ¿© FDA°¡ Æ¯º°ÇÑ ÁÖÀÇ »çÇ×ÀÌ³ª °ü¸®¸¦ ¿ä±¸ÇÏ°Å³ª ±Ç°íÇÏ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/052fd4ca0c_control of components 6 animal derived ingredients.pdf", "size": 169534, "headers": {"Date": "Thu, 04 Sep 2025 07:44:59 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"2963e-63c8b01ab0406\"", "Accept-Ranges": "bytes", "Content-Length": "169534", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:44:59.989043Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%207%20primary%20concerns%20animal%20derived%20ingredients.pdf", "anchor": "µ¿¹° À¯·¡ ¼ººÐÀÇ º´¿ø¼º ÀÎÀÚ ¿À¿°¿¡ ´ëÇÏ¿© FDA°¡ °¡Àå ¿ì·ÁÇÏ´Â ºÎºÐÀº ¹«¾ùÀÎ°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/5946df5ba8_control of components 7 primary concerns animal derived ingredients.pdf", "size": 152168, "headers": {"Date": "Thu, 04 Sep 2025 07:45:00 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"25268-63c8b01ab4e3f\"", "Accept-Ranges": "bytes", "Content-Length": "152168", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:00.256008Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%208%20manufacturing%20contamination%20risks.pdf", "anchor": "º´¿ø¼º ÀÎÀÚ À¯Çüº° Á¦Á¶ ¿À¿° ¸®½ºÅ©´Â? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c59812ddf8_control of components 8 manufacturing contamination risks.pdf", "size": 188144, "headers": {"Date": "Thu, 04 Sep 2025 07:45:00 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"2def0-63c8b01ab90a7\"", "Accept-Ranges": "bytes", "Content-Length": "188144", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:00.503385Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%209%20minimizing%20pathogenic%20agent.pdf", "anchor": "ÀÔ°í µ¿¹° À¯·¡ ¿ø·áÀÇ º´¿ø¼º ÀÎÀÚ ¿À¿° ÃÖ¼ÒÈ­¸¦ À§ÇÑ ¹æ¹ýÀº? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/868758c357_control of components 9 minimizing pathogenic agent.pdf", "size": 188109, "headers": {"Date": "Thu, 04 Sep 2025 07:45:00 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"2decd-63c8b01abd6f8\"", "Accept-Ranges": "bytes", "Content-Length": "188109", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:00.764121Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2010%20control%20measures%20for%20minimizing%20pathogenic%20agent.pdf", "anchor": "µ¿¹° À¯·¡ ÀÇ¾àÇ° ¼ººÐ Á¦Á¶ ½Ã¼³¿¡¼­ º´¿ø¼º ÀÎÀÚ ¿À¿°À» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ´Â °ü¸® ´ëÃ¥ÀÌ ÀÖ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/1650e269e4_control of components 10 control measures for minimizing pathogenic agent.pdf", "size": 174032, "headers": {"Date": "Thu, 04 Sep 2025 07:45:00 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"2a7d0-63c8b01a79cea\"", "Accept-Ranges": "bytes", "Content-Length": "174032", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:01.006396Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2011%20formation%20of%20glass%20lamellae.pdf", "anchor": "¼Ò¿ë·® À¯¸® ¹ÙÀÌ¾Ë¿¡ ÃæÀüÇÏ´Â ÁÖ»çÁ¦¿¡ À¯¸® ¹ÚÆÇ(À¯¸® ÆÄÆí)ÀÌ Çü¼ºµÇÁö ¾Êµµ·Ï ÇÏ·Á¸é ÀÇ¾àÇ° Á¦Á¶¾÷Ã¼°¡ ¾î¶»°Ô ÇØ¾ß ÇÏ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4039b6d2d6_control of components 11 formation of glass lamellae.pdf", "size": 195658, "headers": {"Date": "Thu, 04 Sep 2025 07:45:01 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"2fc4a-63c8b01a7e33a\"", "Accept-Ranges": "bytes", "Content-Length": "195658", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:01.248896Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2012%20flexible%20intravenous%20solution%20bags.pdf", "anchor": "ÇÃ·º¼­ºí IV ¿ë¾× ¹éÀÇ Ãë±Þ ¶Ç´Â °¡°ø°ú °ü·ÃÇÏ¿© Æ¯È÷ ¿ì·ÁµÇ´Â °ÍÀÌ ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/1fc2c45230_control of components 12 flexible intravenous solution bags.pdf", "size": 148521, "headers": {"Date": "Thu, 04 Sep 2025 07:45:01 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"24429-63c8b01a85483\"", "Accept-Ranges": "bytes", "Content-Length": "148521", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:01.483893Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2013%20compromised%20IV%20solution%20bag%20integrity.pdf", "anchor": "¶óº§ ÀÛ¾÷ µµÁß IV ¿ë¾× ¹éÀÇ ¿ÏÀü¼º ÈÑ¼Õ ¶§¹®¿¡ Á¦Ç°ÀÇ ¹«±Õ »óÅÂ°¡ »ó½ÇµÇ´Â °ÍÀ» ¹æÁöÇÏ±â À§ÇÏ¿© IV ÀÇ¾àÇ° Á¦Á¶¾÷Ã¼°¡ ¾î¶»°Ô ÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/01c1d987dc_control of components 13 compromised IV solution bag integrity.pdf", "size": 152336, "headers": {"Date": "Thu, 04 Sep 2025 07:45:01 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"25310-63c8b01a8a68b\"", "Accept-Ranges": "bytes", "Content-Length": "152336", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:01.737250Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2014%20must%20each%20batch%20of%20a%20USP%20grade%20API%20be%20tested.pdf", "anchor": "USP µî±Þ API °¢ ¹èÄ¡¸¦ USP ¸ð³ë±×·¡ÇÁ¿¡ ±ÔÁ¤µÈ ºÐ¼® ¹æ¹ýÀ¸·Î ½ÃÇèÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/5198a9fc34_control of components 14 must each batch of a USP grade API be tested.pdf", "size": 144128, "headers": {"Date": "Thu, 04 Sep 2025 07:45:01 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"23300-63c8b01a8fc7c\"", "Accept-Ranges": "bytes", "Content-Length": "144128", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:02.010239Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/control%20of%20components%2015%20who%20is%20responsible%20for%20analytically%20testing%20APIs.pdf", "anchor": "API °¡ ÁöÁ¤ ±Ô°Ý°ú USP ±âÁØ¿¡ ºÎÇÕÇÏ´ÂÁö È®ÀÎÇÏ´Â ºÐ¼® ½ÃÇèÀ» ´©°¡ Ã¥ÀÓÁö´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/1c076fb5d5_control of components 15 who is responsible for analytically testing APIs.pdf", "size": 167293, "headers": {"Date": "Thu, 04 Sep 2025 07:45:02 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"28d7d-63c8b01a971ac\"", "Accept-Ranges": "bytes", "Content-Length": "167293", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:02.274700Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%201%20status%20label.pdf", "anchor": "¼³ºñ »óÅÂ Ç¥½Ã ¶óº§À» ¹èÄ¡ ±â·Ï¼­³ª ´Ù¸¥ ÆÄÀÏ¿¡ º¸°üÇØ¾ß ÇÏ´Â°¡? ÁÖ¿ä ¼³ºñº°·Î \"¼¼Ã´ ¹× »ç¿ë ÀÏÁö\"¸¦ °®Ãß°í ÀÌ ¹®¼­¸¦ ÀûÀýÇÏ°Ô º¸°üÇÑ´Ù¸é, ÀÌ·± \"Äü ·¹ÆÛ·±½º\" ¼³ºñ Ç¥½Ã ¶óº§À» Æó±âÇØµµ µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a3cadcaf23_production control 1 status label.pdf", "size": 153279, "headers": {"Date": "Thu, 04 Sep 2025 07:45:02 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"256bf-63c8b01b92d1a\"", "Accept-Ranges": "bytes", "Content-Length": "153279", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:02.942595Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%204%20record%20control%201%20reject%20rate.pdf", "anchor": "ÀÏºÎ Á¦Ç° (¿¹, °æÇÇ ÆÐÄ¡)ÀÇ Á¦Á¶ °øÁ¤Àº ´Ù¸¥ Á¦Ç°°ú °øÁ¤¿¡ ºñÇØ °øÁ¤ ¹°Ç°ÀÇ ºÒ·® ºñÀ²ÀÌ ÈÎ¾À ³ô´Ù. ±×·¡µµ ±¦ÂúÀº°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0ccbaac1e3_production control 4 record control 1 reject rate.pdf", "size": 154152, "headers": {"Date": "Thu, 04 Sep 2025 07:45:03 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"25a28-63c8b01be70c9\"", "Accept-Ranges": "bytes", "Content-Length": "154152", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:03.202311Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%205%20validation%20batch.pdf", "anchor": "»õ·Î¿î API ¶Ç´Â ¿ÏÁ¦ ÀÇ¾àÇ°À» ÃâÇÏ ½ÂÀÎÇÏ°í À¯ÅëÇÏ±â¿¡ ¾Õ¼­ °øÁ¤ ¹ë¸®µ¥ÀÌ¼Ç ¹èÄ¡ 3°³°¡ ¸ðµÎ ÀûÇÕÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ad5abac8e6_production control 5 validation batch.pdf", "size": 177681, "headers": {"Date": "Thu, 04 Sep 2025 07:45:03 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2b611-63c8b01bee211\"", "Accept-Ranges": "bytes", "Content-Length": "177681", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:03.454439Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%206%20ISO.pdf", "anchor": "¹«±Õ °øÁ¤À¸·Î ¹«±Õ ÀÇ¾àÇ°À» »ý»êÇÏ´Â Á¦Á¶¾÷Ã¼°¡ ISO 14644-1°ú ISO 14644-2¿¡¸¸ ±Ù°ÅÇÏ¿© ½Ã¼³ Àû°Ý¼ºÆò°¡¸¦ ÇÑ´Ù¸é, ÀÌ´Â CGMP °üÁ¡¿¡¼­ ÀÎÁ¤µÉ ¼ö ÀÖ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/40852c5c36_production control 6 ISO.pdf", "size": 159095, "headers": {"Date": "Thu, 04 Sep 2025 07:45:03 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"26d77-63c8b01bf2862\"", "Accept-Ranges": "bytes", "Content-Length": "159095", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:03.713226Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%207%20pat.pdf", "anchor": "2004 ³â¿¡ FDA ´Â \"PAT-Çõ½ÅÀûÀÎ ÀÇ¾àÇ° °³¹ß, Á¦Á¶, Ç°Áú º¸Áõ ÇÁ·¹ÀÓ¿öÅ©\"¸¦ ¹ßÇàÇÏ¿©, °øÁ¤ °ü¸® °­È­¸¦ ÅëÇØ Á¦Á¶¸¦ Çö´ëÈ­ÇÒ °ÍÀ» ±ÇÀåÇß´Ù. PAT¸¦ ¾î¶»°Ô ±¸ÃàÇÒ ¼ö ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ce1291eb9d_production control 7 pat.pdf", "size": 163384, "headers": {"Date": "Thu, 04 Sep 2025 07:45:03 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"27e38-63c8b01bf9d92\"", "Accept-Ranges": "bytes", "Content-Length": "163384", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:03.962825Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%208%20how%20do%20i%20contact%20cder.pdf", "anchor": "PAT ¿Í °ü·ÃÇÏ¿© CDER¿¡ ¹®ÀÇÇÏ·Á¸é ¾î¶»°Ô ÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c17914165f_production control 8 how do i contact cder.pdf", "size": 109854, "headers": {"Date": "Thu, 04 Sep 2025 07:45:04 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"1ad1e-63c8b01bfebb3\"", "Accept-Ranges": "bytes", "Content-Length": "109854", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:04.217702Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%209%20how%20do%20i%20contact%20cber.pdf", "anchor": "PAT ¿Í °ü·ÃÇÏ¿© CBER¿¡ ¹®ÀÇÇÏ·Á¸é ¾î¶»°Ô ÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a9a8dd6598_production control 9 how do i contact cber.pdf", "size": 109102, "headers": {"Date": "Thu, 04 Sep 2025 07:45:04 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"1aa2e-63c8b01c02a33\"", "Accept-Ranges": "bytes", "Content-Length": "109102", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:04.464577Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2010%20media%20fill%20frequency.pdf", "anchor": "ÀÛ¾÷Á¶ ¼ö¿Í °ü·ÃÇÏ¿© ¹èÁö ÃæÀü ½ÃÇè ÁÖ±â¸¦ ¾î¶»°Ô Á¤ÇØ¾ß ÇÏ´Â°¡? ÀÏ¹ÝÀûÀ¸·Î ¹èÁö ÃæÀü ½ÃÇèÀ» ¸Å³â ¶óÀÎº°·Î ÀÛ¾÷Á¶º°·Î 2È¸ ¹Ýº¹ÇØ¾ß ÇÑ´Ù. ¾ÆÀÌ¼Ö·¹ÀÌÅÍ¿¡¼­ ¼öÇàÇÏ´Â °øÁ¤ÀÎ °æ¿ì¿¡µµ ÁÖ±â¸¦ µ¿ÀÏÇÏ°Ô Á¤ÇÏ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0674926261_production control 10 media fill frequency.pdf", "size": 177436, "headers": {"Date": "Thu, 04 Sep 2025 07:45:04 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2b51c-63c8b01b986f2\"", "Accept-Ranges": "bytes", "Content-Length": "177436", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:04.717831Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2011%20concerns%20about%20human%20topical%20antiseptic%20drug%20products.pdf", "anchor": "FDA °¡ ±¹¼Ò ¼Òµ¶ ÀÇ¾àÇ°¿¡ ´ëÇØ ¿ì·ÁÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀÎ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/16aa893c5d_production control 11 concerns about human topical antiseptic drug products.pdf", "size": 117389, "headers": {"Date": "Thu, 04 Sep 2025 07:45:04 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"1ca8d-63c8b01b9dce3\"", "Accept-Ranges": "bytes", "Content-Length": "117389", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:04.988202Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2012%20cgmp%20regulations%20human%20topical%20antiseptic%20drug%20products.pdf", "anchor": "CGMP ±ÔÁ¤ °¡¿îµ¥ ¾î¶² ºÎºÐÀÌ ±¹¼Ò ¼Òµ¶ ÀÇ¾àÇ° Á¦Á¶¾÷Ã¼¿¡ µµ¿òÀÌ µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/52953abc24_production control 12 cgmp regulations human topical antiseptic drug products.pdf", "size": 189947, "headers": {"Date": "Thu, 04 Sep 2025 07:45:05 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2e5fb-63c8b01ba2333\"", "Accept-Ranges": "bytes", "Content-Length": "189947", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:05.223344Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2013%20microbiological%20contamination%20of%20human%20topical%20antiseptic%20drug%20products.pdf", "anchor": "±¹¼Ò ¼Òµ¶Á¦ÀÇ ¹Ì»ý¹° ¿À¿° ¸®½ºÅ©¸¦ Á¦Á¶¾÷Ã¼°¡ ¾î¶»°Ô Æò°¡ÇÏ°í ´ëÃ³ÇÒ ¼ö ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7695019335_production control 13 microbiological contamination of human topical antiseptic drug products.pdf", "size": 166629, "headers": {"Date": "Thu, 04 Sep 2025 07:45:05 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"28ae5-63c8b01ba6983\"", "Accept-Ranges": "bytes", "Content-Length": "166629", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:05.467283Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2014%20leptospira%20species%20penetrate%20sterilizing%20grade%20filters.pdf", "anchor": "Leptospira Á¾ÀÌ Á¦±Õ µî±Þ ÇÊÅÍ¸¦ Åë°úÇÒ ¼ö ÀÖ´Â°¡? ±×·¸´Ù¸é ¹Ì»ý¹° °ü¸®¸¦ À§ÇÑ Áö¼ÓÀûÀÎ ¶óÀÌÇÁ»çÀÌÅ¬ ¸®½ºÅ© °ü¸® È°µ¿À» Á¦Á¶¾÷Ã¼°¡ ¾î¶»°Ô ÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/02c9a57c01_production control 14 leptospira species penetrate sterilizing grade filters.pdf", "size": 226879, "headers": {"Date": "Thu, 04 Sep 2025 07:45:05 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"3763f-63c8b01baea6c\"", "Accept-Ranges": "bytes", "Content-Length": "226879", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:05.711828Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2015%20withdrawal%20of%20its%20draft%20guidance%20for%20industry%20on%20powder%20blends%20and%20finished%20dosage%20units.pdf", "anchor": "FDA ´Â °¡ÀÌµå ÃÊ¾È ¹®¼­ \"ºÐ¸» ºí·»µå ¹× ÃÖÁ¾ Á¦Á¦ - ÃþÈ­ °øÁ¤ Á¦Á¦ °ËÃ¼ Ã¤Ãë ¹× Æò°¡\"¸¦ Ã¶È¸Çß´Ù. FDA°¡ »ý°¢ÇÏ±â¿¡ ÀÌ °¡ÀÌµå ¹®¼­¿¡¼­ °¡Àå ¹®Á¦°¡ µÇ´Â °ÍÀÌ ¹«¾ùÀÌ¾ú´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6c7f042335_production control 15 withdrawal of its draft guidance for industry on powder blends and finished dosage units.pdf", "size": 159347, "headers": {"Date": "Thu, 04 Sep 2025 07:45:05 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"26e73-63c8b01bb30bc\"", "Accept-Ranges": "bytes", "Content-Length": "159347", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:05.956471Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2016%20proper%20sampling%20of%20powder%20blends.pdf", "anchor": "ºÐ¸» ºí·»µåÀÇ ÀûÀýÇÑ °ËÃ¼ Ã¤Ãë¿¡ ´ëÇØ FDA´Â ¿Ö ±×·¸°Ô ½Å°æÀ» ¾²´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/2fb9384e99_production control 16 proper sampling of powder blends.pdf", "size": 150838, "headers": {"Date": "Thu, 04 Sep 2025 07:45:06 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"24d36-63c8b01bb770d\"", "Accept-Ranges": "bytes", "Content-Length": "150838", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:06.212035Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2017%20innovative%20approaches%20to%20adequacy%20of%20mixing%20of%20powder%20blends.pdf", "anchor": "ºÐ¸» ºí·»µåÀÇ È¥ÇÕ ÀûÀý¼ºÀ» È®ÀÎÇÏ´Â Çõ½ÅÀûÀÎ ¹æ¹ýÀ¸·Î´Â ¾î¶² °ÍÀÌ ÀÖ´Â°¡ | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | ºÐ¸» ºí·»µåÀÇ È¥ÇÕ ÀûÀý¼ºÀ» È®ÀÎÇÏ´Â Çõ½ÅÀûÀÎ ¹æ¹ýÀ¸·Î´Â ¾î¶² °ÍÀÌ ÀÖ´Â°¡ ?", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/3f9028655a_production control 17 innovative approaches to adequacy of mixing of powder blends.pdf", "size": 151366, "headers": {"Date": "Thu, 04 Sep 2025 07:45:06 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"24f46-63c8b01bbd4cd\"", "Accept-Ranges": "bytes", "Content-Length": "151366", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:06.444949Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2018%20in%20process%20stratified%20sampling.pdf", "anchor": "ÃÖÁ¾ Á¦Á¦ÀÇ ÃþÈ­ °øÁ¤ °ËÃ¼ Ã¤Ãë¿¡ ´ëÇÑ FDAÀÇ ±ÇÀå »ç Ç×Àº ¹«¾ùÀÎ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c6b49e96ba_production control 18 in process stratified sampling.pdf", "size": 130037, "headers": {"Date": "Thu, 04 Sep 2025 07:45:06 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"1fbf5-63c8b01bc1736\"", "Accept-Ranges": "bytes", "Content-Length": "130037", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:06.701946Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2019%20for%20a%20nonsterile%20compendial%20drug%20product%20that%20includes%20an%20antimicrobial%20preservative%20in%20its%20formulation.pdf", "anchor": "Ç×¹Ì»ý¹° º¸Á¸Á¦¸¦ ÇÔÀ¯ÇÏ´Â °øÁ¤¼­ ¼öÀç ºñ¹«±Õ ÀÇ¾àÇ°ÀÎ °æ¿ì, ÃÑ»ý±Õ¼ö ½ÃÇè °á°ú°¡ Ã³À½¿¡´Â ±Ô°Ý¿¡ ºÎÇÕÇÏÁö ¾Ê¾ÒÀ¸³ª 2ÁÖ µÚ¿¡´Â ½ÃÇè ±âÁØ¿¡ ºÎÇÕÇÏ¸é, ÀÌ ÀÇ¾àÇ° ·ÎÆ®¸¦ ÃâÇÏ ½ÂÀÎÇÏ°í ÆÇ¸Å ÇØµµ µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c5bce4c12f_production control 19 for a nonsterile compendial drug product that includes an antimicrobial preservative in its formulation.pdf", "size": 160709, "headers": {"Date": "Thu, 04 Sep 2025 07:45:06 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"273c5-63c8b01bc78de\"", "Accept-Ranges": "bytes", "Content-Length": "160709", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:06.944946Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2020%20do%20pharmaceutical%20manufacturers%20need%20to%20have%20written%20procedures.pdf", "anchor": "ºñ¹«±Õ ÀÇ¾àÇ°ÀÇ ¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº ¹Ì»ý¹° ¿À¿° ¹æÁö¸¦ À§ÇÑ ÀýÂ÷ ¹®¼­¸¦ ÀÇ¾àÇ° Á¦Á¶¾÷Ã¼°¡ ±¸ºñÇÒ ÇÊ¿ä°¡ ÀÖ´Â°¡? \"¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº\"Àº ¾î¶² ÀÇ¹ÌÀÎ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/144712bfc3_production control 20 do pharmaceutical manufacturers need to have written procedures.pdf", "size": 173200, "headers": {"Date": "Thu, 04 Sep 2025 07:45:07 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2a490-63c8b01bcc316\"", "Accept-Ranges": "bytes", "Content-Length": "173200", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:07.190807Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2021%20for%20drug%20products%20formulated%20with%20preservatives.pdf", "anchor": "¹Ì»ý¹° Áõ½ÄÀ» ÀúÇØÇÏ´Â º¸Á¸Á¦°¡ ÇÔÀ¯µÈ ÀÇ¾àÇ°ÀÎ °æ¿ì, ¹èÄ¡ ÃâÇÏ ½ÂÀÎ ½ÃÇè°ú ¾ÈÁ¤¼º ½ÃÇè ½Ã¿¡ º¸Á¸Á¦ ½ÃÇèÀ» ÇÒ ÇÊ¿ä°¡ ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c573a123ae_production control 21 for drug products formulated with preservatives.pdf", "size": 127322, "headers": {"Date": "Thu, 04 Sep 2025 07:45:07 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"1f15a-63c8b01bd3077\"", "Accept-Ranges": "bytes", "Content-Length": "127322", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:07.450580Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2022%20parametric%20release%20for%20products%20not%20terminally%20sterilized.pdf", "anchor": "»çÈÄ ¸ê±Õ Á¦Ç°ÀÌ ¾Æ´Ñ ¹«±Õ ÀÇ¾àÇ°ÀÎ °æ¿ì¿¡ ÆÄ¶ó¹ÌÅÍ ±â¹Ý ÃâÇÏ ½ÂÀÎÀÌ ÀûÀýÇÑ °ü¸® Àü·«ÀÎ°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0bee4cacc2_production control 22 parametric release for products not terminally sterilized.pdf", "size": 188273, "headers": {"Date": "Thu, 04 Sep 2025 07:45:07 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2df71-63c8b01bd9220\"", "Accept-Ranges": "bytes", "Content-Length": "188273", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:07.710567Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/production%20control%2023%20ophthalmic%20drug%20products.pdf", "anchor": "¾È°ú ÀÇ¾àÇ°ÀÌ À¯È¿ ±â°£ µ¿¾È ¹«±Õ¼ºÀ» º¸ÁõÇÏ´Â Á¶°Ç¿¡¼­ Á¦Á¶µÇÁö ¾Ê°í, ´ÙÈ¸ ¿ë·® Á¦Ç°ÀÎ °æ¿ì¿¡ »ç¿ë ±â°£ µ¿¾È À¯ÇØ ¹Ì»ý¹° ¿À¿°À» ¹æÁöÇÏ´Â Á¶°Ç¿¡¼­ Á¦Á¶µÇÁö ¾ÊÀ¸¸é ºÒ·® ÀÇ¾àÇ°À¸·Î °£ÁÖµÇ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0eabe612a5_production control 23 ophthalmic drug products.pdf", "size": 216821, "headers": {"Date": "Thu, 04 Sep 2025 07:45:07 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"34ef5-63c8b01bdf7b0\"", "Accept-Ranges": "bytes", "Content-Length": "216821", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:07.950389Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%201%20what%20is%20recall.pdf", "anchor": "¸®ÄÝÀÌ¶õ ¹«¾ùÀÎ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/d5db16fcbe_holding and distribution 1 what is recall.pdf", "size": 120982, "headers": {"Date": "Thu, 04 Sep 2025 07:45:08 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1d896-63c8b01b18037\"", "Accept-Ranges": "bytes", "Content-Length": "120982", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:08.204700Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%202%20can%20fda%20mandate%20a%20recall.pdf", "anchor": "FDA °¡ »ç¶÷ ÀÇ¾àÇ°ÀÇ ¸®ÄÝÀ» °­Á¦ÇÒ ¼ö ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/68ff6f68ff_holding and distribution 2 can fda mandate a recall.pdf", "size": 126646, "headers": {"Date": "Thu, 04 Sep 2025 07:45:08 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1eeb6-63c8b01b1e5c8\"", "Accept-Ranges": "bytes", "Content-Length": "126646", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:08.457561Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%203%20are%20otc%20drugs%20subject%20to%20the%20same%20recall%20provisions.pdf", "anchor": "OTC ÀÇ¾àÇ°µµ Ã³¹æ ÀÇ¾àÇ°°ú µ¿ÀÏÇÑ ¸®ÄÝ ±ÔÁ¤ÀÇ Àû¿ëÀ» ¹Þ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/9efd5ed0c5_holding and distribution 3 are otc drugs subject to the same recall provisions.pdf", "size": 116051, "headers": {"Date": "Thu, 04 Sep 2025 07:45:08 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1c553-63c8b01b23fa0\"", "Accept-Ranges": "bytes", "Content-Length": "116051", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:08.716777Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%204%20do%20manufacturers%20of%20otc%20products%20have%20to%20report%20quality%20defects.pdf", "anchor": "OTC Á¦Ç° Á¦Á¶¾÷Ã¼°¡ Ç°Áú °áÇÔÀ» º¸°íÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e9843f5486_holding and distribution 4 do manufacturers of otc products have to report quality defects.pdf", "size": 137891, "headers": {"Date": "Thu, 04 Sep 2025 07:45:08 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"21aa3-63c8b01b29d61\"", "Accept-Ranges": "bytes", "Content-Length": "137891", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:08.969582Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%205%20does%20fda%20expect%20firms%20to%20investigate.pdf", "anchor": "ÃâÇÏ ½ÂÀÎ ·ÎÆ®¿Í ºÎÀûÇÕ ·ÎÆ®¸¦ Á¶»çÇÏ¿© ¸®ÄÝ °¡´É¼ºÀ» °ËÅäÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e891fb583b_holding and distribution 5 does fda expect firms to investigate.pdf", "size": 127173, "headers": {"Date": "Thu, 04 Sep 2025 07:45:09 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1f0c5-63c8b01b302f1\"", "Accept-Ranges": "bytes", "Content-Length": "127173", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:09.233295Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/holding%20and%20distribution%206%20what%20happens%20if%20a%20firm%20does%20not%20voluntarily%20recall.pdf", "anchor": "ÀÚÀ²ÀûÀ¸·Î °áÇÔ Á¦Ç°À» ¸®ÄÝÇÏÁö ¾ÊÀ¸¸é ¾î¶»°Ô µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/f581bf03e6_holding and distribution 6 what happens if a firm does not voluntarily recall.pdf", "size": 123875, "headers": {"Date": "Thu, 04 Sep 2025 07:45:09 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1e3e3-63c8b01b3455a\"", "Accept-Ranges": "bytes", "Content-Length": "123875", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:09.906479Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%202%20stress%20test.pdf", "anchor": "ÀÇ¾àÇ° ¾ÈÁ¤¼º ½ÃÇè ¹æ¹ýÀÌ ¾ÈÁ¤¼º Áö½Ã¼ºÀ» °®°í ÀÖ´ÂÁö È®ÀÎÇÒ ¶§, ÀÇ¾àÇ°ÀÇ °­Á¦ ºÐÇØ ½ÃÇèÀ» ¹Ýµå½Ã ÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0c091d4513_lab control 2 stress test.pdf", "size": 164731, "headers": {"Date": "Thu, 04 Sep 2025 07:45:10 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2837b-63c8b01b698ee\"", "Accept-Ranges": "bytes", "Content-Length": "164731", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:10.172921Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%203%20LVP%20particulate%20matter.pdf", "anchor": "USP <788> \"LVP ÁÖ»çÁ¦ÀÇ ¹Ì¸³ÀÚ ½ÃÇè\"À» ÇÒ ¶§, ½ÃÇè ´ë»ó Á¦Ç°ÀÇ Æò±Õ°ªÀ» ±¸ÇÏ¿© ¹èÄ¡°¡ ±Ô°Ý¿¡ ºÎÇÕÇÏ´ÂÁö Æò°¡ÇØµµ µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6de5e2ecee_lab control 3 LVP particulate matter.pdf", "size": 171471, "headers": {"Date": "Thu, 04 Sep 2025 07:45:10 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"29dcf-63c8b01b7064f\"", "Accept-Ranges": "bytes", "Content-Length": "171471", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:10.625776Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%205%20laser%20oxygen%20analyzer.pdf", "anchor": "ÆÄ¶ó¸¶±×³×Æ½ ¶Ç´Â ·¹ÀÌÀú »ê¼Ò ºÐ¼® ÀåÄ¡°¡ ÀÇ·á¿ë °¡½º¿¡ Á¸ÀçÇÏ´Â ¸ðµç ¿À¿° ¹°Áú ¶Ç´Â ºÒ¼ø¹°À» °ËÃâÇÒ ¼ö ÀÖ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/16e50fa4f8_lab control 5 laser oxygen analyzer.pdf", "size": 148481, "headers": {"Date": "Thu, 04 Sep 2025 07:45:10 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"24401-63c8b01b767f7\"", "Accept-Ranges": "bytes", "Content-Length": "148481", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:10.906769Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%206%20expiration%20dating.pdf", "anchor": "2005 ³â 5¿ù ¹ßÇàµÈ CPG ¼½¼Ç 480.200 °³Á¤¾È \"´ÜÀ§ ¿ë·® ÀçÆ÷Àå ÀÇ¾àÇ°ÀÇ À¯È¿ ±â°£\"(7132b.11)¿¡ ±Ù°ÅÇÏ¿©, ´ÜÀ§ ¿ë·® ¿ë±â¿¡ ÀçÆ÷ÀåµÈ ³»¿ë °íÇüÁ¦ ¹× ¾×Á¦ÀÇ À¯È¿±â°£À» ÃÖ´ë 12°³¿ù±îÁö ºÎ¿©ÇÒ ¼ö ÀÖ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/57aa319b66_lab control 6 expiration dating.pdf", "size": 159719, "headers": {"Date": "Thu, 04 Sep 2025 07:45:11 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"26fe7-63c8b01b7cd88\"", "Accept-Ranges": "bytes", "Content-Length": "159719", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:11.171568Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%207%20unvalidated%20method.pdf", "anchor": "ÀÇ¾àÇ° ¿ø·á³ª Á¦Ç°À» ¹ë¸®µ¥ÀÌ¼ÇµÇÁö ¾ÊÀº ¹æ¹ýÀ¸·Î ½ÃÇèÇÒ ¼ö ÀÖ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/356abc19e0_lab control 7 unvalidated method.pdf", "size": 155878, "headers": {"Date": "Thu, 04 Sep 2025 07:45:11 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"260e6-63c8b01b82f30\"", "Accept-Ranges": "bytes", "Content-Length": "155878", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:11.399101Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%208%20lal%20method.pdf", "anchor": "»ç¶÷/µ¿¹° ºñ°æ±¸ ÀÇ¾àÇ°, »ý¹°ÇÐÀû Á¦Ç°, ÀÇ·á±â±âÀÇ ÃÖÁ¾ Á¦Ç° ¿£µµÅå½Å ½ÃÇè¹ýÀÎ LAL ½ÃÇè¹ýÀÇ ¹ë¸®µ¥ÀÌ¼Ç¿¡ °üÇÑ 1987³â °¡ÀÌµå¶óÀÎÀ» Ã¶È¸Çß´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4558d76aea_lab control 8 lal method.pdf", "size": 118312, "headers": {"Date": "Thu, 04 Sep 2025 07:45:11 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"1ce28-63c8b01b88521\"", "Accept-Ranges": "bytes", "Content-Length": "118312", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:11.641647Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%209%20endotoxin%20testing.pdf", "anchor": "¿£µµÅå½Å ½ÃÇè¿¡ °üÇÑ Á¤º¸¸¦ ¾îµð¼­ ±¸ÇÒ ¼ö ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a8c3fe86a7_lab control 9 endotoxin testing.pdf", "size": 122390, "headers": {"Date": "Thu, 04 Sep 2025 07:45:11 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"1de16-63c8b01b8def9\"", "Accept-Ranges": "bytes", "Content-Length": "122390", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:11.909782Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2010%20is%20it%20acceptable%20to%20release%20non%20penicillin%20finished%20drug%20products.pdf", "anchor": "ºñÆä´Ï½Ç¸° ¿ÏÁ¦ ÀÇ¾àÇ°ÀÌ Æä´Ï½Ç¸°¿¡ ³ëÃâµÇ¾úÀ» °¡´É¼ºÀÌ ÀÖÁö¸¸, ºñÆä´Ï½Ç¸° Á¦Ç°À» ½ÃÇèÇÏ¿© Æä´Ï½Ç¸° ÀÜ·ù¹°ÀÌ °ËÃâµÇÁö ¾ÊÀ¸¸é, ÀÌ Á¦Ç°À» ÃâÇÏÇØµµ µÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/07a7d8d967_lab control 10 is it acceptable to release non penicillin finished drug products.pdf", "size": 152021, "headers": {"Date": "Thu, 04 Sep 2025 07:45:12 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"251d5-63c8b01b3aed2\"", "Accept-Ranges": "bytes", "Content-Length": "152021", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:12.168830Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2011%20can%20a%20facility%20that%20produced%20penicillin%20dosage%20forms%20be%20decontaminated%20and%20renovated.pdf", "anchor": "Æä´Ï½Ç¸° ¿ÏÁ¦ Á¦ÇüÀ» Á¦Á¶Çß´ø ½Ã¼³À» ¿À¿° Á¦°Å Ã³¸®ÇÏ°í °³ÃàÇÑ ´ÙÀ½¿¡ ºñÆä´Ï½Ç¸° Á¦Ç°À» »ý»êÇØµµ µÇ´Â°¡? °³Ãà ½Ã¼³¿¡¼­´Â Æä´Ï½Ç¸° Á¦Ç°À» ´õ ÀÌ»ó »ý»êÇÏÁö ¾Ê´Â´Ù . | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/b2b564f315_lab control 11 can a facility that produced penicillin dosage forms be decontaminated and renovated.pdf", "size": 151764, "headers": {"Date": "Thu, 04 Sep 2025 07:45:12 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"250d4-63c8b01b4184b\"", "Accept-Ranges": "bytes", "Content-Length": "151764", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:12.399870Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2012%20is%20there%20an%20acceptable%20level%20of%20penicillin%20residue.pdf", "anchor": "ºñÆä´Ï½Ç¸° ÀÇ¾àÇ°¿¡ Á¸ÀçÇÏ´Â Æä´Ï½Ç¸° ÀÜ·ù¹°ÀÇ Çã¿ë ¼öÁØÀÌ ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ba13aeb62e_lab control 12 is there an acceptable level of penicillin residue.pdf", "size": 127546, "headers": {"Date": "Thu, 04 Sep 2025 07:45:12 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:46 GMT", "ETag": "\"1f23a-63c8b01b4760b\"", "Accept-Ranges": "bytes", "Content-Length": "127546", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:12.653514Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2013%20for%20injectable%20drugs%20in%20multiple%20dose%20containers.pdf", "anchor": "´ÙÈ¸ Åõ¿©¿ë ÁÖ»çÁ¦ ÀÇ¾àÇ°ÀÎ °æ¿ì¿¡ ÀÏÈ¸ Åõ¿© ¿ë·®À» »Ì¾Æ³»´Â ÇàÀ§¸¦ ÇÏ´Â È½¼ö°¡ À¯È¿±â°£ ¼³Á¤ ½Ã¿¡ °í·ÁÇØ¾ß ÇÏ´Â ¿ä¼ÒÀÎ°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/d05f005726_lab control 13 for injectable drugs in multiple dose containers.pdf", "size": 156262, "headers": {"Date": "Thu, 04 Sep 2025 07:45:12 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"26266-63c8b01b4c814\"", "Accept-Ranges": "bytes", "Content-Length": "156262", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:12.902566Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2014%20how%20long%20may%20a%20firm%20store%20in%20process%20intermediates.pdf", "anchor": "º°µµ ¾ÈÁ¤¼º ½ÃÇè ¾øÀÌ ¹ÝÁ¦Ç° ºÐ¸» ºí·»µå¿Í ºÐ¼â¹°, ¼­¹æÇü Æç·¿/ºñµå, Á¤Á¦ ÄÚ¾î¸¦ ¾ó¸¶³ª ¿À·¡ º¸°üÇÑ ´ÙÀ½¿¡ ¿ÏÁ¦ ÀÇ¾àÇ° Á¦Á¶¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/1861788954_lab control 14 how long may a firm store in process intermediates.pdf", "size": 152807, "headers": {"Date": "Thu, 04 Sep 2025 07:45:13 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"254e7-63c8b01b521ec\"", "Accept-Ranges": "bytes", "Content-Length": "152807", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:13.148760Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2015%20what%20material%20can%20be%20used%20as%20calibration%20standards%20for%20chromatographic%20systems.pdf", "anchor": "Å©·Î¸¶Åä±×·¡ÇÇ ½Ã½ºÅÛÀÇ ÀåÄ¡ ±³Á¤ Ç¥ÁØÇ°À¸·Î ¾î¶² °ÍÀ» »ç¿ëÇÒ ¼ö ÀÖ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/76a54756b4_lab control 15 what material can be used as calibration standards for chromatographic systems.pdf", "size": 141856, "headers": {"Date": "Thu, 04 Sep 2025 07:45:13 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"22a20-63c8b01b58b65\"", "Accept-Ranges": "bytes", "Content-Length": "141856", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:13.388289Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2016%20what%20material%20can%20be%20used%20for%20system%20suitability.pdf", "anchor": "½Ã½ºÅÛ ÀûÇÕ¼º ½ÃÇè¿¡ ¾î¶² °ÍÀ» »ç¿ëÇÒ ¼ö ÀÖ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a7e05a53a7_lab control 16 what material can be used for system suitability.pdf", "size": 142915, "headers": {"Date": "Thu, 04 Sep 2025 07:45:13 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"22e43-63c8b01b5d1b5\"", "Accept-Ranges": "bytes", "Content-Length": "142915", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:13.651222Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/lab%20control%2017%20is%20it%20ever%20appropriate%20to%20perform%20a%20trial%20injection%20of%20samples.pdf", "anchor": "°ËÃ¼ÀÇ \"½Ã¹ü ÁÖÀÔ\"Àº ÀûÀýÇÑ°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/e1911e0d27_lab control 17 is it ever appropriate to perform a trial injection of samples.pdf", "size": 151700, "headers": {"Date": "Thu, 04 Sep 2025 07:45:13 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"25094-63c8b01b63f16\"", "Accept-Ranges": "bytes", "Content-Length": "151700", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:14.306297Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/record%20control%2003%20records%20not%20accessible%20to%20fda.pdf", "anchor": "FDA°¡ Á¢±ÙÇÏÁö ¸øÇÏ´Â ±â·Ï¿¡ ÀÇÁ¸ÇÏ´Â »óÈ²¿¡¼­ CGMP ÁØ¼ö¸¦ Áõ¸íÇÒ ¼ö ÀÖ´Â°¡? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/39ac352b8e_record control 03 records not accessible to fda.pdf", "size": 189322, "headers": {"Date": "Thu, 04 Sep 2025 07:45:14 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2e38a-63c8b01c08bdc\"", "Accept-Ranges": "bytes", "Content-Length": "189322", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:14.557697Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/record%20control%2004%20part%2011%20regulations%20and%20predicate%20rule.pdf", "anchor": "ÀÇ¾àÇ° Á¦Á¶ ¹× ½ÃÇè¿¡ »ç¿ëµÇ´Â ÄÄÇ»ÅÍÈ­ ½ÃÇè ½Ã½ºÅÛ¿¡ ÀÇÇØ »ý¼ºµÈ ÀüÀÚ ±â·Ï¼­¿Í °ü·Ã Å©·Î¸¶Åä±×·¥ ÀÎ¼â¹°¿¡ ÆÄÆ® 11 ±ÔÁ¤°ú \"ÁöÁ¤ ±ÔÄ¢ ±âÁØ\"(21 CFR ÆÄÆ® 211)ÀÌ ¾î¶»°Ô Àû¿ëµÇ´Â°¡ | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | ÀÇ¾àÇ° Á¦Á¶ ¹× ½ÃÇè¿¡ »ç¿ëµÇ´Â ÄÄÇ»ÅÍÈ­ ½ÃÇè ½Ã½ºÅÛ¿¡ ÀÇÇØ »ý¼ºµÈ ÀüÀÚ ±â·Ï¼­¿Í °ü·Ã Å©·Î¸¶Åä±×·¥ ÀÎ¼â¹°¿¡ ÆÄÆ® 11 ±ÔÁ¤°", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/1766f9d63e_record control 04 part 11 regulations and predicate rule.pdf", "size": 190157, "headers": {"Date": "Thu, 04 Sep 2025 07:45:14 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2e6cd-63c8b01c0f554\"", "Accept-Ranges": "bytes", "Content-Length": "190157", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:15.038864Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/record%20control%2005%20expiry%20dating%20for%20chemicals%20reagents%20solutiosn%20solvents.pdf", "anchor": "È­ÇÐ¹°Áú , ½Ã¾à , ¿ë¾×, ¿ë¸ÅÀÇ À¯È¿ ±â°£ ¼³Á¤¿¡ °üÇÑ ±ÔÁ¤(21 CFR ÆÄÆ® 211)À» FDA´Â ¾î ¶»°Ô ÇØ¼®ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a0928226c1_record control 05 expiry dating for chemicals reagents solutiosn solvents.pdf", "size": 163140, "headers": {"Date": "Thu, 04 Sep 2025 07:45:15 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"27d44-63c8b01c156fd\"", "Accept-Ranges": "bytes", "Content-Length": "163140", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:15.282719Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/returned%20n%20salvaged%201%20natural%20disaster.pdf", "anchor": "ÀÚ¿¬ ÀçÇØ¸¦ ÀÔÀº °Í°ú °°ÀÌ ºÎÀûÀýÇÑ º¸°ü Á¶°Ç¿¡ ³ëÃâµÇ¾ú´ø ÀÇ¾àÇ°ÀÌ³ª ¿ø·á¸¦ ¾î¶»°Ô Ã³¸®ÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/bff1233f3c_returned n salvaged 1 natural disaster.pdf", "size": 169776, "headers": {"Date": "Thu, 04 Sep 2025 07:45:15 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"29730-63c8b01c1cc2d\"", "Accept-Ranges": "bytes", "Content-Length": "169776", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:15.518872Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/returned%20n%20salvaged%202%20toxic%20fumes%20radiation.pdf", "anchor": "ºÎÀûÀýÇÑ º¸°ü Á¶°Ç¿¡ µ¶¼º ¿¬¹«³ª ¹æ»ç¼± ³ëÃâµµ Æ÷ÇÔµÇ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/b03391e794_returned n salvaged 2 toxic fumes radiation.pdf", "size": 129769, "headers": {"Date": "Thu, 04 Sep 2025 07:45:15 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"1fae9-63c8b01c235a6\"", "Accept-Ranges": "bytes", "Content-Length": "129769", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:15.760637Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/usfda/cgmp%20q%20and%20a/returned%20n%20salvaged%203%20radioactive%20materials.pdf", "anchor": "ÀÇ¾àÇ°ÀÌ³ª ÀÇ¾àÇ°ÀÇ ¿ø·á ¶Ç´Â Æ÷Àå ÀÚÀç°¡ ¹æ»ç¼º ¹°Áú¿¡ ¿À¿°µÇ¾ú´ÂÁö Æò°¡ÇÒ ¶§ ¾î¶² Á¡À» °ËÅäÇØ¾ß ÇÏ´Â°¡ ? | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/b10dfbeabb_returned n salvaged 3 radioactive materials.pdf", "size": 175119, "headers": {"Date": "Thu, 04 Sep 2025 07:45:15 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:47 GMT", "ETag": "\"2ac0f-63c8b01c2a6ee\"", "Accept-Ranges": "bytes", "Content-Length": "175119", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:16.516547Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/uk%20mhra%20gxp%20data%20integrity%20guidance%20and%20definitions%202018%203.pdf", "anchor": "GXP Data Integrity Guidance and Definitions (2018 3) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/f8711f953e_uk mhra gxp data integrity guidance and definitions 2018 3.pdf", "size": 456031, "headers": {"Date": "Thu, 04 Sep 2025 07:45:16 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"6f55f-63c8b014a45e3\"", "Accept-Ranges": "bytes", "Content-Length": "456031", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:16.897923Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/uk%20mhra%20data%20integrity%20definitions%20%20and%20guidance%20for%20industry%20withdrawn.pdf", "anchor": "GMP Data Integrity Definitions and Guidance for Industry (withdrawn) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/aeb799501a_uk mhra data integrity definitions  and guidance for industry withdrawn.pdf", "size": 698599, "headers": {"Date": "Thu, 04 Sep 2025 07:45:16 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:39 GMT", "ETag": "\"aa8e7-63c8b0149a1d3\"", "Accept-Ranges": "bytes", "Content-Length": "698599", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:17.282114Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/pics%20good%20practices%20for%20data%20management%20and%20integrity%202021%207.pdf", "anchor": "Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1, 1 July 2021) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/48abbc47b0_pics good practices for data management and integrity 2021 7.pdf", "size": 975750, "headers": {"Date": "Thu, 04 Sep 2025 07:45:17 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:39 GMT", "ETag": "\"ee386-63c8b01490592\"", "Accept-Ranges": "bytes", "Content-Length": "975750", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:17.532181Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/data%20integrity%20references/who%20guideline%20on%20data%20integrity%20trs%201033%202021.pdf", "anchor": "Guideline on Data Integrity (2021) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "WHO", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/WHO/c9cb85fc40_who guideline on data integrity trs 1033 2021.pdf", "size": 174329, "headers": {"Date": "Thu, 04 Sep 2025 07:45:17 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:40 GMT", "ETag": "\"2a8f9-63c8b014cd627\"", "Accept-Ranges": "bytes", "Content-Length": "174329", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:19.610152Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/ema%20fda%20pilot%20program%20for%20parallel%20assessment%20of%20quality%20by%20design%20applications.pdf", "anchor": "EMA-FDA pilot program for parallel assessment of\r\nQuality-by-Design applications: lessons learnt and Q&A resulting from the\r\nfirst parallel assessment | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0585660da0_ema fda pilot program for parallel assessment of quality by design applications.pdf", "size": 205680, "headers": {"Date": "Thu, 04 Sep 2025 07:45:19 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:41 GMT", "ETag": "\"32370-63c8b01676afb\"", "Accept-Ranges": "bytes", "Content-Length": "205680", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:19.900491Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/euemea/guidelines/q%20and%20a%20design%20space%20verification.pdf", "anchor": "Questions and Answers on\r\nDesign Space Verification | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/9d7b2d48f1_q and a design space verification.pdf", "size": 202254, "headers": {"Date": "Thu, 04 Sep 2025 07:45:19 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:42 GMT", "ETag": "\"3160e-63c8b016eba1d\"", "Accept-Ranges": "bytes", "Content-Length": "202254", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:20.163634Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/q%20and%20a%20level%20of%20detail%20in%20the%20regulatory%20submissions.pdf", "anchor": "Questions and Answers on Level of Detail in the Regulatory Submissions | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/e8c50867f6_q and a level of detail in the regulatory submissions.pdf", "size": 230619, "headers": {"Date": "Thu, 04 Sep 2025 07:45:20 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"384db-63c8b019e32b5\"", "Accept-Ranges": "bytes", "Content-Length": "230619", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:20.447216Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/q%20and%20a%20nor%20par%20dsp%20normal%20variability.pdf", "anchor": "Questions and Answers: Improving the Understanding of NORs, PARs, DSp | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/f6d3f682bf_q and a nor par dsp normal variability.pdf", "size": 285723, "headers": {"Date": "Thu, 04 Sep 2025 07:45:20 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"45c1b-63c8b019ec33e\"", "Accept-Ranges": "bytes", "Content-Length": "285723", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:21.004102Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/MockP2discussionpaper-20070904-002-EN-v1.pdf", "anchor": "EFPIA Draft Mock P2 Document for \"Examplain\" Hydrochloride | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/08ecbcdbe1_MockP2discussionpaper-20070904-002-EN-v1.pdf", "size": 710847, "headers": {"Date": "Thu, 04 Sep 2025 07:45:21 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"ad8bf-63c8b0198b856\"", "Accept-Ranges": "bytes", "Content-Length": "710847", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:21.258770Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/efpia%20mock%20p2%20discussion%20paper%20kr.pdf", "anchor": "¹ø¿ª¹® | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/4083d2fc70_efpia mock p2 discussion paper kr.pdf", "size": 183842, "headers": {"Date": "Thu, 04 Sep 2025 07:45:21 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"2ce22-63c8b01958019\"", "Accept-Ranges": "bytes", "Content-Length": "183842", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:21.536908Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/MockP2presentation-20070904-001-EN-v1.pdf", "anchor": "EFPIA Mock P2 Presentation | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/012f20ef2b_MockP2presentation-20070904-001-EN-v1.pdf", "size": 396358, "headers": {"Date": "Thu, 04 Sep 2025 07:45:21 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"60c46-63c8b01995496\"", "Accept-Ranges": "bytes", "Content-Length": "396358", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:22.027312Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/QBD_ACE_Case_History.pdf", "anchor": "\"ACE Tablets\" Pharmaceutical Development Case Study | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/48180a5fba_QBD_ACE_Case_History.pdf", "size": 1429794, "headers": {"Date": "Thu, 04 Sep 2025 07:45:21 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"15d122-63c8b01a2a373\"", "Accept-Ranges": "bytes", "Content-Length": "1429794", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:22.268524Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/QBD_ACE_Case_History%20kr.pdf", "anchor": "¹ø¿ª¹® | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/e84d56fda3_QBD_ACE_Case_History kr.pdf", "size": 171205, "headers": {"Date": "Thu, 04 Sep 2025 07:45:22 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"29cc5-63c8b01a17a91\"", "Accept-Ranges": "bytes", "Content-Length": "171205", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:22.561842Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/qos%20mock%20p2%20sakura%20tablet.pdf", "anchor": "\"Sakura Tablet\" Case Study Materials (NIHS, Japan) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/fdf21b553d_qos mock p2 sakura tablet.pdf", "size": 528860, "headers": {"Date": "Thu, 04 Sep 2025 07:45:22 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"811dc-63c8b01a318a4\"", "Accept-Ranges": "bytes", "Content-Length": "528860", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:22.821713Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/mhlw%20quality%20overall%20summary%20mock%20p2%20kr.pdf", "anchor": "¹ø¿ª¹® | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/a3e6b63612_mhlw quality overall summary mock p2 kr.pdf", "size": 143336, "headers": {"Date": "Thu, 04 Sep 2025 07:45:22 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"22fe8-63c8b0197e17c\"", "Accept-Ranges": "bytes", "Content-Length": "143336", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:23.820556Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/PQLI_A_Mab_Case_Study_Version_2_1[1].pdf", "anchor": "A-Mab: A Case Study in Bioprocess Development | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/7c6fbb934b_PQLI_A_Mab_Case_Study_Version_2_1[1].pdf", "size": 4760212, "headers": {"Date": "Thu, 04 Sep 2025 07:45:23 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"48a294-63c8b019db99c\"", "Accept-Ranges": "bytes", "Content-Length": "4760212", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:24.074674Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/PQLI%20A%20Mab%20Case%20Study%20kr.pdf", "anchor": "¹ø¿ª¹® | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/87baab1288_PQLI A Mab Case Study kr.pdf", "size": 208347, "headers": {"Date": "Thu, 04 Sep 2025 07:45:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"32ddb-63c8b01999ecf\"", "Accept-Ranges": "bytes", "Content-Length": "208347", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:24.549826Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/Example%20QbD%20for%20IR%20Tablet%202012.pdf", "anchor": "Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms (April, 2012)", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/50a4dff77c_Example QbD for IR Tablet 2012.pdf", "size": 1552241, "headers": {"Date": "Thu, 04 Sep 2025 07:45:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"17af71-63c8b01979b2c\"", "Accept-Ranges": "bytes", "Content-Length": "1552241", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:24.777393Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/Example%20QbD%20for%20IR%20Tablet%202012%20kr.pdf", "anchor": "¹ø¿ª¹® | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/04b20bab6a_Example QbD for IR Tablet 2012 kr.pdf", "size": 149717, "headers": {"Date": "Thu, 04 Sep 2025 07:45:24 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"248d5-63c8b0195c282\"", "Accept-Ranges": "bytes", "Content-Length": "149717", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:25.371942Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/qbd%20modified%20release%20tablet%202011%20final.pdf", "anchor": "Quality by Design for ANDAs: An Example for Modified Release Dosage Forms | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù. | Quality by Design for ANDAs: An Example for Modified Release Dosage Forms (December 2011)", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/324e37f2bb_qbd modified release tablet 2011 final.pdf", "size": 2302867, "headers": {"Date": "Thu, 04 Sep 2025 07:45:25 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"232393-63c8b01a124a1\"", "Accept-Ranges": "bytes", "Content-Length": "2302867", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:25.608072Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/qbd%20modified%20release%20tablet%202011%20final%20kr.pdf", "anchor": "¹ø¿ª¹® | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/1f0d543b16_qbd modified release tablet 2011 final kr.pdf", "size": 212559, "headers": {"Date": "Thu, 04 Sep 2025 07:45:25 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:45 GMT", "ETag": "\"33e4f-63c8b019f0d76\"", "Accept-Ranges": "bytes", "Content-Length": "212559", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:25.901272Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/quality%20by%20design/a%20vax%20applying%20quality%20by%20design%20to%20vaccines%202012%20kr.pdf", "anchor": "A-VAX: Applying Quality by Design to Vaccines | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "OTHER", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/OTHER/e4744725b5_a vax applying quality by design to vaccines 2012 kr.pdf", "size": 191304, "headers": {"Date": "Thu, 04 Sep 2025 07:45:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"2eb48-63c8b019539c9\"", "Accept-Ranges": "bytes", "Content-Length": "191304", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:26.603691Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%201%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/3a14181447_us fda wl 483 vol 1 sample pages.pdf", "size": 136479, "headers": {"Date": "Thu, 04 Sep 2025 07:45:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"2151f-63c8b023022db\"", "Accept-Ranges": "bytes", "Content-Length": "136479", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:26.882008Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%202%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8dc4e932fd_us fda wl 483 vol 2 sample pages.pdf", "size": 131506, "headers": {"Date": "Thu, 04 Sep 2025 07:45:26 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"201b2-63c8b02306543\"", "Accept-Ranges": "bytes", "Content-Length": "131506", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:27.135893Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%203%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/7d1c5be283_us fda wl 483 vol 3 sample pages.pdf", "size": 141301, "headers": {"Date": "Thu, 04 Sep 2025 07:45:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"227f5-63c8b0230a7ab\"", "Accept-Ranges": "bytes", "Content-Length": "141301", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:27.375216Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%204%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4664b5bd76_us fda wl 483 vol 4 sample pages.pdf", "size": 126515, "headers": {"Date": "Thu, 04 Sep 2025 07:45:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"1ee33-63c8b0231150c\"", "Accept-Ranges": "bytes", "Content-Length": "126515", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:27.610056Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%205%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/28e167d125_us fda wl 483 vol 5 sample pages.pdf", "size": 133027, "headers": {"Date": "Thu, 04 Sep 2025 07:45:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"207a3-63c8b0231538c\"", "Accept-Ranges": "bytes", "Content-Length": "133027", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:27.885887Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%206%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/5034acd7e3_us fda wl 483 vol 6 sample pages.pdf", "size": 132598, "headers": {"Date": "Thu, 04 Sep 2025 07:45:27 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"205f6-63c8b023195f5\"", "Accept-Ranges": "bytes", "Content-Length": "132598", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:28.143887Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%20483%20vol%207%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/eae9eecfbb_us fda wl 483 vol 7 sample pages.pdf", "size": 147846, "headers": {"Date": "Thu, 04 Sep 2025 07:45:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"24186-63c8b0231dc45\"", "Accept-Ranges": "bytes", "Content-Length": "147846", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:28.401463Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202016%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/d7ae7342c2_us fda wl 2016 sample pages.pdf", "size": 198106, "headers": {"Date": "Thu, 04 Sep 2025 07:45:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"305da-63c8b022b6fb4\"", "Accept-Ranges": "bytes", "Content-Length": "198106", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:28.651587Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202017%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/434826ee69_us fda wl 2017 sample pages.pdf", "size": 178157, "headers": {"Date": "Thu, 04 Sep 2025 07:45:28 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2b7ed-63c8b022be4e5\"", "Accept-Ranges": "bytes", "Content-Length": "178157", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:28.935086Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202018%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4eaf2cc5da_us fda wl 2018 sample pages.pdf", "size": 196119, "headers": {"Date": "Thu, 04 Sep 2025 07:45:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2fe17-63c8b022c5dfe\"", "Accept-Ranges": "bytes", "Content-Length": "196119", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:29.203930Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202019%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/25d447d3a3_us fda wl 2019 sample pages.pdf", "size": 174547, "headers": {"Date": "Thu, 04 Sep 2025 07:45:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2a9d3-63c8b022cdafe\"", "Accept-Ranges": "bytes", "Content-Length": "174547", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:29.447238Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202020%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/6b29110cc1_us fda wl 2020 sample pages.pdf", "size": 199357, "headers": {"Date": "Thu, 04 Sep 2025 07:45:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"30abd-63c8b022d502f\"", "Accept-Ranges": "bytes", "Content-Length": "199357", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:29.702517Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202021%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c0c98e3d26_us fda wl 2021 sample pages.pdf", "size": 191934, "headers": {"Date": "Thu, 04 Sep 2025 07:45:29 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"2edbe-63c8b022dc55f\"", "Accept-Ranges": "bytes", "Content-Length": "191934", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:29.965745Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202022%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c6af8db49e_us fda wl 2022 sample pages.pdf", "size": 289531, "headers": {"Date": "Thu, 04 Sep 2025 07:45:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"46afb-63c8b022e1b50\"", "Accept-Ranges": "bytes", "Content-Length": "289531", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:30.234522Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202023%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/595f33969d_us fda wl 2023 sample pages.pdf", "size": 297554, "headers": {"Date": "Thu, 04 Sep 2025 07:45:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"48a52-63c8b022e80e0\"", "Accept-Ranges": "bytes", "Content-Length": "297554", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:30.511656Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202024%201st%20half%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/8e85dce7b7_us fda wl 2024 1st half sample pages.pdf", "size": 311583, "headers": {"Date": "Thu, 04 Sep 2025 07:45:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"4c11f-63c8b022eee41\"", "Accept-Ranges": "bytes", "Content-Length": "311583", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:30.791634Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202024%202nd%20half%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/d2da3c8401_us fda wl 2024 2nd half sample pages.pdf", "size": 305676, "headers": {"Date": "Thu, 04 Sep 2025 07:45:30 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"4aa0c-63c8b022f6372\"", "Accept-Ranges": "bytes", "Content-Length": "305676", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:31.059652Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20wl%202025%201st%20half%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/01bffeea9d_us fda wl 2025 1st half sample pages.pdf", "size": 315992, "headers": {"Date": "Thu, 04 Sep 2025 07:45:31 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:55 GMT", "ETag": "\"4d258-63c8b022fe072\"", "Accept-Ranges": "bytes", "Content-Length": "315992", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:31.316775Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202020%202021%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/0347f35da1_us fda 483 2020 2021 sample pages.pdf", "size": 331943, "headers": {"Date": "Thu, 04 Sep 2025 07:45:31 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"510a7-63c8b022879e0\"", "Accept-Ranges": "bytes", "Content-Length": "331943", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:31.592009Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202022%201st%20half%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/2f140d69a1_us fda 483 2022 1st half sample pages.pdf", "size": 284552, "headers": {"Date": "Thu, 04 Sep 2025 07:45:31 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"45788-63c8b0228e359\"", "Accept-Ranges": "bytes", "Content-Length": "284552", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:31.896355Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202022%202nd%20half%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/ab990cbe5b_us fda 483 2022 2nd half sample pages.pdf", "size": 300442, "headers": {"Date": "Thu, 04 Sep 2025 07:45:31 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"4959a-63c8b022954a1\"", "Accept-Ranges": "bytes", "Content-Length": "300442", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:32.164296Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202023%201st%20half%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/946884f3ee_us fda 483 2023 1st half sample pages.pdf", "size": 282935, "headers": {"Date": "Thu, 04 Sep 2025 07:45:32 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"45137-63c8b0229c9d2\"", "Accept-Ranges": "bytes", "Content-Length": "282935", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:32.441221Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202023%202nd%20half%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/c3b1b6a022_us fda 483 2023 2nd half sample pages.pdf", "size": 296746, "headers": {"Date": "Thu, 04 Sep 2025 07:45:32 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"4872a-63c8b022a2f63\"", "Accept-Ranges": "bytes", "Content-Length": "296746", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:32.714609Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202024%201st%20half%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/a51717731a_us fda 483 2024 1st half sample pages.pdf", "size": 289419, "headers": {"Date": "Thu, 04 Sep 2025 07:45:32 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"46a8b-63c8b022aa493\"", "Accept-Ranges": "bytes", "Content-Length": "289419", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:32.980815Z", "url": "http://www.gmpeye.co.kr/specialtyservices/us%20fda%20483%202024%202nd%20half%20sample%20pages.pdf", "anchor": "¸ñÂ÷ ¹× »ùÇÃ ÆäÀÌÁö º¸±â | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/4ecf020838_us fda 483 2024 2nd half sample pages.pdf", "size": 268930, "headers": {"Date": "Thu, 04 Sep 2025 07:45:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:54 GMT", "ETag": "\"41a82-63c8b022b2964\"", "Accept-Ranges": "bytes", "Content-Length": "268930", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:33.498448Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%201%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20products%20in%20Kor%20Eng%202022%2012%2029%20effective%20from%202023%201%201.pdf", "anchor": "º°Ç¥ 1: ÀÇ¾àÇ° Á¦Á¶ ¹× Ç°Áú°ü¸® ±âÁØ(2022.12.29. °³Á¤)[2023.1.1. ½ÃÇà] | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/eb71e8ef9b_annex 1 Korean good manufacturing practices for medicinal products in Kor Eng 2022 12 29 effective from 2023 1 1.pdf", "size": 147067, "headers": {"Date": "Thu, 04 Sep 2025 07:45:33 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"23e7b-63c8b0190f01b\"", "Accept-Ranges": "bytes", "Content-Length": "147067", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:33.962967Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%201%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20products%20in%20Kor%20Eng%202022%2012%2029%20effective%20from%202023%2012%208.pdf", "anchor": "º°Ç¥ 1: ÀÇ¾àÇ° Á¦Á¶ ¹× Ç°Áú°ü¸® ±âÁØ(2022.12.29. °³Á¤)[2023.12.8. ½ÃÇà] | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/d94b51fe92_annex 1 Korean good manufacturing practices for medicinal products in Kor Eng 2022 12 29 effective from 2023 12 8.pdf", "size": 147272, "headers": {"Date": "Thu, 04 Sep 2025 07:45:34 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"23f48-63c8b019151c4\"", "Accept-Ranges": "bytes", "Content-Length": "147272", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:34.402967Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%201-2%20Korean%20good%20manufacturing%20practices%20for%20active%20pharmaceutical%20ingredients%20in%20Kor%20Eng%202022%2012%2029.pdf", "anchor": "º°Ç¥ 1ÀÇ 2: ¿ø·áÀÇ¾àÇ° Á¦Á¶ ¹× Ç°Áú°ü¸®±âÁØ(2022.12.29. °³Á¤)[2023.1.1. ½ÃÇà] | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/8837bd7c94_annex 1-2 Korean good manufacturing practices for active pharmaceutical ingredients in Kor Eng 2022 12 29.pdf", "size": 139309, "headers": {"Date": "Thu, 04 Sep 2025 07:45:34 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"2202d-63c8b0191ab9c\"", "Accept-Ranges": "bytes", "Content-Length": "139309", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:34.895097Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%203%20Korean%20good%20manufacturing%20practices%20for%20biological%20products%20in%20Kor%20Eng%202021%209%2010.pdf", "anchor": "º°Ç¥ 3: »ý¹°ÇÐÀûÁ¦Á¦µî Á¦Á¶ ¹× Ç°Áú°ü¸®±âÁØ(2021.9.10) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/cd84fb1694_annex 3 Korean good manufacturing practices for biological products in Kor Eng 2021 9 10.pdf", "size": 148410, "headers": {"Date": "Thu, 04 Sep 2025 07:45:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"243ba-63c8b01921515\"", "Accept-Ranges": "bytes", "Content-Length": "148410", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:35.343454Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%203-2%20Korean%20good%20manufacturing%20practices%20for%20radiopharmaceuticals%20in%20Kor%20Eng%202021%209%2010.pdf", "anchor": "º°Ç¥ 3ÀÇ 2: ¹æ»ç¼ºÀÇ¾àÇ° Á¦Á¶ ¹× Ç°Áú°ü¸®±âÁØ(2021.9.10) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/9ebdc0d255_annex 3-2 Korean good manufacturing practices for radiopharmaceuticals in Kor Eng 2021 9 10.pdf", "size": 174244, "headers": {"Date": "Thu, 04 Sep 2025 07:45:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"2a8a4-63c8b01928e2d\"", "Accept-Ranges": "bytes", "Content-Length": "174244", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:35.787679Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%203-3%20Korean%20good%20manufacturing%20practices%20for%20medicinal%20gases%20in%20Kor%20Eng%202014%208%2021.pdf", "anchor": "º°Ç¥ 3ÀÇ 3: ÀÇ·á¿ë °í¾Ð°¡½º Á¦Á¶ ¹× Ç°Áú°ü¸®±âÁØ(2014.8.21) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "EU", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/EU/d8c4dca624_annex 3-3 Korean good manufacturing practices for medicinal gases in Kor Eng 2014 8 21.pdf", "size": 245683, "headers": {"Date": "Thu, 04 Sep 2025 07:45:35 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"3bfb3-63c8b0192dc4e\"", "Accept-Ranges": "bytes", "Content-Length": "245683", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:36.239379Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/annex%204-2%20Korean%20good%20manufacturing%20practices%20for%20investigational%20products%20in%20Kor%20Eng%202016%2010%2028.pdf", "anchor": "º°Ç¥ 4ÀÇ 2: ÀÓ»ó½ÃÇè¿ëÀÇ¾àÇ° Á¦Á¶ ¹× Ç°Áú°ü¸®±âÁØ(2016.10.28) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "FDA", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/FDA/2d7f1c616d_annex 4-2 Korean good manufacturing practices for investigational products in Kor Eng 2016 10 28.pdf", "size": 140078, "headers": {"Date": "Thu, 04 Sep 2025 07:45:36 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"2232e-63c8b01931ace\"", "Accept-Ranges": "bytes", "Content-Length": "140078", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:36.693943Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/pharmaceutical%20facilities%20standard%20decree%20in%20Kor%20Eng%202021%2010%2019.pdf", "anchor": "ÀÇ¾àÇ° µîÀÇ Á¦Á¶¾÷ ¹× ¼öÀÔÀÚÀÇ ½Ã¼³ ±âÁØ·É(2021.10.19) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "MFDS", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/MFDS/1f5c92d578_pharmaceutical facilities standard decree in Kor Eng 2021 10 19.pdf", "size": 167847, "headers": {"Date": "Thu, 04 Sep 2025 07:45:36 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"28fa7-63c8b01940147\"", "Accept-Ranges": "bytes", "Content-Length": "167847", "Connection": "close", "Content-Type": "application/pdf"}}
{"ts": "2025-09-04T07:45:37.130057Z", "url": "http://www.gmpeye.co.kr/gmpguidesandguidelines/kgmp/pharmaceutical%20facilities%20standard%20decree%20enforcement%20regulation%20in%20Kor%20Eng%202021%2011%2019.pdf", "anchor": "ÀÇ¾àÇ° µîÀÇ Á¦Á¶¾÷ ¹× ¼öÀÔÀÚÀÇ ½Ã¼³ ±âÁØ·É ½ÃÇà±ÔÄ¢(2021.11.19) | gmpeye´Â ´ëÇÑ¹Î±¹ Á¦¾à¾÷°èÀÇ GMP Think-Tank¸¦ Ãß±¸ÇÕ´Ï´Ù.", "source": "MFDS", "filepath": "C:/Users/MASTER/Desktop/auto_gmp_periodically_review/data/raw/MFDS/91c6b28304_pharmaceutical facilities standard decree enforcement regulation in Kor Eng 2021 11 19.pdf", "size": 151209, "headers": {"Date": "Thu, 04 Sep 2025 07:45:37 GMT", "Server": "Server", "Last-Modified": "Sun, 17 Aug 2025 07:59:44 GMT", "ETag": "\"24ea9-63c8b01938c17\"", "Accept-Ranges": "bytes", "Content-Length": "151209", "Connection": "close", "Content-Type": "application/pdf"}}
